
<html lang="en"     class="pb-page"  data-request-id="9fabb0c7-cac5-45c9-b30c-a63520eedd8c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2011.54.issue-2;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm1012787"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P2 Ligands: Structure−Activity Studies and Biological Evaluation" /></meta><meta name="dc.Creator" content="Arun K.  Ghosh" /></meta><meta name="dc.Creator" content="Bruno D.  Chapsal" /></meta><meta name="dc.Creator" content="Abigail  Baldridge" /></meta><meta name="dc.Creator" content="Melinda P.  Steffey" /></meta><meta name="dc.Creator" content="D. Eric  Walters" /></meta><meta name="dc.Creator" content="Yasuhiro  Koh" /></meta><meta name="dc.Creator" content="Masayuki  Amano" /></meta><meta name="dc.Creator" content="Hiroaki  Mitsuya" /></meta><meta name="dc.Description" content="The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-deriv..." /></meta><meta name="Description" content="The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-deriv..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 31, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm1012787" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm1012787" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm1012787" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm1012787" /></link>
        
    
    

<title>Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P2 Ligands: Structure−Activity Studies and Biological Evaluation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm1012787" /></meta><meta property="og:title" content="Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P2 Ligands: Structure−Activity Studies and Biological Evaluation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0007.jpeg" /></meta><meta property="og:description" content="The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-derived urethane as the P2-ligand. The current ligand is designed based upon the X-ray structure of 1a-bound HIV-1 protease. The synthesis of (3aS,4S,7aR)-hexahydro-2H-furo[2,3-b]pyran-4-ol, (−)-7, was carried out in optically active form. Incorporation of this ligand provided inhibitor 35a, which has shown excellent enzyme inhibitory activity and antiviral potency. Our structure−activity studies have indicated that the stereochemistry and the position of oxygens in the ligand are important to the observed potency of the inhibitor. Inhibitor 35a has maintained excellent potency against multidrug-resistant HIV-1 variants. An active site model of 35a was created based upon the X-ray structure of 1b-bound HIV-1 protease. The model offers molecular insights regarding ligand-binding site interactions of the hexahydrofuropyranol-derived novel P2-ligand." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm1012787"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm1012787">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm1012787&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm1012787&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm1012787&amp;href=/doi/10.1021/jm1012787" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 622-634</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm101394n" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm101251q" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P<sub>2</sub> Ligands: Structure−Activity Studies and Biological Evaluation</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arun+K.++Ghosh">Arun K. Ghosh</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruno+D.++Chapsal">Bruno D. Chapsal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Abigail++Baldridge">Abigail Baldridge</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melinda+P.++Steffey">Melinda P. Steffey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=D.+Eric++Walters">D. Eric Walters</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yasuhiro++Koh">Yasuhiro Koh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masayuki++Amano">Masayuki Amano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroaki++Mitsuya">Hiroaki Mitsuya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Chemistry, and</span></div><div class="aff-info" id="aff1b"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Medicinal Chemistry</span></div><div class="aff-info" id="pu"><span class="aff-text">Purdue University, West Lafayette, Indiana 47907, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Department of Biochemistry and Molecular Biology, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Hematology</span></div><div class="aff-info" id="aff3b"><span class="aff-symbol">⊥</span> <span class="aff-text">Department of Infectious Diseases</span></div><div class="aff-info" id="kusm"><span class="aff-text">Kumamoto University School of Medicine, Kumamoto 860-8556, Japan</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">#</span> <span class="aff-text">Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland 20892, United States</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: (765)-494-5323. Fax: (765)-496-1612. E-mail: <a href="/cdn-cgi/l/email-protection#ccada7aba4a3bfa48cbcb9bea8b9a9e2a9a8b9"><span class="__cf_email__" data-cfemail="27464c404f48544f6757525543524209424352">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm1012787&amp;href=/doi/10.1021%2Fjm1012787" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 622–634</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 31, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 October 2010</li><li><span class="item_label"><b>Published</b> online</span>31 December 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 January 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm1012787" title="DOI URL">https://doi.org/10.1021/jm1012787</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D622%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DArun%2BK.%2BGhosh%252C%2BBruno%2BD.%2BChapsal%252C%2BAbigail%2BBaldridge%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D2%26contentID%3Djm1012787%26title%3DDesign%2Band%2BSynthesis%2Bof%2BPotent%2BHIV-1%2BProtease%2BInhibitors%2BIncorporating%2BHexahydrofuropyranol-Derived%2BHigh%2BAffinity%2BP2%2BLigands%253A%2BStructure%25E2%2588%2592Activity%2BStudies%2Band%2BBiological%2BEvaluation%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D634%26publicationDate%3DJanuary%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm1012787"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2655</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">62</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm1012787" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P2 Ligands: Structure−Activity Studies and Biological Evaluation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Arun&quot;,&quot;last_name&quot;:&quot;K. Ghosh&quot;},{&quot;first_name&quot;:&quot;Bruno&quot;,&quot;last_name&quot;:&quot;D. Chapsal&quot;},{&quot;first_name&quot;:&quot;Abigail&quot;,&quot;last_name&quot;:&quot;Baldridge&quot;},{&quot;first_name&quot;:&quot;Melinda&quot;,&quot;last_name&quot;:&quot;P. Steffey&quot;},{&quot;first_name&quot;:&quot;D.&quot;,&quot;last_name&quot;:&quot;Eric Walters&quot;},{&quot;first_name&quot;:&quot;Yasuhiro&quot;,&quot;last_name&quot;:&quot;Koh&quot;},{&quot;first_name&quot;:&quot;Masayuki&quot;,&quot;last_name&quot;:&quot;Amano&quot;},{&quot;first_name&quot;:&quot;Hiroaki&quot;,&quot;last_name&quot;:&quot;Mitsuya&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;622-634&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm1012787&quot;},&quot;abstract&quot;:&quot;The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-derived urethane as the P2-ligand. The current ligand is designed based upon the X-ray structure of 1a-bound HIV-1 protease. The synthesis of (3aS,4S,7aR)-hexahydro-2H-furo[2,3-b]pyran-4-ol, (−)-7, was carried out in optically active form. Incorporation of this ligand provided inhibitor 35a, which has shown excellent enzyme inhibitory activity and antiviral potency. Our structure−activity studies have indicated that the stereochemistry and the position of oxygens in the ligand are important to the observed potency of the inhibitor. Inhibitor 35a has maintained excellent potency against multidrug-resistant HIV-1 variants. An active site model of 35a was created based upon the X-ray structure of 1b-bound HIV-1 protease. The model offers molecular insights regarding ligand-binding site interactions of the hexahydrofuropyran&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm1012787&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1012787" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm1012787&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1012787" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm1012787&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1012787" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm1012787&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm1012787&amp;href=/doi/10.1021/jm1012787" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm1012787" /></input><a href="/doi/pdf/10.1021/jm1012787" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm1012787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm1012787%26sid%3Dliteratum%253Aachs%26pmid%3D21194227%26genre%3Darticle%26aulast%3DGhosh%26date%3D2011%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BPotent%2BHIV-1%2BProtease%2BInhibitors%2BIncorporating%2BHexahydrofuropyranol-Derived%2BHigh%2BAffinity%2BP2%2BLigands%253A%2BStructure%25E2%2588%2592Activity%2BStudies%2Band%2BBiological%2BEvaluation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D2%26spage%3D622%26epage%3D634%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292534" title="Oxygen">Oxygen</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jmcmar.2011.54.issue-2/production/jmcmar.2011.54.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The design, synthesis, and evaluation of a new series of hexahydrofuropyranol-derived HIV-1 protease inhibitors are described. We have designed a stereochemically defined hexahydrofuropyranol-derived urethane as the P2-ligand. The current ligand is designed based upon the X-ray structure of <b>1a</b>-bound HIV-1 protease. The synthesis of (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-ol, (−)-<b>7</b>, was carried out in optically active form. Incorporation of this ligand provided inhibitor <b>35a</b>, which has shown excellent enzyme inhibitory activity and antiviral potency. Our structure−activity studies have indicated that the stereochemistry and the position of oxygens in the ligand are important to the observed potency of the inhibitor. Inhibitor <b>35a</b> has maintained excellent potency against multidrug-resistant HIV-1 variants. An active site model of <b>35a</b> was created based upon the X-ray structure of <b>1b</b>-bound HIV-1 protease. The model offers molecular insights regarding ligand-binding site interactions of the hexahydrofuropyranol-derived novel P2-ligand.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HIV-1 protease inhibitors are critical components of highly active antiretroviral therapy (HAART<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a><div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: bis-THF, bis-tetrahydrofuran; Cp-THF, cyclopentanyltetrahydrofuran; Tp-THF, tetrahydropyranyltetrahydrofuran; PI, protease inhibitor; HAART, highly active antiretroviral therapy; APV, amprenavir; DRV, darunavir; SQV, saquinavir; IDV, indinavir; LPV, lopinavir; RTV, ritonavir; ATV, atazanavir.</p></div> The HAART treatment regimens significantly reduced HIV/AIDS-related mortality.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> However, the rapid emergence of drug-resistant HIV-1 strains and the appearance of cross-resistance are severely limiting long-term treatment options.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> An estimated 10−25% of newly infected patients harbor at least one viral strain that is resistant to current medications.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> In addition, PI regimens suffer from a number of other drawbacks including high pill burden, treatment cost, poor ADMET properties, debilitating side effects, and toxicity issues.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Therefore, the development of novel PIs with broad-spectrum activity against multidrug-resistant HIV-1 variants remains a major therapeutic objective.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of inhibitors <b>1</b>−<b>3</b> and <b>35a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our continuing interest to develop novel protease inhibitors (PI) with broad-spectrum activity against multidrug-resistant HIV-1 variants, we have reported a series of PIs including PIs <b>1a</b>, <b>1b</b>, <b>2</b>, and <b>3</b>.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> These inhibitors exhibited excellent antiviral activity against multidrug-resistant HIV-1 variants. Darunavir (TMC-114, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) has been recently approved by the FDA.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> It has displayed a high genetic barrier to resistance and retained high potency against multidrug resistant HIV-1 strains. It has been demonstrated that resistance to <b>1a</b> is significantly delayed compared to other approved PIs.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19-21)</a></div><div class="NLM_p">Our structure-based design of <b>1a</b> and other PIs is inspired by the premise that an inhibitor engaged in multiple interactions, especially hydrogen bonding with the HIV protease backbone atoms, should retain these affinities with mutant strains.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> As the enzyme backbone conformation is only minimally distorted when mutations occur, backbone atoms−PI interactions are likely maintained, therefore sustaining the inhibitor affinity and potency. Inhibitor <b>1a</b>’s superb resistance profile likely originates from the extensive interactions the inhibitor makes within the HIV-1 protease’s binding site and particularly with the backbone atoms of the enzyme.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> Extensive studies of <b>1a</b>-bound HIV-1 protease crystal structures have consistently revealed tight hydrogen bonding between the inhibitor and the protease backbone.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23-25)</a> The stereochemically defined bis-tetrahydrofuran (bis-THF) P<sub>2</sub> ligand in <b>1a</b> forms a strong hydrogen bonding network between its two cyclic ether oxygens and the backbone amide NH bonds of the protease residues, Asp29 and Asp30.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> These observations likely provide explanations for <b>1a</b>’s outstanding antiviral activity. Not surprisingly, several other protease inhibitors featuring the bis-THF as the P<sub>2</sub> ligand have exhibited equally impressive antiviral activities and resistance profiles.<a onclick="showRef(event, 'ref22 ref26'); return false;" href="javascript:void(0);" class="ref ref22 ref26">(22, 26)</a></div><div class="NLM_p last">The bis-THF ligand represents an intriguing pharmacophoric scaffold for the development of PIs to combat drug resistance. To further optimize the bis-THF structural template, we have now investigated ligands that could enhance the backbone-binding as well as improve hydrophobic interactions with the protease active site. The X-ray structure of <b>1a</b>-bound HIV-1 protease has shown a distance of about 3.0−3.2 Å between the bis-THF cyclic oxygens and the Asp30 NH amide bond, while a shorter 2.9 Å distance was observed with the Asp29 NH bond.<a onclick="showRef(event, 'ref23 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref25">(23, 25)</a> In order to maximize and promote closer hydrogen bonding with the Asp30 backbone NH bond, we thought a larger ring on the P<sub>2</sub> ligand should increase the dihedral angle of the bicyclic acetal, bring the oxygen closer, give more flexibility to the structure, and offer a more optimal alignment of the cyclic oxygen with the Asp30 NH bond. Such factors could realistically promote tighter hydrogen bonding with the Asp30 backbone NH bond. Besides, this extra methylene group in the “inner” ring would also provide more favorable van der Waals interactions within the hydrophobic pocket created by Ile47, Val32, Ile84, Leu76, and Ile50′ residues in the protease S<sub>2</sub> subsite. In addition, a larger ring could potentially lead to better flexibility and adaptability to protease mutations. Herein, we report the design, synthesis, and biological evaluation of a series of highly potent PIs that combined a (<i>R</i>)-hydroxyethylsulfonamide isostere with the furopyranol ligand (−)-<b>7</b>. Among all inhibitors of the series, <b>35a</b> showed the most impressive inhibitory and antiviral activity (<i>K</i><sub>i</sub> = 2.7 pM, IC<sub>50</sub> = 0.5 nM). Moreover, inhibitor <b>35a</b> was evaluated against a panel of multidrug-resistant HIV-1 viruses. It retained potent activity against a variety of multidrug-resistant clinical HIV-1 strains with EC<sub>50</sub> values in low nanomolar range, which is superior to other PIs and comparable to <b>1a</b>. Modeling of <b>35a</b> based upon the X-ray structure of <b>1b</b>-bound HIV-1 protease active site has provided critical molecular insight into the ligand-binding site interactions.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63534" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63534" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of enantiomerically pure (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-ol is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. It was achieved starting from known enantiomerically pure lactone <b>4</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Lactone <b>4</b> was reduced into the corresponding diol using lithium aluminum hydride in 95% yield. Selective monoacetylation at the primary alcohol using AcCl and 2,4,6-collidine at −78 °C <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and subsequent silylation of the remaining free hydroxyl furnished intermediate <b>5</b> in 86% yield (two steps). Removal of the acetate group, followed by ozonolysis of the olefin, furnished a bicyclic bis-acetal intermediate. Reduction of the hemiacetal moiety using Et<sub>3</sub>SiH and BF<sub>3</sub>−Et<sub>2</sub>O afforded bicyclic intermediate <b>6</b> in 55% yield in three steps. Removal of the silyl group with TBAF in THF furnished the desired hexahydrofuropyran-4-ol ligand (−)-<b>7</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Ligand (−)-<b>7</b> and Its Respective Enantiomer (+)-<b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To demonstrate the importance of the absolute stereochemistry of the bicyclic structure of ligand (−)-<b>7</b>, its corresponding enantiomer (+)-<b>7</b> was synthesized starting from intermediate <b>8</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Intermediate <b>8</b> was synthesized by an enzyme-catalyzed desymmetrization of cyclopentene <i>meso</i>-diacetate followed by a Claisen rearrangement step.<a onclick="showRef(event, 'cit27b ref29'); return false;" href="javascript:void(0);" class="ref cit27b ref29">(27b, 29)</a> The resulting diester was reduced by LAH to provide <b>8</b>. It was used for the synthesis of (+)-<b>7</b> and subjected to the same synthetic sequence applied from lactone (−)-<b>4</b> in the synthesis of (−)-<b>7</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). To examine the importance of each of the two cyclic ether oxygens in the furopyranol ligand (−)-<b>7</b>, we prepared the corresponding cyclohexane and cyclopentane derivatives (Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Furocyclohexanol P<sub>2</sub> Ligand (−)-<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of 4-hydroxyoctahydrobenzofuran ligand (−)-<b>12</b> is shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Reaction of diazocyclohexanedione <b>9</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> with ethyl vinyl ether in presence of a catalytic amount of Rh<sub>2</sub>(OAc)<sub>4</sub> at 23 °C gave derivative <b>10</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Hydrogenation of the ketofuran in the presence of Pd/C under H<sub>2</sub> (1 atm) furnished the corresponding crude ketone <b>11</b> as a 9:1 mixture of diastereoisomers. A one-pot procedure involving L-selectride reduction of the ketone followed by Et<sub>3</sub>SiH/TMSOTf-promoted reduction of the acetal furnished the racemic alcohol (±)-<b>12</b> (71% from <b>10</b>). Enzymatic resolution of (±)-<b>12</b> using lipase Amano PS-30 provided the desired enantiopure alcohol (−)-<b>12</b> (98.8% ee by chiral HPLC analysis of the 2,4-dinitrobenzoate derivative), after ∼55% conversion to the acetate.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Ligands (−)-<b>18</b> and (−)-<b>19</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of cyclopentapyranol ligand (−)-<b>18</b> is shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Pentanone <b>14</b> was treated with LDA and then reacted with <i>tert</i>-butyldimethylsilyloxypropionaldehyde<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> to furnish intermediate <b>15</b> (dr 3:1) in 95% yield. A DMSO-TFAA promoted oxidation of the free hydroxy group followed by TFA-promoted cyclocondensation furnished the bicyclic α,β-unsaturated ketone <b>16</b>. Hydrogenation in presence of 10% Pd/C followed by L-selectride reduction of the ketone gave racemic alcohol (±)-<b>18</b> as a single diastereomer in 68% yield over two steps. Lipase-catalyzed resolution of the alcohol provided enantiomerically pure alcohol (−)-<b>18</b>. For the synthesis of a P2 ligand devoid of any cyclic oxygen, known tetrahydroindanone <b>17</b><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> was similarly hydrogenated in presence of 10% Pd/C to give the corresponding bicyclic ketone. Accordingly, L-selectride-promoted reduction of the ketone provided the corresponding alcohol (dr = 10:1, as observed by <sup>1</sup>H and <sup>13</sup>C NMR). Lipase-mediated resolution of the major <i>cis</i>-alcohol gave the respective chiral ligand (−)-<b>19</b> (90% ee determined by chiral HPLC).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Hexahydrofuro[3,4-<i>b</i>]pyran-4-ol Ligand <b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since the introduction of a six-membered ring in the P<sub>2</sub> ligand structure may introduce more structural flexibility, we set out to explore ligands in which the cyclic oxygens were moved to adjacent positions. Such ligands would also demonstrate the importance of the oxygen positions in the bicyclic structure of ligand (−)-<b>7</b>. Thus, isomeric ligand <b>25</b> was synthesized with the furan oxygen moved to its vicinal position. The synthesis of 4-hydroxyhexahydro-2<i>H</i>-furo[3,4-<i>b</i>]pyran <b>25</b> is shown in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Iodoalkoxylation of the 2,5-dihydrofuran <b>22</b> using propanediol in the presence of <i>N</i>-iodosuccinimide and catalytic NH<sub>4</sub>OAc provided iodo alcohol <b>23</b>. Swern oxidation gave aldehyde <b>24</b> in 86% yield. An intramolecular Barbier-type reaction was then conducted using indium in the presence of copper(I) iodide and iodine to furnish a mixture of diastereoisomeric alcohols.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Oxidation followed by stereoselective reduction using NaBH<sub>4</sub> furnished the racemic <i>cis,cis</i>-bicyclic alcohol (±)-<b>25</b> as the sole product. Lipase-mediated resolution finally gave the enantiomerically pure alcohol <b>25</b>.</div><div class="NLM_p">To ascertain the importance of the position of the urethane in (−)-<b>7</b>, we have synthesized hexahydrofuropyran-5-ol ligand <b>30</b> shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. The free hydroxyl on the pyran ring was moved to the C3 position. The synthesis was accomplished starting from enantiomerically pure bis-THF ligand <b>27</b> synthesized by us previously.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Dess−Martin oxidation of <b>27</b> provided the corresponding ketone. Homologation of the resulting ketone using trimethylsilyldiazomethane in the presence of AlMe<sub>3</sub> followed by treatment of the crude mixture with TBAF and acetic acid provided furanopyranone <b>29</b>. Stereoselective reduction of ketone <b>29</b> using L-selectride furnished alcohol <b>30</b> as a mixture of inseparable diastereoisomers (dr = 5:1). Both isomers were separated after formation of the corresponding activated mixed carbonate <b>31g</b>.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Hexahydrofuro[2,3-<i>b</i>]pyran-5-ol Ligand <b>30</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of the protease inhibitors was accomplished in a two-step sequence shown in Schemes <a class="ref internalNav" href="#sch6" aria-label="6">6</a> and <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. Each ligand alcohol synthesized above was reacted with 4-nitrophenyl chloroformate in the presence of pyridine to form mixed activated carbonates <b>31a</b>−<b>g</b> in 70−99% yield. The syntheses of the corresponding protease inhibitors were achieved by coupling the mixed activated carbonates with previously reported hydroxyethylsulfonamide isosteres <b>32</b>−<b>34</b> (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>).<a onclick="showRef(event, 'ref15 ref35'); return false;" href="javascript:void(0);" class="ref ref15 ref35">(15, 35)</a> The syntheses of various HIV-PIs containing the Tp-THF (−)-<b>7</b> were achieved by respectively treating the Boc-protected isosteres <b>32</b>−<b>34</b> with TFA in CH<sub>2</sub>Cl<sub>2</sub> and subsequently by coupling the resulting free amine isosteres with activated mixed carbonate <b>31a</b> in THF/CH<sub>3</sub>CN in the presence of Et<sub>3</sub>N. The corresponding inhibitors <b>35a</b>, <b>36</b>, and <b>37</b> were obtained in good yields (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>). Inhibitors <b>35b</b>−<b>g</b> were made in a similar manner.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Activated Mixed Carbonates <b>31a</b>−<b>g</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Syntheses of Inhibitors <b>35a</b>−<b>g</b>, <b>36</b>, and <b>37</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned above, our preliminary modeling suggested that a hexahydrofuropyranol (−)-<b>7</b> ligand may interact with backbone atoms and residues in the protease S2-site. All inhibitors in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> were evaluated in enzyme inhibitory assays following a protocol described by Toth and Marshall.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Inhibitors that showed potent <i>K</i><sub>i</sub> values were further evaluated through in vitro antiviral assays. As can be seen, inhibitor <b>35a</b>, with Tp-THF (−)-<b>7</b>, exhibited an enzyme <i>K</i><sub>i</sub> value of 2.7 pM. Antiviral activity of <b>35a</b> and other inhibitors were determined in MT-2 human-T-lymphoid cells exposed to HIV-1<sub>LAI</sub>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> As shown, <b>35a</b> has displayed remarkable antiviral potency (IC<sub>50</sub> = 0.5 nM), comparable to those of PIs <b>1a</b> and <b>1b</b>. The bicyclic ring stereochemistry of the P<sub>2</sub> ligand proved to be important as inhibitor <b>35b</b>, with enantiomeric ligand (+)-<b>7</b>, displayed a significant reduction in enzyme inhibitory potency (>20-fold increase in <i>K</i><sub>i</sub>) as well as antiviral activity (IC<sub>50</sub> = 19 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Enzymatic Inhibitory and Antiviral Activity of Compounds <b>35a</b>−<b>g</b>, <b>36</b>, and <b>37</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></div></div></div><div class="scrollable-table-wrap"><table class="table single-image frame_bottom"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0005.gif" alt="" id="fx1" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are the mean of at least two experiments.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Human T-lymphoid (MT-2) cells (2 × 10<sup>3</sup>) were exposed to 100 TCID<sub>50</sub> of HIV-1<sub>LAI</sub> and cultured in the presence of each PI, and IC<sub>50</sub> values were determined using the MTT assay. The IC<sub>50</sub> values of amprenavir (APV), saquinavir (SQV), and indinavir (IDV) were 0.03, 0.015, and 0.03 μM, respectively.</p></div></div></div><div class="NLM_p">To probe the importance of the cyclic ether oxygens in the bicyclic structure of (−)-<b>7</b>, inhibitors <b>35c</b>−<b>e</b> were synthesized and evaluated. As shown, inhibitor <b>35c</b>, with a cyclohexane ring in place of the tetrahydropyran ring, only displayed a 2-fold reduction in <i>K</i><sub>i</sub> values but a 16-fold decrease in antiviral activity compared to inhibitor <b>35a</b>. A more dramatic loss of enzymatic potency was observed with compound <b>35d</b> with a cyclopentane ring in place of a THF ring in the P2 ligand. The <i>K</i><sub>i</sub> value dropped to 1.43 nM. Inhibitor <b>35e</b>, which lacks both cyclic ether oxygens, displayed even lower <i>K</i><sub>i</sub> and no appreciable antiviral activity. Those results clearly demonstrated the critical role of both cyclic ether oxygens in ligand (−)-<b>7</b>. Furthermore, the difference of activity observed between <b>35a</b> and <b>35c</b> suggests that the O1 oxygen on the THF-ring of (−)-<b>7</b> exerts a stronger interaction with the enzyme compared to the pyran oxygen. Inhibitor <b>35f</b>, in which the THF-oxygen of the P<sub>2</sub> ligand is located at a vicinal position, also exhibited a substantial loss of potency (i.e., <i>K</i><sub>i</sub> = 5.3 nM) and no antiviral activity. These results corroborated our previous observations with the bis-THF ligand in PIs <b>1a</b> and <b>1b</b>. The THF-oxygen in (−)-<b>7</b> likely has a stronger hydrogen bonding interaction with the Asp29 backbone NH and may form a weak hydrogen bond with Asp30, in the S<sub>2</sub> subsite of the HIV protease. We have investigated the position of the urethane oxygen on the bicyclic ligand in inhibitor <b>35g</b>. This has resulted in a substantial loss of protease inhibitory activity. Furthermore, we have examined the potency enhancing effect of the Tp-THF ligand with various hydroxyethylsulfonamide isosteres to give inhibitors <b>36</b> and <b>37</b>. The 4-methoxysulfonamide derivative <b>35a</b> appears to be the most potent inhibitor in the series comparable to inhibitor <b>2</b>. However, the 4-amino derivative <b>36</b> exhibited very comparable enzyme inhibitory and antiviral potency similar to <b>1a</b>.</div><div class="NLM_p">We have examined inhibitor <b>35a</b> for its activity against a panel of multidrug-resistant HIV-1 variants and compared it with that of other clinically available PIs including <b>1a</b>. The results are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. All inhibitors showed high antiviral activity against an HIV-1 clinical strain isolated from a drug-naive patient (wild-type).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Compound <b>35a</b> displayed the most potent activity with an EC<sub>50</sub> of 1.9 nM. When tested against multidrug-resistant HIV-1 variants, compound <b>35a</b> retained impressively high activity to all variants with EC<sub>50</sub> values ranging from 2.6 to 27.5 nM. In contrast, other inhibitors, except <b>1a</b>, exhibited substantial loss of activity. Interestingly, <b>1a</b> and <b>35a</b> showed similar fold-change of EC<sub>50</sub> against most multidrug-resistant HIV strains. The results indicated that <b>35a</b> is highly active against multidrug-resistant HIV-1 variants. This inhibitor outperformed the clinically available PIs with exceedingly high antiviral activity and compared well with <b>1a</b>, which currently stands as the leading PI for the treatment of drug-resistant HIV infection.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of the Antiviral Activity of <b>35a</b> and Other PIs against Multidrug Resistant Clinical Isolates in PHA-PBMs Cells<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="4" align="center">EC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">virus</th><th class="colsep0 rowsep0" align="center"><b>35a</b></th><th class="colsep0 rowsep0" align="center">ATV</th><th class="colsep0 rowsep0" align="center">LPV</th><th class="colsep0 rowsep0" align="center">DRV (<b>1a</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>ERS104pre</sub> (X4)</td><td class="colsep0 rowsep0" align="left">0.0019 ± 0.0015</td><td class="colsep0 rowsep0" align="left">0.0027 ± 0.0006</td><td class="colsep0 rowsep0" align="left">0.031 ± 0.004</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>MDR/B</sub> (X4)</td><td class="colsep0 rowsep0" align="left">0.0145 ± 0.0001 (8)</td><td class="colsep0 rowsep0" align="left">0.470 ± 0.007 (174)</td><td class="colsep0 rowsep0" align="left">>1 (>32)</td><td class="colsep0 rowsep0" align="left">0.034 ± 0.008 (9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>MDR/C</sub> (X4)</td><td class="colsep0 rowsep0" align="left">0.0037 ± 0.0018 (2)</td><td class="colsep0 rowsep0" align="left">0.039 ± 0.003 (14)</td><td class="colsep0 rowsep0" align="left">0.437 ± 0.004 (14)</td><td class="colsep0 rowsep0" align="left">0.009 ± 0.005 (2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>MDR/G</sub> (X4)</td><td class="colsep0 rowsep0" align="left">0.0026 ± 0.0004 (1)</td><td class="colsep0 rowsep0" align="left">0.019 ± 0.008 (7)</td><td class="colsep0 rowsep0" align="left">0.181 ± 0.023 (6)</td><td class="colsep0 rowsep0" align="left">0.026 ± 0.009 (7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>MDR/TM</sub> (X4)</td><td class="colsep0 rowsep0" align="left">0.0275 ± 0.0055 (14)</td><td class="colsep0 rowsep0" align="left">0.075 ± 0.003 (28)</td><td class="colsep0 rowsep0" align="left">0.423 ± 0.082 (14)</td><td class="colsep0 rowsep0" align="left">0.022 ± 0.015 (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>MDR/MM</sub> (R5)</td><td class="colsep0 rowsep0" align="left">0.0050 ± 0.0023 (3)</td><td class="colsep0 rowsep0" align="left">0.205 ± 0.024 (76)</td><td class="colsep0 rowsep0" align="left">0.762 ± 0.115 (25)</td><td class="colsep0 rowsep0" align="left">0.017 ± 0.005 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV-1<sub>MDR/JSL</sub> (R5)</td><td class="colsep0 rowsep0" align="left">0.0275 ± 0.0009 (14)</td><td class="colsep0 rowsep0" align="left">0.293 ± 0.099 (109)</td><td class="colsep0 rowsep0" align="left">>1 (>32)</td><td class="colsep0 rowsep0" align="left">0.023 ± 0.005 (6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">The amino acid substitutions identified in the protease-encoding region of HIV-1<sub>ERS104pre</sub>, HIV-1<sub>B</sub>, HIV-1<sub>C</sub>, HIV-1<sub>G</sub>, HIV-1<sub>TM</sub>, HIV-1<sub>MM</sub>, HIV-1<sub>JSL</sub> compared to the consensus type B sequence cited from the Los Alamos database include L63P; L10I, K14R, L33I, M36I, M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, I93L; L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q,V82A, L89M; L10I, V11I, T12E, I15V, L19I, R41K, M46L, L63P, A71T, V82A, L90M; L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M; I93L, L10I, K43T, M46L, I54V, L63P, A71V, V82A, L90M, Q92K; and L10I, L24I, I33F, E35D, M36I, N37S, M46L, I54V, R57K, I62V, L63P, A71V, G73S, V82A, respectively. HIV-1<sub>ERS104pre</sub> served as a source of wild-type HIV-1. The EC<sub>50</sub> values were determined by using PHA-PBMs as target cells, and the inhibition of p24 Gag protein production by each drug was used as an end point. The numbers in parentheses represent the fold changes of EC<sub>50</sub> values for each isolate compared to the EC<sub>50</sub> values for wild-type HIV-1<sub>ERS104pre</sub>. All assays were conducted in duplicate, and the data shown represent mean values (±1 standard deviations) derived from the results of two or three independent experiments.</p></div></div></div><div class="NLM_p">In order to obtain molecular insights into the enzyme−inhibitor interactions of <b>35a</b> in the protease active site, an active model of <b>35a</b> was created. A stereoview of the overlaid structure of <b>35a</b> with the X-ray structure of inhibitor <b>1b</b>-bound HIV-1 protease is shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. Inhibitor <b>35a</b> was modeled starting from the X-ray crystal structure of <b>1b</b>. The conformation of <b>35a</b> was optimized using the MMFF94 force field,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> as implemented in Molecular Operating Environment (version 2009.10, Chemical Computing Group, Montreal, Canada). The modeled structure maintains the important binding interactions (hydroxyl group with Asp25 and Asp25′ carboxylates; cyclic ether oxygens with Asp29 and Asp30 backbone NH bonds; methoxy oxygen with the Asp30′ backbone NH bond; carbonyl oxygen and sulfonamide oxygen with a water molecule binding to Ile50 and Ile50′) that are observed in the crystal structure of <b>1b</b>-bound HIV-1 protease.</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Stereoview of inhibitor <b>35a</b> modeled into the active site of HIV-1 protease and superimposed on the X-ray crystal structure of <b>1b</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I7E">3I7E</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have reported the structure-based design of novel HIV-1 protease inhibitors incorporating a stereochemically defined 4-hexahydrofuropyranol-derived urethanes as the P2-ligand. The inhibitors were designed to make extensive interactions including hydrogen bonding with the protein backbone of the HIV-1 protease active site. The synthesis of (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-ol [(−)-<b>7</b>, Tp-THF] was carried out in optically active form using (3a<i>R</i>,6a<i>S</i>)-3,3a,6,6a-tetrahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-2-one as the starting material. Inhibitor <b>35a</b> has shown excellent enzyme inhibitory activity and antiviral potency comparable to that of approved PI <b>1a</b>. Furthermore, it has shown excellent activity against multi-PI-resistant variants, superior to other FDA approved inhibitors examined. The data are comparable to those of <b>1a</b>. We have carried out detailed structure−activity studies that indicated that the stereochemistry of the Tp-THF ligand and position of its oxygens are critical to the ligand’s high enzyme affinity. An active model of <b>35a</b> was created based upon the X-ray crystal structure of <b>1b</b>-bound HIV-1 protease. The overlaid structures revealed that both oxygens of the Tp-THF ligand can interact with the Asp29 and Asp30 backbone NHs, similar to the bis-THF ligand oxygens. Furthermore, the extra methylene unit in the Tp-THF ligand appears to fill in the hydrophobic pocket in the S2-site more effectively compared to the bis-THF in <b>1a</b>. The design of an inhibitor targeting the protein backbone may serve as an important guide to combat drug resistance. Further design and chemical modifications are currently underway.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Experimental Methods</h3><div class="NLM_p last">All anhydrous solvents were obtained according to the following procedures: diethyl ether and tetrahydrofuran (THF) were distilled from sodium/benzophenone under argon; toluene, methanol, acetonitrile, and dichloromethane were distilled from calcium hydride; benzene was distilled from sodium. Other solvents were used without purification. All moisture-sensitive reactions were carried out in flame-dried flasks under argon atmosphere. Reactions were monitored by thin layer chromatography (TLC) using Silicycle 60A-F254 silica gel precoated plates. Flash column chromatography was performed using Silicycle 230−400 mesh silica gel. Yields refer to chromatographically and spectroscopically pure compounds. Optical rotations were recorded on a Perkin-Elmer 341 polarimeter. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Varian Inova-300 (300 and 75 MHz), Bruker Avance ARX- 400 (400 and 100 MHz), or DRX- 500 (500 and 125 MHz). High and low resolution mass spectra were carried out by the Mass Spectroscopy Center at Purdue University. The purity of all test compounds was determined by HRMS and HPLC analysis in the different solvent systems. All test compounds showed ≥95% purity.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (1<i>S</i>,2<i>R</i>)-2-[1-(<i>tert</i>-Butyldimethylsilyloxy)cyclopent-3-en-2-yl]ethyl Acetate (<b>5</b>)</h3><div class="NLM_p">To a stirred suspension of lithium aluminum hydride (93 mg, 2.45 mmol) in dry Et<sub>2</sub>O (6 mL) was added dropwise a solution of (−)-(1<i>S</i>,5<i>R</i>)-2-oxabicyclo[3.3.0]oct-6-en-3-one (<b>4</b>) (150 mg, 1.19 mmol) in Et<sub>2</sub>O (4 mL + 1 mL rinse) at 0 °C under argon. The reaction mixture was vigorously stirred at this temperature for 1.5 h. Water (0.1 mL) was then carefully added followed by addition of 3 M NaOH (0.1 mL) and then water (0.3 mL). The solution was stirred until formation of a white precipitate was complete. EtOAc (3 mL) and then Na<sub>2</sub>SO<sub>4</sub> were added, and the resulting suspension was filtered out. The amorphous solid was washed several times with EtOAc (5 × 5 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude oil was purified by flash chromatography on silica gel using hexanes/EtOAc (1:1) as the eluent to give the resulting diol (145 mg, 95%) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.28 (hexanes/EtOAc = 1:2). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 5.74 (m, 1H), 5.56 (m, 1H), 4.48 (dt, <i>J</i> = 2.4, 6.6 Hz, 1H), 3.84 (m, 1H), 3.71 (ddd, <i>J</i> = 3.6, 8.7, 10.0 Hz, 1H), 2.75 (m, 1H), 2.67 (m, 1H), 2.36 (d, <i>J</i> = 17.1 Hz, 1H), 1.98−1.75 (m, 1H).</div><div class="NLM_p">To a stirred solution of the diol (76 mg, 0.59 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added 2,4,6-collidine (1.2 mmol, 155 μL) followed by acetyl chloride (50 μL, 0.71 mmol) at −78 °C under argon. The resulting solution was stirred at this temperature for 5 h at which point additional acetyl chloride (0.25 μL, 0.24 mmol) was added. The solution was stirred for 2 h, and then saturated aqueous NaHCO<sub>3</sub> solution was added. The two layers were separated, and the aqueous layer was washed with CH<sub>2</sub>Cl<sub>2</sub> (3 × 5 mL). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude oil was purified by flash chromatography on silica gel using hexanes/EtOAc (6:1, then 4:1) as the eluent to give the monoacetate (88 mg, 87%) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.26 (hexanes/EtOAc = 2:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 5.80−5.72 (m, 1H), 5.64−5.58 (m, 1H), 4.40 (dt, <i>J</i> = 2.4, 5.6 Hz, 1H), 4.20 (t, <i>J</i> = 7.2 Hz, 2H), 2.74−2.56 (m, 2H), 2.33 (d, <i>J</i> = 17.1 Hz, 1H), 2.06 (s, 3H), 2.04−1.88 (m, 1H), 1.87−1.73 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 171.1, 132.4, 128.4, 72.7, 63.9, 47.2, 42.1, 26.8, 21.0. HRMS-ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub>H<sub>15</sub>O<sub>3</sub> 171.1021; found 171.1020.</div><div class="NLM_p last">To a stirred solution of the above acetate (54 mg, 0.32 mmol) and 2,6-lutidine (74 μL, 0.63 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added <i>tert</i>-butyldimethylsilyl trifluoromethanesulfonate (125 mg, 108 μL) at −78 °C under argon. The mixture was stirred for 10 min, at which point reaction completion was observed. Saturated aqueous NaHCO<sub>3</sub> solution (1 mL) and additional CH<sub>2</sub>Cl<sub>2</sub> (2 mL) were added. The two layers were separated, and the aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 2 mL). The combined organic layer was washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude oil was purified by column chromatography on silica gel using hexanes/EtOAc (20:1) as the eluent to afford silylated product <b>5</b> (90 mg, > 99%) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.68 (hexanes/EtOAc = 3:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 5.68 (s, 2H), 4.45 (dt, <i>J</i> = 5.1, 6.3 Hz, 1H), 4.14 (t, <i>J</i> = 6.9 Hz, 2H), 2.67−2.55 (m, 1H), 2.47 (dd, <i>J</i> = 6.9, 15.4 Hz, 1H), 2.23 (dd, <i>J</i> = 4.8, 15.4 Hz, 1H), 2.04 (s, 3H), 2.01−1.85 (m, 1H), 1.72−1.56 (m, 1H), 0.88 (s, 9H), 0.06 (s, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 171.2, 132.7, 128.4, 73.6, 63.8, 45.9, 41.0, 27.4, 25.8, 21.0, 18.1, −4.6, −5.0.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> (4<i>S</i>,4a<i>S</i>,7a<i>R</i>)-4-(<i>tert</i>-Butyldimethylsilyloxy)hexahydrofuro[2,3-<i>b</i>]pyrane (<b>6</b>)</h3><div class="NLM_p">To a stirred solution of <b>5</b> (76 mg, 0.27 mmol) in MeOH (2 mL) was added K<sub>2</sub>CO<sub>3</sub> (37 mg, 0.27 mmol). The solution was stirred at 23 °C for 2 h. Then saturated aqueous NH<sub>4</sub>Cl solution (2 mL) was added to the mixture. EtOAc was added, and the two layers were separated. The aqueous layer was extracted with EtOAc (4 × 3 mL). The combined organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting oil was purified by flash chromatography on silica gel using hexanes/EtOAc (7:1) as the eluent to give the corresponding alcohol (64 mg, 98%) as a colorless oil. This intermediate was used immediately for the subsequent reaction. TLC: <i>R</i><sub><i>f</i></sub> = 0.29 (hexanes/EtOAc = 5:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 5.72.5.62 (m, 2H), 4.52 (dt, <i>J</i> = 6.0, 6.9 Hz, 1H), 3.74−3.60 (m, 2H), 2.80−2.68 (m, 1H), 2.49 (ddt, <i>J</i> = 1.8, 7.2, 16.3 Hz, 1H), 2.34−2.29 (m, 1H), 2.06 (br s, 1H), 1.90−1.62 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 132.9, 128.3, 74.0, 61.1, 46.5, 40.6, 31.2, 25.8, 18.2, −4.7, −5.0.</div><div class="NLM_p last">A stream of ozonized oxygen was bubbled through a solution of the above alcohol (63.8 mg, 0.26 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) at −78 °C until the blue color persisted (5 min). After the solution was flushed with nitrogen, Me<sub>2</sub>S (0.5 mL) was added. The solution was warmed to 0 °C and stirred over a 2 h period following which anhydrous Na<sub>2</sub>SO<sub>4</sub> was added. The solution was left at room temperature overnight and then filtered and concentrated in vacuo. The resulting solid was quickly passed through a short column of silica gel using hexanes/EtOAc (3:1) as the eluent to afford the hemiacetal (99 mg) as a white-solid mixture of isomers which was submitted directly to the next step. TLC: <i>R</i><sub><i>f</i></sub> = 0.26 (hexanes/EtOAc = 3:1). To an ice-cold solution of the crude diacetal (∼0.25 mmol) and Et<sub>3</sub>SiH (0.16 mL, 1.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) under argon, was slowly added BF<sub>3</sub>−Et<sub>2</sub>O (60 μL, 0.5 mmol). The mixture was stirred at 0 °C for 10 min. Saturated aqueous NaHCO<sub>3</sub> solution (2 mL) and additional CH<sub>2</sub>Cl<sub>2</sub> were added. The two phases were separated and the aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 2 mL). The combined organic layer was washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. The crude oil was purified by column chromatography on silica gel using hexanes/EtOAc (7:1) as the eluent to give bicyclic acetal <b>6</b> (38 mg, 55% 3 steps) as an amorphous solid. TLC: <i>R</i><sub><i>f</i></sub> = 0.50 (hexanes/EtOAc = 3:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.95 (d, <i>J</i> = 3.4 Hz, 1H), 4.24−4.08 (m, 2H), 3.92 (dt, <i>J</i> = 8.1, 9.1 Hz, 1H), 3.85 (ddd, <i>J</i> = 2.0, 4.5, 12.2 Hz, 1H), 3.30 (dt, <i>J</i> = 2.0, 12.3 Hz, 1H), 2.39 (m, 1H), 2.07 (tt, <i>J</i> = 9.4, 12.0 Hz, 1H), 1.91−1.66 (m, 2H), 1.58−1.48 (m, 1H), 0.89 (s, 9H), 0.07 (s, 3H), 0.067 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 101.2, 68.4, 67.8, 61.1, 47.2, 30.3, 25.7, 22.4, 18.2, −4.6, −4.8.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4ol [(−)-<b>7</b>]</h3><div class="NLM_p last">Bicyclic compound <b>6</b> (36 mg, 0.139 mmol) was dissolved in THF (1 mL), and tetrabutylammonium fluoride (1 M solution THF, 0.21 mL, 0.21 mmol) was added to the solution. The mixture was stirred for 2 h at 23 °C. Saturated aqueous NH<sub>4</sub>Cl solution was added (2 mL), followed by EtOAc (2 mL). The two phases were separated, and the aqueous layer was further extracted with EtOAc (4 × 3 mL). The combined organic layer was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo. The resulting compound was purified by flash chromatography on silica gel using hexanes/EtOAc (1:2 then 1:3) as the eluent to afford pure alcohol (−)-<b>7</b> (19 mg, 94%) as an amorphous solid. TLC: <i>R</i><sub><i>f</i></sub> = 0.15 (hexanes/EtOAc = 1:3). [α]<sub class="stack">D</sub><sup class="stack">23</sup> −29.6 (<i>c</i> 1.06, CHCl<sub>3</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.99 (d, <i>J</i> = 2.7 Hz, 1H), 4.25−4.16 (m, 2H), 3.96 (q, <i>J</i> = 7.5 Hz, 1H), 3.90 (ddd, <i>J</i> = 2.4, 4.8, 12.3 Hz, 1H), 3.34 (td, <i>J</i> = 3.0, 11.7 Hz, 1H), 2.58−2.45 (m, 1H), 2.14−1.98 (m, 1H), 1.96−1.82 (m, 1H), 1.80−1.62 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 101.4, 68.4, 67.5, 61.0, 46.3, 29.4, 21.8. HRMS-CI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>9</sub>H<sub>15</sub>O<sub>3</sub> 127.0759; found 127.0757.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (3a<i>R</i>,4<i>R</i>,7a<i>S</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-ol [(+)-<b>7</b>]</h3><div class="NLM_p last">Cyclopentenediol <b>8</b> was prepared as described previously.<a onclick="showRef(event, 'cit27b'); return false;" href="javascript:void(0);" class="ref cit27b">(27b)</a> The same synthetic sequence was the applied on the diol as for the synthesis of (−)-<b>7</b>. Ligand (+)-<b>7</b> was obtained in high enantiomeric purity [99% ee, [α]<sub class="stack">D</sub><sup class="stack">23</sup> +22.3 (<i>c</i> 0.22, CHCl<sub>3</sub>)].</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 2-Ethoxy-2,3,6,7-tetrahydrobenzofuran-4(5<i>H</i>)-one (<b>10</b>)</h3><div class="NLM_p last">To a stirred solution of 2-diazo-1,3-cyclohexanedione (300 mg, 2.17 mmol) in freshly distilled ethyl vinyl ether (5 mL) was added [Rh<sub>2</sub>(OAc)<sub>4</sub>] (10 mg, 0.02 mmol). The mixture was stirred at room temperature for 5 h, after which the reaction was diluted with Et<sub>2</sub>O and a few drops of pyridine were added. A red precipitate formed. The solution was filtered on a short pad of silica, flushing with Et<sub>2</sub>O/THF (4:1) as eluent. After evaporation, the residue was purified by column chromatography on silica gel using hexanes/CH<sub>2</sub>Cl<sub>2</sub>/THF (8:1:1) as the eluent to furnish benzofuranone derivative <b>17</b> (347 mg, 88%). TLC: <i>R</i><sub><i>f</i></sub> = 0.29 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 5.72 (dd, <i>J</i> = 3.3, 7.4 Hz, 1H), 3.88 (m, 1H), 3.62 (m, 1H), 2.92 (ddt, <i>J</i> = 2.2, 7.4, 15.8 Hz, 1H), 2.70−2.62 (m, 1H), 2.52−2.37 (m, 2H), 2.33 (t, <i>J</i> = 6.5 Hz, 2H), 2.12−1.95 (m, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 Hz) δ 195.2, 175.7, 112.3, 108.5, 65.0, 36.3, 32.7, 23.8, 21.5, 14.9.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 2-Ethoxyhexahydrobenzofuran-4(2<i>H</i>)-one (<b>11</b>)</h3><div class="NLM_p last">To a solution of the ketone <b>10</b> (140 mg, 0.77 mmol) in EtOAc (9 mL) was added 5% Pd/C (128 mg, 60 μmol), and the mixture was stirred under H<sub>2</sub> (1 atm) for 1.5 h at room temperature. The mixture was then filtered on Celite and the pad washed with EtOAc. Evaporation of the solvent furnished the corresponding crude ketone <b>11</b> as an essentially pure mixture of diastereoisomers (130 mg, dr = 9:1). The ketone was directly submitted to the next step without purification. TLC major isomer: <i>R<sub>f</sub></i> = 0.35 (hexanes/EtOAc = 2:1).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>cis</i>-Octahydrobenzofuran-4-ol [(±)-<b>12</b>]</h3><div class="NLM_p last">A solution of ketone <b>11</b> (130 mg, ca. 0.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was cooled to −78 °C under Ar. L-Selectride (1 M solution, 0.9 mL, 0.9 mmol) was slowly added to the solution over 5 min and the reaction mixture was stirred for 1.5 h at −78 °C. Upon complete conversion, Et<sub>3</sub>SiH (0.6 mL, 437 mg, 3.7 mmol) was added followed by dropwise addition of TMSOTf (380 μL, 466 mg, 2.1 mmol). The solution was stirred for 2.5 h while slowly warming to 0 °C. The reaction was quenched by addition of saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The two phases were separated, and the aqueous phase was extracted with Et<sub>2</sub>O (5×). The combined organic layer was washed with brine, dried (MgSO<sub>4</sub>), and evaporated under vacuum. The residue was purified by column chromatography on silica gel using hexanes/EtOAc (3:1 to 2:1) as the eluent to yield the desired alcohol (±)-<b>12</b> (78 mg, 71% over two steps) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.25 (hexanes/EtOAc = 1:2). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.01 (dt, <i>J</i> = 4.6, 8.8 Hz, 1H), 3.88−3.82 (m, 2H), 3.78 (dt, <i>J</i> = 7.1, 8.7 Hz, 1H), 2.31 (m, 1H), 2.12−1.90 (m, 2H), 1.74−1.50 (m, 5H), 1.32−1.22 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 Hz) δ 77.6, 69.1, 66.7, 43.2, 30.2, 26.9, 25.9, 16.2.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-Octahydrobenzofuran-4-ol [(−)-<b>12</b>]</h3><div class="NLM_p last">Racemic alcohol <b>12</b> (70 mg, 0.5 mmol) was dissolved in THF (5 mL), and vinyl acetate (120 μL, 1.25 mmol) was added. Amano lipase PS-30 (30 mg) was added, and the resulting suspension was stirred at 15−17 °C. After 48 h, 30 mg of additional enzyme was added and the mixture was left for additional 48 h until ∼54% conversion was reached (NMR and GC). The resulting suspension was diluted with Et<sub>2</sub>O and filtered on Celite and the filter cake rinsed with Et<sub>2</sub>O. After evaporation of the remaining solvent, the residue was purified by column chromatography using hexanes/EtOAc (5:1, 3:1, then 2:1) as the eluent to yield acetyl furanol <b>13</b> (38 mg, 41%) and the desired enantioenriched (−)-hexahydrobenzofuranol (−)-<b>12</b> (24 mg, 35%). The enantiomeric excess of the 2,4-dinitrobenzoate derivative of (−)-<b>12</b> was determined to be 98.8% ee by chiral HPLC: column ChiralPak IA, hexane/isopropanol (90/10 to 50/50, 40 min), 1 mL/min, 35 °C, λ = 254 nm, <i>t</i><sub>R</sub> major = 16.54 min, <i>t</i><sub>R</sub> minor = 37.1 min.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-[3-(<i>tert</i>-Butyldimethylsilyl)oxy)-1-hydroxypropyl]cyclopentanone (<b>15</b>)</h3><div class="NLM_p last">A solution of lithium diisopropylamide (14 mmol), freshly prepared by adding <i>n</i>-BuLi (1.6 M solution in hexanes, 8.75 mL, 14 mmol) to diisopropylamine (1.97 mL, 1.42 g, 14 mmol) in THF (30 mL) at 0 °C under argon followed by stirring for 30 min, was cooled to −78 °C, and cyclopentanone <b>14</b> (1.12 mL, 1.07 g, 12.7 mmol) in THF (5 mL) was added dropwise over 10 min. After being stirred at −78 °C for 1.5 h, 3-<i>tert</i>-butyldimethylsilyloxypropionaldehyde (1.55 g, 8.2 mmol) in THF (20 mL) was added dropwise over 5 min. The mixture was stirred for an additional 2 h, and the reaction was quenched by addition of saturated aqueous NH<sub>4</sub>Cl solution (10 mL). Following dilution with Et<sub>2</sub>O, the two phases were separated, and the aqueous phase was extracted with Et<sub>2</sub>O (2×). The combined organic phase was washed with brine, dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was quickly purified by column chromatography on silica gel using hexanes/EtOAc (20:1 to 10:1) as the eluent to give <b>15</b> as a 3:1 mixture of diastereoisomers (2.13 g, 95%). Light yellow oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.37 and 0.23 (hexanes/EtOAc = 5:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.27 (dt, <i>J</i> = 3.1, 9.3 Hz, 0.3H), 4.10 (s, 1H), 3.91 (m, 1H), 3.87 (m, 0.3H), 3.85−3.75 (m, 2.6H), 2.38−2.30 (m, 6.5H), 1.80−1.56 (m, 5.2H), 0.88 (brs, 12H), 0.06 (s, 2H), 0.05 (s, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 222.8, 220.4, 70.4, 70.2, 62.6, 60.5, 54.5, 53.9, 39.1, 38.7, 37.0, 36.6, 26.4, 25.9, 25.8, 23.5, 20.7, 20.5, 18.2, −5.5, −5.6. HRMS-CI (<i>m</i>/<i>z</i>): [M − OH]<sup>+</sup> calcd for C<sub>14</sub>H<sub>27</sub>O<sub>2</sub>Si 255.1780; found 255.1785.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 2,3,6,7-Tetrahydrocyclopenta[<i>b</i>]pyran-4(5<i>H</i>)-one (<b>16</b>)</h3><div class="NLM_p">To a solution of DMSO (425 μL, 468 mg, 6 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added (CF<sub>3</sub>CO)<sub>2</sub>O (406 μL, 609 mg, 2.9 mmol) dropwise at −78 °C under argon. The resulting mixture was stirred at that temperature for 45 min. Then a precooled solution of ketone <b>15</b> (272 mg, 1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added. The reaction mixture was stirred at −78 °C for 30 min, then at −15 °C for 15 min and cooled back to −78 °C. Et<sub>3</sub>N (1.25 mL, 911 mg, 9 mmol) was added, and the mixture was stirred at −78 °C for 45 min. The reaction was quenched by addition of saturated aqueous NH<sub>4</sub>Cl solution and the mixture warmed to room temperature. The two phases were separated and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×) and then EtOAc (1×). The combined organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography using hexanes/EtOAc (20:1, then 15:1 with a few drops of acetic acid) as the eluent to give the corresponding diketone (221 mg, 82%) as a light orange oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.37 (hexanes/EtOAc = 10:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 12.7 (br s, 1H), 3.90 (t, <i>J</i> = 6.2 Hz, 0.66H), 3.89 (t, <i>J</i> = 6.5 Hz, 2H), 3.46 (t, <i>J</i> = 7.8 Hz, 0.33H), 2.86 (dt, <i>J</i> = 3.0, 6.2 Hz, 0.66H), 2.58 (t, <i>J</i> = 7.2 Hz, 2H), 2.45 (t, <i>J</i> = 6.5 hz, 2H), 2.40 (t, <i>J</i> = 7.9 Hz, 2H), 2.31−2.19 (m, 0.66H), 2.10−1.97 (m, 0.66H), 1.95−1.82 (m, 2H), 0.86 (s, 9H), 0.86 (s, 3H), 0.04 (s, 1H), 0.03 (s, 1H), 0.03 (s, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 212.9, 206.1, 203.6, 175.4, 110.9, 62.4, 59.6, 58.5, 45.6, 38.7, 37.8, 37.0, 25.7, 25.6, 25.0, 20.6, 20.3, 18.1, −5.6. HRMS-CI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>26</sub>O<sub>3</sub>Si 271.1729; found 271.1733.</div><div class="NLM_p last">Diketone (54 mg, 0.2 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) and cooled to 0 °C under argon. Trifluoroacetic acid (90 μL, 134 mg, 1.2 mmol) was then added dropwise. The mixture was stirred at 0 °C for 30 min and then warmed to room temperature and stirred for 4 h. As completion was reached, solid NaHCO<sub>3</sub> (∼150 mg) was then added and the mixture diluted with EtOAc. After being stirred for 10 min, the suspension was filtered on a small Celite pad. The solvent was evaporated under reduced pressure and the residue purified by column chromatography on silica gel using hexanes/EtOAc (4:1) as the eluent to furnish α,β-unsaturated ketone <b>16</b> (26 mg, 94%) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.23 (hexanes/EtOAc = 3:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.49 (t, <i>J</i> = 6.9 Hz, 2H), 2.59−2.45 (m, 6H), 1.89 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 189.6, 178.5, 114.5, 69.5, 35.4, 32.6, 25.6, 19.0.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Octahydrocyclopenta[<i>b</i>]pyran-4-ol [(±)-<b>18</b>]</h3><div class="NLM_p">A solution of α,β-unsaturated ketone <b>16</b> (109 mg, 0.79 mmol) in EtOAc (6 mL) was loaded with 10% Pd/C (50 mg, 0.047 mmol) and carefully placed under H<sub>2</sub> (1 atm). The mixture was stirred at room temperature for 12 h. The suspension was then filtered over a Celite pad, the pad washed with EtOAc, and the resulting solution evaporated under reduced pressure. The essentially pure ketone (81 mg) was directly carried out to the next step without further purification. TLC: <i>R</i><sub><i>f</i></sub> = 0.37 (hexanes/EtOAc = 3:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.22−4.15 (m, 2H), 3.69 (td, <i>J</i> = 2.8, 12.0 Hz, 1H), 2.71 (ddd, <i>J</i> = 7.2, 12.3, 15.7 Hz, 1H), 2.48 (dt, <i>J</i> = 4.0, 9.0 Hz, 1H), 2.23 (ddt, <i>J</i> = 1.4, 2.8, 15.7 Hz, 1H), 2.00−1.80 (m, 5H), 1.71−1.63 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 210.2, 82.8, 65.9, 55.1, 38.5, 33.3, 28.4, 22.8.</div><div class="NLM_p last">The ketone was diluted in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under argon and cooled to −78 °C. L-Selectride (1 M solution in THF, 0.80 mL, 0.8 mmol) was added dropwise, and the resulting mixture was stirred at this temperature for 2 h. Hydrogen peroxide (30% aqueous solution, 3 mL) and 3 N NaOH aqueous solution were added, and the mixture was warmed to 23 °C and stirred for 5 h. The phases were separated and the aqueous phase extracted with CH<sub>2</sub>Cl<sub>2</sub> (4×). The combined organic phase was washed with brine, dried (Mg<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using hexanes/EtOAc (4:1, then 1.5:1) as the eluent to yield <i>cis</i>-bicyclic alcohol (±)-<b>18</b> (77 mg, 68% two steps) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.13 (hexanes/EtOAc = 2:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.11 (dt, <i>J</i> = 5.6, 11.1 Hz, 1H), 3.91 (ddd, <i>J</i> = 2.0, 4.5, 11.7 Hz, 1H), 3.84−3.81 (m, 1H), 3.33 (dt, <i>J</i> = 2.3, 11.9 Hz, 1H), 2.17−2.08 (m, 1H), 1.92−1.81 (m, 1H), 1.79−1.55 (m, 7H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ 80.5, 68.3, 65.4, 47.0, 32.6, 29.7, 21.6, 21.3.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (4<i>S</i>,4a<i>S</i>,7a<i>S</i>)-Octahydrocyclopenta[<i>b</i>]pyran-4-ol [(−)-<b>18</b>]</h3><div class="NLM_p last">Racemic alcohol (±)-<b>18</b> (68 mg, 0.48 mmol) was dissolved in THF (5 mL), and vinyl acetate (225 μL, 2.4 mmol) was added. Amano lipase PS-30 (30 mg) was added, and the resulting suspension was stirred at 15−20 °C. The mixture was left stirring for >48 h until around 50% conversion was reached (as seen by NMR). The resulting suspension was diluted with Et<sub>2</sub>O and filtered on Celite, and the filter cake was rinsed with Et<sub>2</sub>O. After evaporation of the remaining solvent, the residue was purified by column chromatography using hexanes/EtOAc (5:1, 3:1, then 1.5:1) to yield the desired enantio enriched pyranol (−)-<b>18</b> (25 mg, 37%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −47.5 (<i>c</i> 1.32, CHCl<sub>3</sub>). An enantiopurity of 94.1% ee for the alcohol was measured by chiral HPLC analysis of the corresponding activated carbonate <b>31d</b>: column ChiralPak IA, 0.7 mL/min, hexanes/IPA (98:2 to 85:15, from 0 to 45 min), λ = 210 nm, <i>T</i> = 30 °C, <i>t</i><sub>R</sub> minor = 22.4 min, <i>t</i><sub>R</sub> major = 23.3 min.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (±)-<i>endo</i>,<i>cis</i>-Bicyclo[4.3.0]nonan-2-ol [(±)-<b>19</b>]</h3><div class="NLM_p last">Enone <b>17</b><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (106 mg, 0.77 mol) was dissolved in THF (10 mL), and the flask was purged with argon. Pd/C 10% (60 mg, 0.06 mmol) was added to the solution, and the resulting suspension was stirred under hydrogen (1 atm). TLC monitoring first shows isomerization of the enone, through migration of the olefin to the internal position, followed by slow formation of the reduced cis-product. After 12 h, the solution was filtered on a pad of Celite and the solvent removed in vacuo. The residue was purifed by flash column chromatography on silica gel using hexanes/EtOAc (30:1 to 10:1) to give the reduced ketone (98 mg, 92%). TLC: <i>R</i><sub><i>f</i></sub> = 0.65 (hexanes/EtOAc = 5:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 2.62−2.54 (m, 1H), 2.48−2.38 (m, 1H), 2.38−2.23 (m, 2H), 2.08−1.98 (m, 1H), 1.94−1.30 (m, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 214.6, 53.1, 42.9, 39.6, 31.0, 27.2, 26.6, 23.8, 23.0. A solution of the ketone (135 mg, 0.98 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was cooled to −78 °C under argon. L-Selectride (1 M solution THF, 1.2 mL) was added dropwise to the solution, and the reaction mixture was stirred at −78 °C for 1 h. Hydrogen peroxide solution (30% solution, 1.5 mL) and then NaOH (3 M solution, 1.5 mL) were added, and the mixture was warmed to 23 °C and stirred for 1 h. After dilution with water (2 mL) and then addition of Na<sub>2</sub>SO<sub>3</sub> saturated aqueous solution (3 mL), the aqueous phase was successively extracted with CH<sub>2</sub>Cl<sub>2</sub> (4×). The combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated in vacuo. The residue was purified by column chromatography on silica gel using hexanes/EtOAc (6:1) to yield racemic alcohol (±)-<b>19</b> (92 mg, 66%) as a colorless oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.25 (hexanes/EtOAc = 5:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 3.96 (m, 1H), 2.26−2.17 (m, 1H), 1.93 (m, 1H), 1.79−1.53 (m, 7H), 1.47−1.15 (5 H), 0.96 (dq, <i>J</i> = 3.3, 13.0 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ 71.6, 46.4, 40.1, 31.5, 29.5, 27.0, 23.9, 21.4, 21.2. HRMS-EI (<i>m</i>/<i>z</i>): [M − OH]<sup>−</sup> calcd for C<sub>9</sub>H<sub>15</sub> 122.1096, found 122.1097.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (1<i>R</i>,2<i>S</i>,6<i>R</i>)-Bicyclo[4.3.0]nonan-2-ol [(−)-<b>19</b>]</h3><div class="NLM_p last">Racemic <b>19</b> (86 mg, 0.62 mmol) was dissolved in THF (5 mL), and vinyl acetate (0.5 mL) was added. Amano lipase PS-30 (60 mg) was added, and the resulting suspension was stirred at 23 °C until 50% conversion was reached (NMR) in ∼6 h. The resulting suspension was diluted with Et<sub>2</sub>O and filtered on Celite, and the filter cake was rinsed with Et<sub>2</sub>O. After evaporation of the remaining solvent, the residue was purified by column chromatography using hexanes/EtOAc (8:1, 6:1, then 4:1) to yield acetate <b>21</b> and the desired enantioenriched (−)-indanol (−)-<b>19</b> (38.5 mg, 45% yield). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −28.3° (<i>c</i> 1.02, CHCl<sub>3</sub>), ([α]<sub class="stack">D</sub><sup class="stack">20</sup> lit. −27.2° (<i>c</i> 1.0, CHCl<sub>3</sub>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The enantiomeric excess of the 2,4-dinitrobenzoate derivative was determined to be 89.9% ee by chiral HPLC, column ChiralPak IA, hexane/isopropanol (100/0 to 90/10, 15 min; 90/10 to 80/20, 15 min), 1 mL/min, <i>t</i><sub>R</sub> minor = 16.58 min, <i>t</i><sub>R</sub> major = 19.5 min.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 3-[(4-Iodotetrahydrofuran-3-yl)oxy]propan-1-ol (<b>23</b>)</h3><div class="NLM_p last">To a solution of freshly distilled 2,5-dihydrofuran (700 mg, 0.740 mL, 10 mmol), in a mixture of dry 1,3-propanediol/dimethoxyethane (1:1, 5 mL) at 0 °C under argon was successively added NH<sub>4</sub>OAc (77 mg, 1 mmol), followed by <i>N</i>-iodosuccinimide (11 mmol, 2.47 g). The mixture was warmed to 23 °C and stirred for 12 h protected from light. The reaction was quenched by addition of saturated aqueous Na<sub>2</sub>SO<sub>3</sub> and then diluted with water. The mixture was extracted with Et<sub>2</sub>O/EtOAc (1:1). The combined organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using hexanes/EtOAc (4:1, 3:1, then 2.5:1) to give iodo alcohol <b>23</b> (1.2 g, 45%) as a pale yellow oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.3 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 4.33 (m, 1H), 4.29−4.19 (m, 3H), 4.04 (dd, <i>J</i> = 2.2, 9.8 Hz, 1H), 3.79 (dd, J = 1.5, 9.8 Hz, 1H), 3.76−3.69 (m, 3H), 3.60 (m, 1H), 1.81 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 88.2, 76.1, 71.8, 67.9, 60.6, 32.3, 23.4.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-[(4-Iodotetrahydrofuran-3-yl)oxy]propanal (<b>24</b>)</h3><div class="NLM_p last">Oxalyl chloride (580 mg, 392 μL, 4.6 mmol) was diluted in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) under argon, and the solution was cooled to −78 °C. Dry DMSO (715 mg, 650 μL, 9.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) was added to the cold solution dropwise, and the mixture was stirred for 30 min. A solution of alcohol <b>23</b> (500 mg, 1.83 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was then added slowly, and the mixture was kept stirring for an additional hour at −78 °C. Et<sub>3</sub>N (1.3 g, 1.8 mL, 12.8 mmol) was then introduced. The white suspension was stirred at −78 °C for 20 min and slowly warmed to room temperature. A 0.5 M phosphate buffer solution pH 5.5 (20 mL) was added. The two phases were separated, and the resulting aqueous phase was extracted with Et<sub>2</sub>O (4×). The combined organic phase was dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was purified by flash column chromatography using hexanes/EtOAc (6:1 to 4:1) to yield the desired aldehyde <b>24</b> (433 mg, 86%) as a light yellow oil. TLC: <i>R</i><sub><i>f</i></sub> = 0.76 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 9.77 (t, <i>J</i> = 1.3 Hz, 1H), 4.35 (m, 1H), 4.30−4.19 (m, 3H), 4.04 (dd, <i>J</i> = 2.3, 9.8 Hz, 1H), 3.92 (ddd, <i>J</i> = 5.3, 6.7, 9.5 Hz, 1H), 3.77 (dd, <i>J</i> = 1.7, 10.1 Hz, 1H), 3.75 (ddd, <i>J</i> = 5.2, 6.2, 9.5 Hz, 1H), 2.69 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 200.1, 88.3, 76.1, 71.8, 63.1, 43.7, 23.3.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Hexahydro-2<i>H</i>-furo[3,4-<i>b</i>]pyran-4-ol [(±)-<b>25</b>]</h3><div class="NLM_p">To a solution of aldehyde <b>24</b> (100 mg, 0.37 mmol) in DME (10 mL) was successively added indium (60 mg, 0.55 mmol), CuI (48 mg, 0.25 mmol), and a catalytic amount of iodine (10 mg, 0.037 mmol). After the suspension was stirred for 5 min, water (4 mL) was added and the mixture was stirred at room temperature for 4 h. The suspension was filtered on a Celite pad, washing the pad with THF. The solvent was reduced under vacuum and the resulting aqueous phase acidified with 1 M HCl and saturated with NaCl. The aqueous phase was extracted with EtOAc, and the combined organic phase was dried over MgSO<sub>4</sub>. After filtration and evaporation, the crude was purified by flash column chromatography on silica gel using hexanes/EtOAc (1:1 to 1:5) to provide the bicyclic alcohol (±)-<b>25</b> (25 mg, 47%) as a mixture of diastereoisomers. TLC: <i>R</i><sub><i>f</i></sub> = 0.28 (EtOAc 100%). Pyridinium chlorochromate (74 mg, 0.346 mmol) was added to a suspension of flame-dried 4 Å molecular sieves in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at room temperature under argon. A solution of the above alcohol (25 mg, 0.173 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was transferred to the suspension at 0 °C, and the solution was stirred for 1 h at 0 °C. The reaction was quenched by addition of isopropanol, and the mixture was filtered on a silica pad, flushing with Et<sub>2</sub>O. After evaporation of the solvent, the corresponding ketone thus obtained was used directly in the next step. TLC: <i>R</i><sub><i>f</i></sub> = 0.45 (hexanes/EtOAc = 1:1). The ketone was redissolved in EtOH (1.5 mL). The solution was cooled to −20 °C, and NaBH<sub>4</sub> (25 mg, 0.66 mmol) was added at once. After being stirred at this temperature for 30 min, the reaction was quenched by addition of saturated aqueous NH<sub>4</sub>Cl solution (1.5 mL). The solution was extracted with EtOAc and the combined organic phase dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. The corresponding racemic alcohol (±)-<b>25</b> was purified by flash column chromatography using hexanes/EtOAc (1:1 to 1:5) as the eluent. Colorless oil (12 mg, 50% two steps). TLC: <i>R</i><sub><i>f</i></sub> = 0.25 (100% EtOAc). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 4.26 (m, 1H), 4.05 (t, <i>J</i> = 3.0 Hz, 1H), 4.04−3.95 (m, 3H), 3.94−3.85 (m, 2H), 3.40 (dt, <i>J</i> = 2.5, 11.8 Hz, 1H), 2.60 (m, 1H), 1.94 (d, <i>J</i> = 4.0 Hz, 1H), 1.80 (ddt, <i>J</i> = 4.6, 11.5, 12.5 Hz, 1H), 1.74 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 78.3, 74.5, 67.1, 66.4, 65.0, 45.5, 30.0.</div><div class="NLM_p last">To a solution of racemic (±)-<b>25</b> (10 mg, 0.07 mmol) in dry THF (1 mL) under an argon atmosphere was added vinyl acetate (60 mg, 65 μL, 0.7 mmol) followed by addition of immobilized Amano Lipase PS-30 (10 mg) on Celite-545. The mixture was stirred at 15−20 °C for 2 days until >50% conversion could be observed by NMR of aliquots. The resulting suspension was diluted in Et<sub>2</sub>O and filtered on a small Celite pad. The solvents were evaporated and the residue was purified by flash chromatography using hexanes/EtOAc (1:1 to 1:5) as the eluent to give enantiomeric alcohol <b>25</b> (4.6 mg, 46%) as a colorless oil. An enantiopurity of >99.5% ee for the alcohol was measured by analysis of the corresponding activated carbonate <b>31f</b> on chiral HPLC (column ChiralPak IC, hexane/isopropanol 52:48, 1 mL/min, λ = 215 nm, <i>T</i> = 24 °C, <i>t</i><sub>R</sub> minor = 14.4 min, <i>t</i><sub>R</sub> major = 15.5 min).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (3a<i>R</i>,6a<i>R</i>)-Tetrahydrofuro[2,3-<i>b</i>]furan-3(2<i>H</i>)-one (<b>28</b>)</h3><div class="NLM_p last">Enantiomerically pure (3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-hexahydrofuro[2,3-<i>b</i>]furan-3-ol (bis-THF) <b>27</b> (85 mg, 0.65 mmol) was diluted in dry CH<sub>2</sub>Cl<sub>2</sub> (6 mL) under argon. The solution was cooled to 0 °C, and anhydrous Na<sub>2</sub>HPO<sub>4</sub> (52 mg, 0.36 mol) was added. Dess−Martin periodinane (360 mg, 0.85 mmol) was added at once at 0 °C and the resulting suspension warmed to 23 °C and stirred for 3 h. The reaction was then quenched by successive addition of saturated aqueous NaHCO<sub>3</sub> and saturated aqueous Na<sub>2</sub>SO<sub>3</sub> solutions (1.5 + 1.5 mL). The phases were separated, and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> and then EtOAc. The combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered on a small pad of silica gel, and evaporated to dryness. The residue was purified by column chromatography on silica gel using hexanes/EtOAc (3:1) to furnish ketone <b>28</b> (73 mg, 87%) as a white crystalline solid. TLC: <i>R</i><sub><i>f</i></sub> = 0.57 (hexanes/EtOAc = 1:1). Spectral data corresponded to those previously reported in the literature.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (3a<i>S</i>,7a<i>R</i>)-Tetrahydro-2<i>H-</i>furo[2,3-<i>b</i>]pyran-5(3<i>H</i>)-one (<b>29</b>)</h3><div class="NLM_p last">AlMe<sub>3</sub> (25% w/w hexanes, 250 μL, 0.6 mmol) was diluted in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) under argon, and the solution was cooled to −78 °C. A solution of ketone <b>28</b> (64 mg, 0.5 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was slowly added dropwise. After 10 min, TMSCHN<sub>2</sub> (2 M solution in Et<sub>2</sub>O, 275 μL, 0.55 mmol) was added. The mixture was stirred for 2 h while warming to −30 °C. Saturated Rochelle’s salt solution (5 mL) was added, and the mixture was stirred for 1 h. The phases were separated. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic phase was dried (MgSO<sub>4</sub>). The solution was filtered on a small silica gel pad, flushing with Et<sub>2</sub>O, and the collected organic phase was evaporated. A crude mixture of the desired ketone along with α-silylated derivatives and isomers was then obtained. The mixture was redissolved in THF (5 mL). AcOH (6 drops) and TBAF (0.5 mL, 0.5 mmol) were successively added. The resulting mixture was stirred at 23 °C for 3 h and evaporated to dryness. The residue was purified by flash column chromatography on silica gel using hexanes/EtOAc (5:1) as the eluent to give ketone <b>29</b> (45 mg, 63%). TLC: <i>R</i><sub><i>f</i></sub> = 0.35 (hexanes/EtOAc = 2:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 5.49 (d, <i>J</i> = 6.8 Hz, 1H), 4.11 (d, <i>J</i> = 18.2 Hz, 1H), 4.10 (m, 1H), 3.92 (d, <i>J</i> = 18.2 Hz, 1H), 3.74 (dt, <i>J</i> = 6.5, 8.9 Hz, 1H), 2.85 (m, 1H), 2.71 (d, <i>J</i> = 6.3, 15.6 Hz, 1H), 2.48 (d, <i>J</i> = 3.9, 15.6 Hz, 1H), 2.15 (m, 1H), 1.55 (ddt, <i>J</i> = 7.7, 8.9, 12.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 210.7, 100.9, 67.5, 67.1, 39.2, 36.2, 31.3.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (3a<i>S</i>,5<i>R</i>,7a<i>R</i>)-Hexahydro-2<i>H-</i>furo[2,3-<i>b</i>]pyran-5-ol (<b>30</b>)</h3><div class="NLM_p last">A solution of ketone <b>29</b> (25 mg, 0.173 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was cooled to −78 °C under argon. L-Selectride (1 M in THF, 200 μL, 0.2 mmol) was added dropwise. The solution was stirred at this temperature for 3 h and quenched by addition of saturated aqueous NH<sub>4</sub>Cl solution. The aqueous phase was extracted with EtOAc. The combined organic extract was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. The crude was purified by column chromatography on silica gel using hexanes/EtOAc (2:1, 1:1, then 1:2) to yield alcohol <b>30</b> as a 5:1 mixture of diastereoisomers (18 mg, cis major). The stereoisomers were separated in the subsequent synthesis of the mixed activated carbonate <b>31g</b>. TLC: <i>R</i><sub><i>f</i></sub> = 0.25 (hexanes/EtOAc = 1:2). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 5.08 (d, <i>J</i> = 3.8 Hz, 0.2H), 5.05 (d, <i>J</i> = 3.3 Hz, 1H), 4.16−4.11 (m, 1.2H), 3.95−3.84 (m, 1.6H), 3.81−3.70 (m, 2H), 3.63 (m, 1H), 3.27 (dd, <i>J</i> = 7.9, 11.2 Hz, 0.2H), 2.35−1.70 (m, 6H).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-yl (4-Nitrophenyl) Carbonate (<b>31a</b>)</h3><div class="NLM_p last">Furopyranol ligand (−)-<b>7</b> (9 mg, 0.063 mmol) was diluted in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) under argon. The solution was cooled to 0 °C, and dry pyridine (17 μL, ∼0.21 mmol) was added. 4-Nitrophenyl chloroformate (24 mg, 0.12 mmol) was added at once to the solution, upon which a white precipitate formed. The mixture was stirred for 2 h while warming to room temperature. Upon completion, the mixture was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel using hexanes/EtOAc (6:1, then 3:1) as the eluent to give the corresponding activated carbonate <b>31a</b> (18 mg, >99%). TLC: <i>R</i><sub><i>f</i></sub> = 0.25 (hexanes/EtOAc = 3:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 8.29 (d, <i>J</i> = 8.7 Hz, 2H), 7.39 (d, <i>J</i> = 8.7 Hz, 2H), 5.30−5.19 (m, 1 H), 5.07 (d, <i>J</i> = 2.7 Hz, 1H), 4.28 (dt, <i>J</i> = 3 Hz, 1H), 4.04−3.95 (m, 2H), 3.47−3.37 (m, 1H), 2.80−2.68 (m, 1H), 2.30−2.10 (m, 1H), 2.05−1.90 (m, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 155.3, 151.7, 145.4, 125.3, 121.7, 101.1, 75.4, 68.5, 60.5, 43.2, 25.8, 22.5.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (3a<i>R</i>,4<i>R</i>,7a<i>S</i>)-Hexahydro-2<i>H-</i>furo[2,3-<i>b</i>]pyran-4-yl (4-Nitrophenyl) Carbonate (<b>31b</b>)</h3><div class="NLM_p last">The title compound was obtained from (+)-<b>7</b> as described for (−)-<b>7</b> in 86% yield after purification by column chromatography on silica gel using hexanes/EtOAc (6:1, then 3:1). Spectral data were consistent with those recorded for <b>31a</b>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (3a<i>R</i>,4<i>S</i>,7a<i>R</i>)-Octahydrobenzofuran-4-yl (4-Nitrophenyl) Carbonate (<b>31c</b>)</h3><div class="NLM_p last">The title compound was obtained from (−)-<b>12</b> as described for (−)-<b>7</b> in 83% yield after purification by column chromatography on silica gel using hexanes/EtOAc (8:1 to 6:1). TLC: <i>R</i><sub><i>f</i></sub> = 0.7 (hexanes/EtOAc = 3:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.28 (d, <i>J</i> = 9.2 Hz, 2H), 7.39 (d, <i>J</i> = 9.2 Hz, 2H), 5.07 (m, 1H), 4.13−4.05 (m, 2H), 3.90 (q, <i>J</i> = 8.2 Hz, 1H), 2.72 (m, 1H), 2.10−2.00 (m, 2H), 1.90−1.68 (m, 4H), 1.55−1.45 (m, 1H), 1.34−1.23 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 155.4, 151.9, 145.2, 125.2, 121.7, 77.7, 77.1, 66.5, 41.2, 27.0, 26.2, 25.4, 18.0.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> ((4<i>S</i>,4a<i>R</i>,7a<i>S</i>)-Octahydrocyclopenta[<i>b</i>]pyran-4-yl) (4-Nitrophenyl) Carbonate (<b>31d</b>)</h3><div class="NLM_p last">The title compound was obtained from (−)-<b>18</b> as described for (−)-<b>7</b> in 85% yield after purification by column chromatography on silica gel using hexanes/CH<sub>2</sub>Cl<sub>2</sub>/THF (4:1:0 then 4:1:0.1) as the eluent. TLC: <i>R</i><sub><i>f</i></sub> = 0.31 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.28 (d, <i>J</i> = 9.1 Hz, 2H), 7.38 (d, <i>J</i> = 9.1 Hz, 2H), 5.21 (m, 1H), 4.00 (ddd, <i>J</i> = 1.8, 4.7, 12.0 Hz, 1H), 3.93 (dt, <i>J</i> = 2.5, 2.7 Hz, 1H), 3.43 (dt, <i>J</i> = 2.1, 12.0 Hz, 1H), 2.36 (m, 1H), 2.04−1.82 (m, 4H), 1.82−1.62 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 155.5, 151.9, 145.3, 125.3, 121.8, 80.7, 77.3, 65.0, 43.7, 32.6, 26.3, 22.3, 21.7.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (3a<i>R</i>,4<i>S</i>,7a<i>R</i>)-Octahydro-1<i>H</i>-inden-4-yl (4-Nitrophenyl) Carbonate (<b>31e</b>)</h3><div class="NLM_p last">The title compound was obtained from (−)-<b>19</b> as described for (−)-<b>7</b> in 90% yield after purification by column chromatography on silica gel using hexanes/EtOAc (20:1 to 10:1) as the eluent. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.27 (d, <i>J</i> = 9.1 Hz, 2H), 7.38 (d, <i>J</i> = 9.1 Hz, 2H), 5.05 (m, 1H), 2.41 (m, 1H), 2.05 (m, 1H), 1.98−1.24 (m, 11H), 1.05 (dq, <i>J</i> = 3.4, 12.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 155.7, 151.9, 145.2, 125.2, 121.8, 80.7, 42.8, 40.2, 31.3, 26.6, 25.7, 23.4, 22.4, 21.3.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (4<i>S</i>,4a<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[3,4-<i>b</i>]pyran-4-yl (4-Nitrophenyl) Carbonate (<b>31f</b>)</h3><div class="NLM_p last">The title was obtained from (−)-<b>25</b> as described for (−)-<b>7</b> in >99% yield following column chromatography purification on silica gel using hexanes/EtOAc (3:1, then 2:1) as the eluent. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.29 (d, <i>J</i> = 9.1 Hz, 2H), 7.38 (d, <i>J</i> = 9.1 Hz, 2H), 5.32 (m, 1H), 4.20−3.88 (m, 6H), 3.50 (m, 1H), 2.81 (m, 1H), 2.10−1.90 (m, 2H).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> [(3a<i>S</i>,5<i>R</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-5-yl] (4-Nitrophenyl) Carbonate (<b>31g</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>30</b> as described for (−)-<b>7</b> in 70% yield. Purification and separation from the 5-<i>epi</i> diastereoisomer were performed following flash column chromatography on silica gel using hexanes/EtOAc (3:1, 2:1, then 1:1) as the eluent. Amorphous solid (70% from a 5:1 mixture of diastereoisomers). TLC: <i>R</i><sub><i>f</i></sub> = 0.16 (hexanes/EtOAc = 2:1). <sup>1</sup>H NMR (C<sub>6</sub>D<sub>6</sub>, 800 MHz) δ 7.64 (d, <i>J</i> = 9.0 Hz, 2H), 6.69 (d, <i>J</i> = 9.0 Hz, 2H), 4.76 d, <i>J</i> = 3.6 Hz, 1H), 4.35 (m, 1H), 4.02 (dt, <i>J</i> = 3.8, 8.6 Hz, 1H), 3.94 (dt, <i>J</i> = 2.8, 13.0 Hz, 1H), 3.60 (q, <i>J</i> = 8.0 Hz, 1H), 3.12 (dd, <i>J</i> = 2.0, 13.0 Hz), 2.04 (m, 1H), 1.67 (dq, <i>J</i> = 3.1, 15.1 Hz, 1H), 1.50 (m, 1H), 1.46−1.38 (m, 2H). <sup>13</sup>C NMR (C<sub>6</sub>D<sub>6</sub>, 200 MHz) δ 154.9, 151.9, 145.2, 124.9, 121.2, 100.7, 72.0, 67.4, 63.8, 35.9, 27.9, 27.3.</div></div><div id="secz" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-yl-(2<i>S</i>,3<i>R</i>)-4-(<i>N</i>-isobutyl-4-methoxyphenyl sulfonamido)-3-hydroxy-1-phenylbutan-2-yl Carbamate (<b>35a</b>)</h3><div class="NLM_p last">. Sulfonamide isostere <b>32</b> (42 mg, 0.08 mmol) was dissolved in a 30% TFA solution in CH<sub>2</sub>Cl<sub>2</sub> (3 mL), the solution was stirred at 23 °C for 2 h after which the solvent was evaporated under reduced pressure. The corresponding Boc-deprotected intermediate (0.08 mmol) was then diluted in dry acetonitrile (0.8 mL) at 0 °C under argon and Et<sub>3</sub>N (0.3 mL, 0.2 mmol) was added. A solution of activated carbonate <b>31a</b> (18.6 mg, 0.06 mmol) in acetonitrile or THF (0.5 mL) was then added to the mixture. The reaction was stirred at 23 °C until completion was reached (2−3 days). The solution was then evaporated <i>in vacuo</i> and the resulting residue purified by flash chromatography on silica gel using hexanes/EtOAc (2:1 then 1:1) as the eluent to afford the inhibitor <b>35a</b> as a amorphous solid (19.8 mg, 55%). TLC <i>R</i><sub><i>f</i></sub> = 0.35 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.71 (d, <i>J</i> = 8.9 Hz, 2H), 7.33−7.17 (m, 5H), 6.97 (d, <i>J</i> = 8.9 Hz, 2H), 5.05−4.90 (m, 1H), 4.93 (d, <i>J</i> = 3.6 Hz, 1H), 4.84 (d, <i>J</i> = 8.4 Hz, 1H), 4.15 (dt, <i>J</i> = 2.4, 9.0 Hz, 1H), 3.87 (s, 3H), 3.98−3.76 (m, 4H), 3.31 (t, <i>J</i> = 11.7 Hz, 1H), 3.22−2.90 (m, 4H), 2.90−2.78 (m, 2H), 2.48−2.32 (m, 1H), 1.96−1.25 (m, 5H), 0.92 (d, <i>J</i> = 6.6 Hz, 3H), 0.87 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz) δ 163.1, 155.5, 137.6, 129.8, 129.4, 128.4, 126.5, 114.3, 101.1, 72.9, 70.2, 68.5, 60.9, 58.9, 55.7, 54.9, 53.8, 43.5, 35.6, 27.3, 26.2, 22.3, 20.2, 19.9. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>2</sub>O<sub>8</sub>NaS 599.2403, found 599.2406.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-yl (2<i>S</i>,3<i>R</i>)-4-(4-Amino-<i>N</i>-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl Carbamate (<b>36</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31a</b> and sulfonamide isostere <b>33</b> as described for inhibitor <b>35a</b>, in 64% yield following purification by flash chromatography using CHCl<sub>3</sub>/2% MeOH as the eluent. TLC: <i>R</i><sub><i>f</i></sub> = 0.45 (hexanes/EtOAc = 1:3). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.55 (d, <i>J</i> = 8.7 Hz, 2H), 7.32−7.16 (m, 5H), 6.67 (d, <i>J</i> = 8.7 Hz, 2H), 4.97 (m, 1H), 4.93 (d, <i>J</i> = 3.4 Hz, 1H), 4.85 (d, <i>J</i> = 8.7 Hz, 1H), 4.20−4.11 (m, 3H), 3.92−3.80 (m, 5H), 3.31 (dt, <i>J</i> = 2.2, 11.9 Hz, 1H), 3.15 (dd, <i>J</i> = 8.1, 15.2 Hz, 1H), 3.05 (dd, <i>J</i> = 4.2, 14.1 Hz, 1H), 3.01−2.80 (m, 3H), 2.75 (dd, <i>J</i> = 6.6, 13.4 Hz, 1H), 2.40 (m, 1H), 1.97−1.60 (m, 4H), 1.46 (m, 1H), 0.92 (d, <i>J</i> = 6.6 Hz, 3H), 0.87 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 155.5, 150.7, 137.7, 129.5, 129.5, 128.4, 126.5, 126.2, 114.1, 101.1, 72.8, 70.1, 68.5, 60.8, 58.9, 54.8, 53.8, 43.4, 35.5, 27.3, 26.2, 22.2, 20.2, 19.9. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>28</sub>H<sub>39</sub>N<sub>3</sub>O<sub>7</sub>NaS 584.2406; found 584.2402.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (3a<i>S</i>,4<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-yl (2<i>S</i>,3<i>R</i>)-3-Hydroxy-4-(4-(hydroxymethyl)-<i>N</i>-isobutylphenylsulfonamido)-1-phenylbutan-2-yl Carbamate (<b>37</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31a</b> and sulfonamide isostere <b>34</b> as described for inhibitor <b>35a</b> in 72% yield following purification by flash chromatography on silica gel using CHCl<sub>3</sub>/2% MeOH as the eluent. Amorphous solid. TLC: <i>R</i><sub><i>f</i></sub> = 0.23 (hexanes/EtOAc = 1:2). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.76 (d, <i>J</i> = 8.1 Hz, 2H), 7.52 (d, <i>J</i> = 8.1 Hz, 2H), 7.32−7.17 (m, 5H), 4.96 (m, 1H), 4.93 (d, <i>J</i> = 3.2 Hz, 1H), 4.85 (d, <i>J</i> = 8.5 Hz, 1H), 4.80 (s, 2H), 4.15 (t, <i>J</i> = 8.5 Hz, 1H), 3.92−3.80 (m, 4H), 3.70 (s, 1H), 3.31 (t, <i>J</i> = 11.6 Hz, 1H), 3.16 (dd, <i>J</i> = 8.0, 15.0 Hz, 1H), 3.10−2.95 (m, 3H), 2.88−2.76 (m, 2H), 2.41 (m, 1H), 2.04 (m, 1H), 1.95−1.78 (m, 2H), 1.76−1.56 (m, 2H), 1.47 (m, 1H), 0.93 (d, <i>J</i> = 6.6 Hz, 3H), 0.88 (d, <i>J</i> = 6.6 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 155.6, 146.2, 137.6, 137.1, 129.4 128.5, 127.6, 127.1, 126.5, 101.1, 72.8, 70.2, 68.4, 64.2, 60.8, 58.8, 54.9, 53.7, 43.4, 35.5, 27.3, 26.2, 22.2, 20.1, 19.9. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>2</sub>O<sub>8</sub>NaS 599.2403, found 599.2414.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (3a<i>R</i>,4<i>R</i>,7a<i>S</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-4-yl ((2<i>S</i>,3<i>R</i>)-3-Hydroxy-4-(<i>N</i>-isobutyl-4-methoxyphenylsulfonamido)-1-phenylbutan-2-yl)carbamate (<b>35b</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31b</b> and sulfonamide isostere <b>32</b> in 65% yield as described for inhibitor <b>35a</b>, following purification by column chromatography on silica gel using hexanes/EtOAc (3:1, then 1.5:1) as the eluent. White amorphous solid. TLC: <i>R</i><sub><i>f</i></sub> = 0.44 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.70 (d, <i>J</i> = 8.9 Hz, 2H), 7.31−7.26 (m, 2H), 7.25−7.20 (m, 3H), 6.98 (d, <i>J</i> = 8.9 Hz, 2H), 5.00 (m, 1H), 4.97 (d, <i>J</i> = 2.7 Hz, 1H), 4.88 (d, <i>J</i> = 8.0 Hz, 1H), 4.17 (t, <i>J</i> = 7.7 Hz, 1H), 3.99−3.72 (m, 6H), 3.87 (s, 3H), 3.31 (dt, <i>J</i> = 1.9, 12.0 Hz, 1H), 3.13 (dd, <i>J</i> = 8.4, 15.0 Hz, 1H), 3.08−2.84 (m, 4H), 2.79 (dd, <i>J</i> = 6.7, 13.4 Hz, 1H), 2.53 (m, 1H), 2.00 (m, 1H), 1.83 (m, 1H), 1.73 (m, 1H), 1.68−1.54 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 163.1, 155.7, 137.7, 129.8, 129.5, 128.5, 126.5, 114.3, 101.2, 72.6, 70.2, 68.4, 60.8, 58.7, 55.6, 55.1, 53.7, 43.6, 35.3, 27.3, 26.2, 22.5, 20.1, 19.9. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>2</sub>O<sub>8</sub>NaS 599.2403, found 599.2407.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (3a<i>R</i>,4<i>S</i>,7a<i>R</i>)-Octahydrobenzofuran-4-yl (2<i>S</i>,3<i>R</i>)-3-Hydroxy-4-(<i>N</i>-isobutyl-4-methoxyphenylsulfonamido)-1-phenylbutan-2-yl Carbamate (<b>35c</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31c</b> and sulfonamide isostere <b>32</b> in 75% yield as described for inhibitor <b>35a</b>, following purification by column chromatography on silica gel using hexanes/EtOAc (3:1, then 2.5:1) as the eluent. TLC: <i>R</i><sub><i>f</i></sub> = 0.39 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.72 (d, <i>J</i> = 8.9 Hz, 2H), 7.311−7.16 (m, 5H), 6.98 (d, <i>J</i> = 8.9 Hz, 2H), 4.83 (m, 2H), 3.95−3.75 (m, 5H), 3.87 (s, 3H), 3.68 (q, <i>J</i> = 8.1 Hz, 1H), 3.14 (dd, <i>J</i> = 8.4, 15.2 Hz, 1H), 3.08 (dd, <i>J</i> = 4.1, 14.1 Hz, 1H), 3.05−2.99 (m, 1H), 2.96 (dd, <i>J</i> = 8.4, 13.4 Hz, 1H), 2.87−2.75 (m, 2H), 2.35 (m, 1H), 1.83 (m, 1H), 1.70−1.40 (m, 7H), 1.20 (m, 1H), 0.92 (d, <i>J</i> = 6.6 Hz, 3H), 0.87 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 163.0, 156.1, 137.7, 129.7, 129.5, 129.4, 128.4, 126.4, 114.3, 73.0, 71.8, 66.6, 58.8, 55.6, 54.7, 53.7, 41.2, 35.6, 27.3, 27.2, 27.0, 25.7, 20.1, 19.9, 17.7. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>42</sub>N<sub>2</sub>O<sub>7</sub>NaS 597.2610, found 597.2621.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (4<i>S</i>,4a<i>R</i>,7a<i>S</i>)-Octahydrocyclopenta[<i>b</i>]pyran-4-yl ((2<i>S</i>,3<i>R</i>)-3-Hydroxy-4-(<i>N</i>-isobutyl-4-methoxyphenylsulfonamido)-1-phenylbutan-2-yl)carbamate (<b>35d</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31d</b> and sulfonamide isostere <b>32</b> in 81% yield as described for inhibitor <b>35a</b>, following purification by column chromatography on silica gel using hexanes/EtOAc (3:1, then 2.5:1) as the eluent. TLC: <i>R</i><sub><i>f</i></sub> = 0.58 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.70 (d, <i>J</i> = 8.9 Hz, 2H), 7.30−7.17 (m, 5H), 6.96 (d, <i>J</i> = 8.9 Hz, 2H), 4.94 (m, 1H), 4.81 (d, <i>J</i> = 8.1 Hz, 1H), 3.86 (s, 3H), 3.90−3.76 (m, 4H), 3.33 (t, <i>J</i> = 11.9 Hz, 1H), 3.13 (dd, AB, <i>J</i> = 8.3, 15.0 Hz, 1H), 3.08−2.91 (m, 3H), 2.85 (m, 1H), 2.79 (dd, <i>J</i> = 6.8, 13.5 Hz, 1H), 2.04 (m, 1H), 1.81 (m, 2H), 1.76−1.64 (m, 3H), 1.64−1.49 (m, 3H), 0.90 (d, <i>J</i> = 6.6 Hz, 3H), 0.86 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 163.0, 156.0, 137.7, 129.8, 129.4, 128.4, 126.4, 114.3, 80.5, 72.7, 71.7, 65.2, 58.7, 55.6, 54.8, 53.7, 44.1, 35.6, 32.5, 27.2, 26.6, 22.0, 21.6, 20.1, 19.8. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>30</sub>H<sub>42</sub>N<sub>2</sub>O<sub>7</sub>S 597.2610, found 597.2612.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (3a<i>R</i>,4<i>S</i>,7a<i>R</i>)-Octahydro-1<i>H</i>-inden-4-yl-(2<i>S</i>,3<i>R</i>)-3-hydroxy-4-(<i>N</i>-isobutyl-4-methoxyphenylsulfonamido)-1-phenylbutan-2-yl Carbamate (<b>35e</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31e</b> and sulfonamide isostere <b>32</b> as described for inhibitor <b>35a</b>. Following preliminary purification by flash chromatography using hexanes/CH<sub>2</sub>Cl<sub>2</sub>/THF (8:1:1) as the eluent, the inhibitor was obtained as a mixture of unseparable isomeric compounds. Compound <b>35e</b> was derivatized into the corresponding <i>N</i>,<i>O-</i>isopropylidene compound by treatment of <b>35e</b> (20 mg) with 2,2-dimethoxypropane (0.1 mL) and a catalytic amount of <i>p</i>TSA (1.5 mg) in dry CH<sub>2</sub>Cl<sub>2</sub> (1 mL) for 8 h at 23 °C. After neutralization with Et<sub>3</sub>N, the organic phase was evaporated to dryness. Following a quick silica gel column (hexanes/EtOAc = 8:1), the resulting inhibitor was purified by HPLC: preparative HPLC column Sunfire Prep C18 OBD, 30 mm × 100 mm, eluent MeOH/H<sub>2</sub>O 85:15 (30 min) and then 90:10 (15 min), flow rate 15 mL·min<sup>−1</sup>, <i>t</i><sub>R</sub> = 42 min. The isopropylidene derivative was then obtained as a colorless oil (24 mg). The product was then taken into MeOH (2 mL). <i>p</i>TSA·H<sub>2</sub>O (36 μmol, 1.5 mg) was added, and the resulting solution was refluxed for 6 h. After neutralization with a few drops of Et<sub>3</sub>N, the solution was evaporated and the residue purified by column chromatography on silica gel using hexanes/CH<sub>2</sub>Cl<sub>2</sub>/THF (8:1:1) to give inhibitor <b>35e</b> (15 mg, 43% from <b>31e</b>). TLC: <i>R</i><sub><i>f</i></sub> = 0.35 (hexanes//EtOAc = 5:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.71 (d, <i>J</i> = 8.9 Hz, 2H), 7.32−7.18 (m, 5H), 6.97 (d, <i>J</i> = 8.9 Hz, 2H), 4.79 (m, 1H), 4.70 (d. <i>J</i> = 8.1 Hz, 1H), 3.90 (m, 1H), 3.87 (s, 3H), 3.81 (m, 1H), 3.18−3.02 (m, 3H), 2.98−2.82 (m, 2H), 2.78 (dd, <i>J</i> = 6.6, 13.2 Hz, 1H), 2.10 (m, 1H), 1.90 (m, 1H), 1.82 (m, 1H), 1.74−1.19 (m, 11H), 0.95 (m, 1H), 0.90 (d, <i>J</i> = 6.6 Hz, 3H), 0.86 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 163.0, 156.4, 137.7, 129.9, 129.5, 129.4, 128.5, 126.4, 114.3, 74.9, 72.8, 58.8, 55.6, 54.8, 53.8, 43.1, 39.9, 35.7, 31.3, 27.2, 26.9, 26.1, 23.5, 22.2, 21.3, 20.1, 19.9. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>31</sub>H<sub>44</sub>N<sub>2</sub>O<sub>6</sub>NaS 595.2818, found 595.2816.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (4<i>S</i>,4a<i>S</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[3,4-<i>b</i>]pyran-4-yl ((2<i>S</i>,3<i>R</i>)-3-Hydroxy-4-(<i>N</i>-isobutyl-4-methoxyphenylsulfonamido)-1-phenylbutan-2-yl)carbamate (<b>35f</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31f</b> and sulfonamide isostere <b>32</b> in 75% yield as described for inhibitor <b>35a</b>, following purification by column chromatography using hexanes/EtOAc (3:1, then 2.5:1) as the eluent. TLC: <i>R</i><sub><i>f</i></sub> = 0.24 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 800 MHz) δ 7.70 (d, <i>J</i> = 8.8 Hz, 2H), 7.30 (m, 2H), 7.24−7.20 (m, 3H), 6.97 (d, <i>J</i> = 8.8 Hz, 2H), 5.05 (m, 1H), 4.83 (d, <i>J</i> = 8.5 Hz, 1H), 4.03 (t, <i>J</i> = 3.2 Hz, 1H), 3.96 (m, 1H), 3.87 (s, 3H), 3.87 (s, 3H), 3.88−3.81 (m, 5H), 3.62 (t, <i>J</i> = 8.3 Hz, 1H), 3.39 (t, <i>J</i> = 11.5 Hz, 1H), 3.14 (dd, <i>J</i> = 8.4, 15.0 Hz, 1H), 3.02 (dd, <i>J</i> = 4.0, 14.1 Hz, 1H), 2.99−2.94 (m, 2H), 2.84 (dd, <i>J</i> = 8.7, 14.1 Hz, 1H), 2.77 (dd, <i>J</i> = 6.6, 13.4 Hz, 1H), 2.51 (m, 1H), 1.81 (m, 1H), 1.78 (dq, <i>J</i> = 4.5, 12.4 Hz, 1H), 1.71 (dd, <i>J</i> = 5.4, 12.4 Hz, 1H), 0.91 (d <i>J</i> = 6.6 Hz, 3H), 0.87 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 200 MHz) δ 163.0, 155.5, 137.5, 129.6, 129.45, 129.38, 128.5, 126.6, 114.3, 78.4, 74.4, 72.6, 70.0, 66.1, 64.9, 58.8, 55.6, 54.9, 53.7, 42.7, 35.4, 27.2, 26.9, 20.1, 19.8. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>2</sub>O<sub>8</sub>S 599.2403, found 599.2397.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (3a<i>S</i>,5<i>R</i>,7a<i>R</i>)-Hexahydro-2<i>H</i>-furo[2,3-<i>b</i>]pyran-5-yl ((2<i>S</i>,3<i>R</i>)-3-Hydroxy-4-(<i>N</i>-isobutyl-4-methoxyphenylsulfonamido)-1-phenylbutan-2-yl)carbamate (<b>35g</b>)</h3><div class="NLM_p last">The title compound was obtained from <b>31g</b> and sulfonamide isostere <b>32</b> in 86% yield as described for inhibitor <b>35a</b>, following purification by column chromatography on silica gel using hexanes/EtOAc (gradient 3:1 to 1.5:1) as the eluent. TLC: <i>R</i><sub><i>f</i></sub> = 0.33 (hexanes/EtOAc = 1:1). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.72 (d, <i>J</i> = 8.9 Hz, 2H), 7.32−7.26 (m, 2H), 7.25−7.17 (m, 3H), 6.98 (d, <i>J</i> = 8.9 Hz, 2H), 4.98 (d, <i>J</i> = 3.5 Hz, 1H), 4.89 (d, <i>J</i> = 8.7 Hz, 1H), 4.54 (m, 1H), 4.11 (dt, <i>J</i> = 3.5, 8.3 Hz, 1H), 3.87 (s, 3H), 3.90−3.77 (m, 4H), 3.74 (m, 1H), 3.56 (d, <i>J</i> = 12.7 Hz, 1H), 3.12 (dd, <i>J</i> = 8.5, 15.1 Hz, 1H), 3.09−2.91 (m, 3H), 2.84 (dd, <i>J</i> = 8.5, 14.1 Hz, 1H), 2.79 (dd, <i>J</i> = 6.8, 13.4 Hz, 1H), 2.08 (m, 1H), 2.04−1.93 (m, 2H), 1.90−1.76 (m, 3H), 0.91 (d, <i>J</i> = 6.6 Hz, 3H), 0.87 (d, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 163.4, 155.7, 137.6, 129.7, 129.5, 128.5, 126.5, 114.4, 101.0, 72.5, 68.0, 67.1, 65.4, 58.8, 55.6, 54.9, 53.8, 36.2, 35.8, 28.3, 27.8, 27.2, 20.1, 19.9. HRMS-ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>2</sub>O<sub>8</sub>NaS 599.2403, found 599.2397.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53"><a href="/doi/suppl/10.1021/jm1012787">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">HPLC and HRMS data of inhibitors <b>35a</b>−<b>g</b>, <b>36</b>, and <b>37</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm1012787/suppl_file/jm1012787_si_001.pdf">jm1012787_si_001.pdf (43.53 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm1012787" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arun K. Ghosh</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, and</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#30515b57585f4358704045425445551e555445"><span class="__cf_email__" data-cfemail="1978727e71766a7159696c6b7d6c7c377c7d6c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruno D. Chapsal</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, and</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abigail Baldridge</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, and</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melinda P. Steffey</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, and</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">D. Eric Walters</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry and Molecular Biology, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yasuhiro Koh</span> - <span class="hlFld-Affiliation affiliation">Department of Hematology</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Infectious Diseases</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masayuki Amano</span> - <span class="hlFld-Affiliation affiliation">Department of Hematology</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Infectious Diseases</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroaki Mitsuya</span> - <span class="hlFld-Affiliation affiliation">Department of Hematology</span>; 
    <span class="hlFld-Affiliation affiliation">Department of Infectious Diseases</span>; 
    <span class="hlFld-Affiliation affiliation">Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland 20892, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The research was supported by the National Institutes of Health (Grant GM53386). This work was also supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, and in part by a Grant-in-Aid for Scientific Research (Priority Areas) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Monbu Kagakusho), a Grant for Promotion of AIDS Research from the Ministry of Health, Welfare, and Labor of Japan (Kosei Rohdosho), and a Grant to the Cooperative Research Project on Clinical and Epidemiological Studies of Emerging and Reemerging Infectious Diseases (Renkei Jigyo) of Monbu-Kagakusho.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Conway, B.</span><span> </span><span class="NLM_article-title">HAART in Treatment-Experienced Patients in the 21st Century: The Audacity of Hope</span> <span class="citation_source-journal">Future Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.2217%2F17460794.4.1.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWju7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=39-41&author=B.+Conway&title=HAART+in+Treatment-Experienced+Patients+in+the+21st+Century%3A+The+Audacity+of+Hope"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HAART in treatment-experienced patients in the 21st century: the audacity of hope</span></div><div class="casAuthors">Conway, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Future Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-41</span>CODEN:
                <span class="NLM_cas:coden">FVUIAM</span>;
        ISSN:<span class="NLM_cas:issn">1746-0794</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Evaluation of: Steigbigel RT, Cooper DA, Kumar PN et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection.  N. Engl. J. Med. 359, 339-354 (2008).  Over the past decade the use of highly active antiretroviral therapy (HAART) has led to a significant increase in life expectancy, at least in drug-naive subjects.  More recently, data generated in the BENCHMRK studies has extended this benefit to treatment-experienced patients, with over 60% of such individuals achieving maximal virol. suppression when treated with the integrase inhibitor raltegravir.  If it is combined with darunavir and etravirine (as was done in the TRIO study), this benefit may be extended to over 90% of these patients.  Similar results may also be achieved using maraviroc, an orally administered chemokine receptor antagonist.  Unless new issues of long-term toxicity or drug resistance arise, we are now in a position to offer new hope to heavily treatment-experienced individuals living with HIV in a way that could not have been possible as recently as 2 or 3 years ago.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5FG4TflFKXrVg90H21EOLACvtfcHk0lgapSewSarzvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWju7rL&md5=f8d6765fecadd3ecb16c0fcc70c6b4a7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2217%2F17460794.4.1.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460794.4.1.39%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DB.%26atitle%3DHAART%2520in%2520Treatment-Experienced%2520Patients%2520in%2520the%252021st%2520Century%253A%2520The%2520Audacity%2520of%2520Hope%26jtitle%3DFuture%2520Virol.%26date%3D2009%26volume%3D4%26spage%3D39%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Bartlett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMasi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moxham, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseau, F.</span><span> </span><span class="NLM_article-title">Overview on the Effectiveness of Triple Combination Therapy in Antiretroviral-Naive HIV-1 Infected Adults</span> <span class="citation_source-journal">AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1369</span><span class="NLM_x">–</span> <span class="NLM_lpage">1377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=1369-1377&author=J.+A.+Bartlettauthor=R.+DeMasiauthor=J.+Quinnauthor=C.+Moxhamauthor=F.+Rousseau&title=Overview+on+the+Effectiveness+of+Triple+Combination+Therapy+in+Antiretroviral-Naive+HIV-1+Infected+Adults"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DJ.%2BA.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DJ.%26aulast%3DMoxham%26aufirst%3DC.%26aulast%3DRousseau%26aufirst%3DF.%26atitle%3DOverview%2520on%2520the%2520Effectiveness%2520of%2520Triple%2520Combination%2520Therapy%2520in%2520Antiretroviral-Naive%2520HIV-1%2520Infected%2520Adults%26jtitle%3DAIDS%26date%3D2001%26volume%3D15%26spage%3D1369%26epage%3D1377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Walensky, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paltiel, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercincavage, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schackman, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedberg, K. A.</span><span> </span><span class="NLM_article-title">The Survival Benefits of AIDS Treatment in the United States</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1086%2F505147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=16741877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADC%252BD28zivVaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2006&pages=11-19&author=R.+P.+Walenskyauthor=A.+D.+Paltielauthor=E.+Losinaauthor=L.+M.+Mercincavageauthor=B.+R.+Schackmanauthor=P.+E.+Saxauthor=M.+C.+Weinsteinauthor=K.+A.+Freedberg&title=The+Survival+Benefits+of+AIDS+Treatment+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The survival benefits of AIDS treatment in the United States</span></div><div class="casAuthors">Walensky Rochelle P; Paltiel A David; Losina Elena; Mercincavage Lauren M; Schackman Bruce R; Sax Paul E; Weinstein Milton C; Freedberg Kenneth A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-9</span>
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    </div><div class="casAbstract">BACKGROUND:  As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States.  METHODS:  We defined eras corresponding to advances in standards of human immunodeficiency virus (HIV) disease care, including opportunistic infection prophylaxis, treatment with ART, and the prevention of mother-to-child transmission (pMTCT) of HIV.  Per-person survival benefits for each era were determined using a mathematical simulation model.  Published estimates provided the number of adult patients with new diagnoses of AIDS who were receiving care in the United States from 1989 to 2003.  RESULTS:  Compared with survival associated with untreated HIV disease, per-person survival increased 0.26 years with Pneumocystis jiroveci pneumonia prophylaxis alone.  Four eras of increasingly effective ART in addition to prophylaxis resulted in per-person survival increases of 7.81, 11.05, 11.57, and 13.33 years, compared with the absence of treatment.  Treatment for patients with AIDS in care in the United States since 1989 yielded a total survival benefit of 2.8 million years. pMTCT averted nearly 2900 infant infections, equivalent to 137,000 additional years of survival benefit.  CONCLUSIONS:  At least 3.0 million years of life have been saved in the United States as a direct result of care of patients with AIDS, highlighting the significant advances made in HIV disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7NsMYkLu_6zEC-75aqa5AfW6udTcc2eaxayrFlwfvBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zivVaksg%253D%253D&md5=31288a5957b51c0aa1908bf7350b67cb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1086%2F505147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F505147%26sid%3Dliteratum%253Aachs%26aulast%3DWalensky%26aufirst%3DR.%2BP.%26aulast%3DPaltiel%26aufirst%3DA.%2BD.%26aulast%3DLosina%26aufirst%3DE.%26aulast%3DMercincavage%26aufirst%3DL.%2BM.%26aulast%3DSchackman%26aufirst%3DB.%2BR.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DWeinstein%26aufirst%3DM.%2BC.%26aulast%3DFreedberg%26aufirst%3DK.%2BA.%26atitle%3DThe%2520Survival%2520Benefits%2520of%2520AIDS%2520Treatment%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2006%26volume%3D194%26spage%3D11%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Sepkowitz, K. A.</span><span> </span><span class="NLM_article-title">AIDS: The First 20 Years</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1764</span><span class="NLM_x">–</span> <span class="NLM_lpage">1772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1056%2FNEJM200106073442306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=11396444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADC%252BD3MzivVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1764-1772&author=K.+A.+Sepkowitz&title=AIDS%3A+The+First+20+Years"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">AIDS--the first 20 years</span></div><div class="casAuthors">Sepkowitz K A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1764-72</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTov3XdeSk_JhBrI9DTGjC0fW6udTcc2eaxayrFlwfvBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MzivVehsg%253D%253D&md5=1048e8fdcd1919e7adb1c095749d7692</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJM200106073442306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200106073442306%26sid%3Dliteratum%253Aachs%26aulast%3DSepkowitz%26aufirst%3DK.%2BA.%26atitle%3DAIDS%253A%2520The%2520First%252020%2520Years%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1764%26epage%3D1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Palella, F. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorman, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loveless, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satten, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aschman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1056%2FNEJM199803263381301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=9516219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADyaK1c7mslyjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=1998&pages=853-860&author=F.+J.+Palellaauthor=K.+M.+Delaneyauthor=A.+C.+Moormanauthor=M.+O.+Lovelessauthor=J.+Fuhrerauthor=G.+A.+Sattenauthor=D.+J.+Aschmanauthor=S.+D.+Holmberg&title=Declining+Morbidity+and+Mortality+among+Patients+with+Advanced+Human+Immunodeficiency+Virus+Infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators</span></div><div class="casAuthors">Palella F J Jr; Delaney K M; Moorman A C; Loveless M O; Fuhrer J; Satten G A; Aschman D J; Holmberg S D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">853-60</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND AND METHODS:  National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS).  To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997.  RESULTS:  Mortality among the patients declined from 29.4 per 100 person-years in the first quarter of 1995 to 8.8 per 100 in the second quarter of 1997.  There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV.  The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997.  In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality.  Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit.  Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid.  CONCLUSIONS:  The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6uVwzPlrzo4IRAdBLKY41fW6udTcc2ebQox4tEUtJAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7mslyjuw%253D%253D&md5=63bd6978cc957517f4bcfae251adc3ef</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM199803263381301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199803263381301%26sid%3Dliteratum%253Aachs%26aulast%3DPalella%26aufirst%3DF.%2BJ.%26aulast%3DDelaney%26aufirst%3DK.%2BM.%26aulast%3DMoorman%26aufirst%3DA.%2BC.%26aulast%3DLoveless%26aufirst%3DM.%2BO.%26aulast%3DFuhrer%26aufirst%3DJ.%26aulast%3DSatten%26aufirst%3DG.%2BA.%26aulast%3DAschman%26aufirst%3DD.%2BJ.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DDeclining%2520Morbidity%2520and%2520Mortality%2520among%2520Patients%2520with%2520Advanced%2520Human%2520Immunodeficiency%2520Virus%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D338%26spage%3D853%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">Anti-HIV Drugs: 25 Compounds Approved within 25 Years after the Discovery of HIV</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1016%2Fj.ijantimicag.2008.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=19108994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=307-320&author=E.+De+Clercq&title=Anti-HIV+Drugs%3A+25+Compounds+Approved+within+25+Years+after+the+Discovery+of+HIV"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative etiol. agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compds. have been formally approved for clin. use in the treatment of AIDS.  These compds. fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse transcriptase inhibitors (NtRTIs: tenofovir); non-nucleoside reverse transcriptase inhibitors (NNRTIs: nevirapine, delavirdine, efavirenz and etravirine); protease inhibitors (PIs: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir); cell entry inhibitors [fusion inhibitors (FIs: enfuvirtide) and co-receptor inhibitors (CRIs: maraviroc)]; and integrase inhibitors (INIs: raltegravir).  These compds. should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsT6dqAjvKIrVg90H21EOLACvtfcHk0liIGJ2X3L5YUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKgs7g%253D&md5=6d8263455e9c912d353ef2ea230a5e15</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2008.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2008.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAnti-HIV%2520Drugs%253A%252025%2520Compounds%2520Approved%2520within%252025%2520Years%2520after%2520the%2520Discovery%2520of%2520HIV%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2009%26spage%3D307%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Pillay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhaskaran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurriaans, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masquelier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gifford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balotta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezza, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Mendoza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poggensee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, K.</span><span> </span><span class="NLM_article-title">The Impact of Transmitted Drug Resistance on the Natural History of HIV Infection and Response to First-Line Therapy</span> <span class="citation_source-journal">AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=21-28&author=D.+Pillayauthor=K.+Bhaskaranauthor=S.+Jurriaansauthor=M.+Prinsauthor=B.+Masquelierauthor=F.+Dabisauthor=R.+Giffordauthor=C.+Nielsenauthor=C.+Pedersenauthor=C.+Balottaauthor=G.+Rezzaauthor=M.+Ortizauthor=C.+de+Mendozaauthor=C.+Kuchererauthor=G.+Poggenseeauthor=J.+Gillauthor=K.+Porter&title=The+Impact+of+Transmitted+Drug+Resistance+on+the+Natural+History+of+HIV+Infection+and+Response+to+First-Line+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPillay%26aufirst%3DD.%26aulast%3DBhaskaran%26aufirst%3DK.%26aulast%3DJurriaans%26aufirst%3DS.%26aulast%3DPrins%26aufirst%3DM.%26aulast%3DMasquelier%26aufirst%3DB.%26aulast%3DDabis%26aufirst%3DF.%26aulast%3DGifford%26aufirst%3DR.%26aulast%3DNielsen%26aufirst%3DC.%26aulast%3DPedersen%26aufirst%3DC.%26aulast%3DBalotta%26aufirst%3DC.%26aulast%3DRezza%26aufirst%3DG.%26aulast%3DOrtiz%26aufirst%3DM.%26aulast%3Dde%2BMendoza%26aufirst%3DC.%26aulast%3DKucherer%26aufirst%3DC.%26aulast%3DPoggensee%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DJ.%26aulast%3DPorter%26aufirst%3DK.%26atitle%3DThe%2520Impact%2520of%2520Transmitted%2520Drug%2520Resistance%2520on%2520the%2520Natural%2520History%2520of%2520HIV%2520Infection%2520and%2520Response%2520to%2520First-Line%2520Therapy%26jtitle%3DAIDS%26date%3D2006%26volume%3D20%26spage%3D21%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Grabar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Corfec, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allavena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlureau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro-Peray, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poizot-Martin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costagliola, D.</span><span> </span><span class="NLM_article-title">Factors Associated with Clinical and Virological Failure in Patients Receiving a Triple Therapy Including a Protease Inhibitor</span> <span class="citation_source-journal">AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1097%2F00002030-200001280-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=10708284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=141-149&author=S.+Grabarauthor=C.+Pradierauthor=E.+Le+Corfecauthor=R.+Lancarauthor=C.+Allavenaauthor=M.+Bentataauthor=P.+Berlureauauthor=C.+Dupontauthor=P.+Fabbro-Perayauthor=I.+Poizot-Martinauthor=D.+Costagliola&title=Factors+Associated+with+Clinical+and+Virological+Failure+in+Patients+Receiving+a+Triple+Therapy+Including+a+Protease+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor</span></div><div class="casAuthors">Grabar, Sophie; Pradier, Christian; Le Corfec, Emmanuelle; Lancar, Remi; Allavena, Clotilde; Bentata, Michelle; Berlureau, Patricia; Dupont, Caroline; Fabbro-Peray, Pascale; Poizot-Martin, Isabelle; Costagliola, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The aim of this study was to det. the predictors of virol. and clin. failure in patients receiving a protease inhibitor as part of triple therapy.  From the French Hospital Database on HIV, 1402 protease inhibitor-naive patients starting a highly active antiretroviral therapy regimen with ritonavir, saquinavir-hard gel capsule (hgc) or indinavir between July 1996 and Mar. 1997, and with measured HIV RNA at baseline and at 12 mo, were studied for progression to a new AIDS-defining event (ADE) or death.  Virol. failure was defined as plasma HIV RNA > 1000 copies/mL at 12 mo.  Multivariate analyses were performed using Cox models for clin. outcomes and logistic regression for virol. outcomes.  During a median follow-up of 14.1 mo, 94 (6.7%) patients experienced an ADE or died.  At 12 mo, 700 patients (49.9%) had virol. failure.  In the multivariate anal., baseline CD4 cell count and viral load were found to be independent predictors of both virol. and clin. failure.  Neither the type of the first protease inhibitor taken nor previous antiretroviral therapy experience was assocd. with risk of clin. progression.  For virol. failure, the use of saquinavir-hgc was assocd. with a significant 1.96-fold increase in risk compared with indinavir; pre-treated patients were at higher risk than antiretroviral therapy-naive patients.  In this study with large samples of patients, the use of saquinavir-hgc was assocd. with higher risk of virol. failure at 12 mo than were ritonavir and indinavir; no differences between protease inhibitors were found for clin. progression.  As biases cannot be excluded, a longer duration of follow-up will be necessary to answer the question of whether the results are really discrepant or simply reflect the delay between virol. failure and clin. manifestations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnZr0XLVQAIbVg90H21EOLACvtfcHk0liIGJ2X3L5YUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvFWmsLg%253D&md5=e805e2d951c8c8e9172c9121b5dddb5a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2F00002030-200001280-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002030-200001280-00009%26sid%3Dliteratum%253Aachs%26aulast%3DGrabar%26aufirst%3DS.%26aulast%3DPradier%26aufirst%3DC.%26aulast%3DLe%2BCorfec%26aufirst%3DE.%26aulast%3DLancar%26aufirst%3DR.%26aulast%3DAllavena%26aufirst%3DC.%26aulast%3DBentata%26aufirst%3DM.%26aulast%3DBerlureau%26aufirst%3DP.%26aulast%3DDupont%26aufirst%3DC.%26aulast%3DFabbro-Peray%26aufirst%3DP.%26aulast%3DPoizot-Martin%26aufirst%3DI.%26aulast%3DCostagliola%26aufirst%3DD.%26atitle%3DFactors%2520Associated%2520with%2520Clinical%2520and%2520Virological%2520Failure%2520in%2520Patients%2520Receiving%2520a%2520Triple%2520Therapy%2520Including%2520a%2520Protease%2520Inhibitor%26jtitle%3DAIDS%26date%3D2000%26volume%3D14%26spage%3D141%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Little, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daar, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellors, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connick, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitcomb, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmann, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, D. D.</span><span> </span><span class="NLM_article-title">Antiretroviral-Drug Resistance among Patients Recently Infected with HIV</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1056%2FNEJMoa013552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=12167680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFKrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=385-394&author=S.+J.+Littleauthor=S.+Holteauthor=J.+P.+Routyauthor=E.+S.+Daarauthor=M.+Markowitzauthor=A.+C.+Collierauthor=R.+A.+Koupauthor=J.+W.+Mellorsauthor=E.+Connickauthor=B.+Conwayauthor=M.+Kilbyauthor=L.+Wangauthor=J.+M.+Whitcombauthor=N.+S.+Hellmannauthor=D.+D.+Richman&title=Antiretroviral-Drug+Resistance+among+Patients+Recently+Infected+with+HIV"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral-drug resistance among patients recently infected with HIV</span></div><div class="casAuthors">Little, Susan J.; Holte, Sarah; Routy, Jean-Pierre; Daar, Eric S.; Markowitz, Marty; Collier, Ann C.; Koup, Richard A.; Mellors, John W.; Connick, Elizabeth; Conway, Brian; Kilby, Michael; Wang, Lei; Whitcomb, Jeannette M.; Hellmann, Nicholas S.; Richman, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estd. at 1 to 11 %.  We performed a retrospective anal. of susceptibility to antiretroviral drugs before treatment and drug-resistance mutations in HIV in plasma samples from 377 subjects with primary HIV infection who had not yet received treatment and who were identified between May 1995 and June 2000 in 10 North American cities.  Responses to treatment could be evaluated in 202 subjects.  Over the five-year period, the frequency of transmitted drug resistance increased significantly.  The frequency of high-level resistance to one or more drugs (indicated by a value of more than 10 for the ratio of the 50 % inhibitory concn. [IC50] for the subject's virus to the IC50 for a drug-sensitive ref. virus) increased from 3.4 % during the period from 1995 to 1998 to 12.4 % during the period from 1999 to 2000 (P = 0.002), and the frequency of multidrug resistance increased from 1.1 % to 6.2 % (P = 0.01).  The frequency of resistance mutations detected by sequence anal. increased from 8.0 % to 22.7 % (P<0.001), and the frequency of multidrug resistance detected by sequence anal. increased from 3.8 % to 10.2 % (P = 0.05).  Among subjects infected with drug-resistant virus, the time to viral suppression after the initiation of antiretroviral therapy was longer (P = 0.05), and the time to virol. failure was shorter (P = 0.05).  The proportion of new HIV infections that involve drug-resistant virus is increasing in North America.  Initial antiretroviral therapy is more likely to fail in patients who are infected with drug-resistant virus.  Testing for resistance to drugs before therapy begins is now indicated even for recently infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMYtEft2HLLVg90H21EOLACvtfcHk0lj0h_AxQ-OyYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFKrt78%253D&md5=e0210630dd7ce7ee727b51342e51ad7f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa013552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa013552%26sid%3Dliteratum%253Aachs%26aulast%3DLittle%26aufirst%3DS.%2BJ.%26aulast%3DHolte%26aufirst%3DS.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DDaar%26aufirst%3DE.%2BS.%26aulast%3DMarkowitz%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DA.%2BC.%26aulast%3DKoup%26aufirst%3DR.%2BA.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DConnick%26aufirst%3DE.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DKilby%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhitcomb%26aufirst%3DJ.%2BM.%26aulast%3DHellmann%26aufirst%3DN.%2BS.%26aulast%3DRichman%26aufirst%3DD.%2BD.%26atitle%3DAntiretroviral-Drug%2520Resistance%2520among%2520Patients%2520Recently%2520Infected%2520with%2520HIV%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D385%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Grant, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmerdam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liegler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petropoulos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmann, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, J. O.</span><span> </span><span class="NLM_article-title">Time Trends in Primary HIV-1 Drug Resistance among Recently Infected Persons</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2002&pages=181-188&author=R.+M.+Grantauthor=F.+M.+Hechtauthor=M.+Warmerdamauthor=L.+Liuauthor=T.+Lieglerauthor=C.+J.+Petropoulosauthor=N.+S.+Hellmannauthor=M.+Chesneyauthor=M.+P.+Buschauthor=J.+O.+Kahn&title=Time+Trends+in+Primary+HIV-1+Drug+Resistance+among+Recently+Infected+Persons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DR.%2BM.%26aulast%3DHecht%26aufirst%3DF.%2BM.%26aulast%3DWarmerdam%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLiegler%26aufirst%3DT.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DHellmann%26aufirst%3DN.%2BS.%26aulast%3DChesney%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DM.%2BP.%26aulast%3DKahn%26aufirst%3DJ.%2BO.%26atitle%3DTime%2520Trends%2520in%2520Primary%2520HIV-1%2520Drug%2520Resistance%2520among%2520Recently%2520Infected%2520Persons%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2002%26volume%3D288%26spage%3D181%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Hue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gifford, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernhill, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillay, D.</span><span> </span><span class="NLM_article-title">On behalf of the UK Collaborative Group on HIV Drug Resistance. Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive Individuals</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">2645</span><span class="NLM_x">–</span> <span class="NLM_lpage">2654</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FJVI.01556-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=19158238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2rtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=2645-2654&author=S.+Hueauthor=R.+J.+Giffordauthor=D.+Dunnauthor=E.+Fernhillauthor=D.+Pillay&title=On+behalf+of+the+UK+Collaborative+Group+on+HIV+Drug+Resistance.+Demonstration+of+Sustained+Drug-Resistant+Human+Immunodeficiency+Virus+Type+1+Lineages+Circulating+among+Treatment-Naive+Individuals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals</span></div><div class="casAuthors">Hue, Stephane; Gifford, Robert J.; Dunn, David; Fernhill, Esther; Pillay, Deenan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2645-2654</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Transmission of human immunodeficiency virus (HIV) drug resistance is well-recognized and compromises response to first-line therapy.  However, the population dynamics of transmitted resistance remains unclear, although previous models have assumed that such transmission reflects direct infection from treated individuals.  We investigated whether population-based phylogenetic analyses would uncover lineages of resistant viruses circulating in untreated individuals.  Through the phylogenetic anal. of 14,061 HIV type 1 (HIV-1) pol gene sequences generated in the United Kingdom from both treatment-naive and -experienced individuals, we identified five treatment-independent viral clusters contg. mutations conferring cross-resistance to antiretroviral drugs prescribed today in the United Kingdom.  These viral lineages represent sustainable reservoirs of resistance among new HIV infections, independent of treatment.  Dated phylogenies reconstructed through Bayesian Markov chain Monte Carlo inference indicated that these reservoirs originated between 1997 and 2003 and have persisted in the HIV-infected population for up to 8 years.  Since our cohort does not represent all infected individuals within the United Kingdom, our results are likely to underestimate the no. and size of the resistant reservoirs circulating among drug-naive patients.  The existence of sustained reservoirs of resistance in the absence of treatment has the capacity to threaten the long-term efficacy of antiretroviral therapy and suggests there is a limit to the decline of transmitted drug resistance.  Given the current decrease in resistance transmitted from treated individuals, a greater proportion of resistance is likely to come from drug-naive lineages.  These findings provide new insights for the planning and management of treatment programs in resource-rich and developing countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5IXepn13UVrVg90H21EOLACvtfcHk0lj0h_AxQ-OyYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2rtb0%253D&md5=5d1b3046cfd58bb7d10aa410d7aca28c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FJVI.01556-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01556-08%26sid%3Dliteratum%253Aachs%26aulast%3DHue%26aufirst%3DS.%26aulast%3DGifford%26aufirst%3DR.%2BJ.%26aulast%3DDunn%26aufirst%3DD.%26aulast%3DFernhill%26aufirst%3DE.%26aulast%3DPillay%26aufirst%3DD.%26atitle%3DOn%2520behalf%2520of%2520the%2520UK%2520Collaborative%2520Group%2520on%2520HIV%2520Drug%2520Resistance.%2520Demonstration%2520of%2520Sustained%2520Drug-Resistant%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Lineages%2520Circulating%2520among%2520Treatment-Naive%2520Individuals%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D2645%26epage%3D2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lucas, G. M.</span><span> </span><span class="NLM_article-title">Antiretroviral Adherence, Drug Resistance, Viral Fitness and HIV Disease Progression: A Tangled Web Is Woven</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1093%2Fjac%2Fdki042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15722389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFWiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=413-416&author=G.+M.+Lucas&title=Antiretroviral+Adherence%2C+Drug+Resistance%2C+Viral+Fitness+and+HIV+Disease+Progression%3A+A+Tangled+Web+Is+Woven"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven</span></div><div class="casAuthors">Lucas, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-416</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The clin. goals of HIV treatment are optimally accomplished through consistent high-level adherence to highly active antiretroviral therapy (HAART) and durable suppression of the viral load.  However, as a result of the need for lifelong therapy and HIV's prodigious replication rate and error-prone reverse transcriptase, varying amts. of antiretroviral drug resistance are common in treated individuals.  Medication adherence is linked to the development of drug resistance, although not by a simple linear relationship.  Recent studies have suggested that extensive drug resistance is not a major determinant of HIV disease progression and death.  Rather, failure to access care and discontinuation of or non-adherence with therapy are arguably the most important factors assocd. with HIV disease progression in the HAART era.  Other data indicate that continued therapy in the setting of extensive drug resistance and the inability to achieve viral suppression can provide continued clin. benefit.  Such benefit may be mediated, at least partially, by redns. in viral fitness assocd. with drug resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMJxPoNSUilLVg90H21EOLACvtfcHk0lgWDzQitZsrEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFWiurw%253D&md5=b18d174da77a7cfb6e7f14af3e36d28f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki042%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DG.%2BM.%26atitle%3DAntiretroviral%2520Adherence%252C%2520Drug%2520Resistance%252C%2520Viral%2520Fitness%2520and%2520HIV%2520Disease%2520Progression%253A%2520A%2520Tangled%2520Web%2520Is%2520Woven%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2005%26volume%3D55%26spage%3D413%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Spaltenstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samano, V.</span><span> </span><span class="NLM_article-title">Discovery of Next Generation Inhibitors of HIV Protease</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1589</span><span class="NLM_x">–</span> <span class="NLM_lpage">1607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.2174%2F156802605775009694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=16375744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD28XislSlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1589-1607&author=A.+Spaltensteinauthor=W.+M.+Kazmierskiauthor=J.+F.+Millerauthor=V.+Samano&title=Discovery+of+Next+Generation+Inhibitors+of+HIV+Protease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of next generation inhibitors of HIV protease</span></div><div class="casAuthors">Spaltenstein, Andrew; Kazmierski, Wieslaw M.; Miller, John F.; Samano, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1589-1607</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Due to factors such as resistance and long-term side effects as well as dosing regimen-related adherence issues, HIV therapy is a constantly moving target.  HIV-1 protease inhibitors had an immediate and dramatic impact on the outcome of HIV/AIDS when launched in late 1995, and the search for new and improved next generation mols. has been under way in many labs.  At GlaxoSmithKline (GSK) and Vertex Pharmaceuticals, this effort focused on 2 key issues, patient compliance and viral resistance.  Using a water-solubilizing prodrug approach, the pill burden in delivering a protease inhibitor, Amprenavir, was dramatically decreased.  By eliminating the large amts. of excipients necessary for the original soft-gel formulation, Fosamprenavir (Lexiva/Telzir) delivers the clin. efficacious dose of Amprenavir with 2 compact tablets per dose, compared to 8 gel capsules.  The efforts to overcome viral resistance to 1st generation protease inhibitors by further elaborating the SAR of the Amprenavir and related scaffolds led to successive and dramatic improvements in wild-type antiviral potencies, and ultimately to the discovery of ultra-potent mols. with very favorable overall resistance profiles.  The selection of GW640385 (Brecanavir - USAN approved only) as a clin. candidate and its progression into current phase 2 dose ranging studies represents the culmination of the effort toward the next generation protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplhByH_w0_47Vg90H21EOLACvtfcHk0lgWDzQitZsrEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislSlsLs%253D&md5=5bf9ffbed174a9cd87b109d7e45410a8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F156802605775009694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802605775009694%26sid%3Dliteratum%253Aachs%26aulast%3DSpaltenstein%26aufirst%3DA.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DMiller%26aufirst%3DJ.%2BF.%26aulast%3DSamano%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520Next%2520Generation%2520Inhibitors%2520of%2520HIV%2520Protease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1589%26epage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumaragurubaran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Bis-tetrahydrofuran: A Privileged Ligand for Darunavir and a New Generation of HIV-Protease Inhibitors That Combat Drug-Resistance</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">950</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=939-950&author=A.+K.+Ghoshauthor=P.+R.+Sridharauthor=N.+Kumaragurubaranauthor=Y.+Kohauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Bis-tetrahydrofuran%3A+A+Privileged+Ligand+for+Darunavir+and+a+New+Generation+of+HIV-Protease+Inhibitors+That+Combat+Drug-Resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DSridhar%26aufirst%3DP.%2BR.%26aulast%3DKumaragurubaran%26aufirst%3DN.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DBis-tetrahydrofuran%253A%2520A%2520Privileged%2520Ligand%2520for%2520Darunavir%2520and%2520a%2520New%2520Generation%2520of%2520HIV-Protease%2520Inhibitors%2520That%2520Combat%2520Drug-Resistance%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D939%26epage%3D950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovalevsky, A. Yu.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedekind, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grum-Tokars, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatanaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5252</span><span class="NLM_x">–</span> <span class="NLM_lpage">5261</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060561m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1Wqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5252-5261&author=A.+K.+Ghoshauthor=P.+R.+Sridharauthor=S.+Leshchenkoauthor=A.+K.+Hussainauthor=J.+Liauthor=A.+Yu.+Kovalevskyauthor=D.+E.+Waltersauthor=J.+E.+Wedekindauthor=V.+Grum-Tokarsauthor=D.+Dasauthor=Y.+Kohauthor=K.+Maedaauthor=H.+Gatanagaauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Structure-Based+Design+of+Novel+HIV-1+Protease+Inhibitors+To+Combat+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance</span></div><div class="casAuthors">Ghosh, Arun K.; Sridhar, Perali Ramu; Leshchenko, Sofiya; Hussain, Azhar K.; Li, Jianfeng; Kovalevsky, Andrey Yu.; Walters, D. Eric; Wedekind, Joseph E.; Grum-Tokars, Valerie; Das, Debananda; Koh, Yasuhiro; Maeda, Kenji; Gatanaga, Hiroyuki; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5252-5261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based design and synthesis of novel HIV protease inhibitors are described.  The inhibitors are designed specifically to interact with the backbone of HIV protease active site to combat drug resistance.  Inhibitor (I) has exhibited exceedingly potent enzyme inhibitory and antiviral potency.  Furthermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a variety of multi-PI-resistant clin. strains.  The inhibitors incorporated a stereochem. defined 5-hexahydrocyclopenta[b]furanyl urethane as the P2-ligand into the (R)-(hydroxyethylamino)sulfonamide isostere.  Optically active (3aS,5R,6aR)-5-hydroxy-hexahydrocyclopenta[b]furan was prepd. by an enzymic asymmetrization of meso-diacetate with acetyl cholinesterase, radical cyclization, and Lewis acid-catalyzed anomeric redn. as the key steps.  A protein-ligand x-ray crystal structure of inhibitor I-bound HIV-1 protease (1.35 Å resoln.) revealed extensive interactions in the HIV protease active site including strong hydrogen bonding interactions with the backbone.  This design strategy may lead to novel inhibitors that can combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdf3BkHGYz7rVg90H21EOLACvtfcHk0lhbRcAHEUvanw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1Wqu7Y%253D&md5=a82e762625bf1dd78bbe129a1b426560</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm060561m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060561m%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DSridhar%26aufirst%3DP.%2BR.%26aulast%3DLeshchenko%26aufirst%3DS.%26aulast%3DHussain%26aufirst%3DA.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKovalevsky%26aufirst%3DA.%2BYu.%26aulast%3DWalters%26aufirst%3DD.%2BE.%26aulast%3DWedekind%26aufirst%3DJ.%2BE.%26aulast%3DGrum-Tokars%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DGatanaga%26aufirst%3DH.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DStructure-Based%2520Design%2520of%2520Novel%2520HIV-1%2520Protease%2520Inhibitors%2520To%2520Combat%2520Drug%2520Resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5252%26epage%3D5261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldridge, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agniswamy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miguel, S. G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Probing Multidrug-Resistance/Protein−Ligand Interaction with New Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1850</span><span class="NLM_x">–</span> <span class="NLM_lpage">1854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1850-1854&author=A.+K.+Ghoshauthor=C.-X.+Xuauthor=K.+V.+Raoauthor=A.+Baldridgeauthor=J.+Agniswamyauthor=Y.-F.+Wangauthor=I.+T.+Weberauthor=M.+Aokiauthor=S.+G.+P.+Miguelauthor=M.+Amanoauthor=H.+Mitsuya&title=Probing+Multidrug-Resistance%2FProtein%E2%88%92Ligand+Interaction+with+New+Oxatricyclic+Designed+Ligands+in+HIV-1+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DXu%26aufirst%3DC.-X.%26aulast%3DRao%26aufirst%3DK.%2BV.%26aulast%3DBaldridge%26aufirst%3DA.%26aulast%3DAgniswamy%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DMiguel%26aufirst%3DS.%2BG.%2BP.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DProbing%2520Multidrug-Resistance%252FProtein%25E2%2588%2592Ligand%2520Interaction%2520with%2520New%2520Oxatricyclic%2520Designed%2520Ligands%2520in%2520HIV-1%2520Protease%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1850%26epage%3D1854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>FDA News Release, June 23, 2006: FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News+Release%2C+June+23%2C+2006%3A+FDA+Approves+New+HIV+Treatment+for+Patients+Who+Do+Not+Respond+to+Existing+Drugs.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2F2006%2Fucm108676.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="note"><p class="first last">On October 21, 2008, FDA expanded approval to Prezista (darunavir), coadministered with ritonavir and with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-naive adult patients. In addition to the traditional approval, a new dosing regimen for treatment-naive adult patients was approved.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilcer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devasamudram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kincaid, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volarath, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaddis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Novel Bis-tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus in Vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3123</span><span class="NLM_x">–</span> <span class="NLM_lpage">3129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FAAC.47.10.3123-3129.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=14506019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVWmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=3123-3129&author=Y.+Kohauthor=H.+Nakataauthor=K.+Maedaauthor=H.+Ogataauthor=G.+Bilcerauthor=T.+Devasamudramauthor=J.+F.+Kincaidauthor=P.+Borossauthor=Y.-F.+Wangauthor=Y.+Tieauthor=P.+Volarathauthor=L.+Gaddisauthor=R.+W.+Harrisonauthor=I.+T.+Weberauthor=A.+K.+Ghoshauthor=H.+Mitsuya&title=Novel+Bis-tetrahydrofuranylurethane-Containing+Nonpeptidic+Protease+Inhibitor+%28PI%29+UIC-94017+%28TMC114%29+with+Potent+Activity+against+Multi-PI-Resistant+Human+Immunodeficiency+Virus+in+Vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro</span></div><div class="casAuthors">Koh, Yasuhiro; Nakata, Hirotomo; Maeda, Kenji; Ogata, Hiromi; Bilcer, Geoffrey; Devasamudram, Thippeswamy; Kincaid, John F.; Boross, Peter; Wang, Yuan-Fang; Tie, Yunfeng; Volarath, Patra; Gaddis, Laquasha; Harrison, Robert W.; Weber, Irene T.; Ghosh, Arun K.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3123-3129</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) contg. a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against lab. HIV-1 strains and primary clin. isolates (50% inhibitory concn. [IC50], ∼0.003 μM; IC90, ∼0.009 μM) with minimal cytotoxicity (50% cytotoxic concn. for CD4+ MT-2 cells, 74 μM).  UIC-94017 blocked the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concns. up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to amprenavir (IC50, 0.22 μM).  UIC-94017 was also potent against multi-PI-resistant clin. HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents.  Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants.  Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxs09jTg7yoLVg90H21EOLACvtfcHk0lhbRcAHEUvanw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVWmsbo%253D&md5=b6b08cabb983eec9e2cc5d7e2bcd16ae</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.10.3123-3129.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.10.3123-3129.2003%26sid%3Dliteratum%253Aachs%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DBilcer%26aufirst%3DG.%26aulast%3DDevasamudram%26aufirst%3DT.%26aulast%3DKincaid%26aufirst%3DJ.%2BF.%26aulast%3DBoross%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DTie%26aufirst%3DY.%26aulast%3DVolarath%26aufirst%3DP.%26aulast%3DGaddis%26aufirst%3DL.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DNovel%2520Bis-tetrahydrofuranylurethane-Containing%2520Nonpeptidic%2520Protease%2520Inhibitor%2520%2528PI%2529%2520UIC-94017%2520%2528TMC114%2529%2520with%2520Potent%2520Activity%2520against%2520Multi-PI-Resistant%2520Human%2520Immunodeficiency%2520Virus%2520in%2520Vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D3123%26epage%3D3129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">De Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azijn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochmans, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bethune, M.-P.</span><span> </span><span class="NLM_article-title">TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2314</span><span class="NLM_x">–</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FAAC.49.6.2314-2321.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15917527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=2314-2321&author=S.+De+Meyerauthor=H.+Azijnauthor=D.+Surlerauxauthor=D.+Jochmansauthor=A.+Tahriauthor=R.+Pauwelsauthor=P.+Wigerinckauthor=M.-P.+de+Bethune&title=TMC114%2C+a+Novel+Human+Immunodeficiency+Virus+Type+1+Protease+Inhibitor+Active+against+Protease+Inhibitor-Resistant+Viruses%2C+Including+a+Broad+Range+of+Clinical+Isolates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates</span></div><div class="casAuthors">De Meyer, Sandra; Azijn, Hilde; Surleraux, Dominique; Jochmans, Dirk; Tahri, Abdellah; Pauwels, Rudi; Wigerinck, Piet; de Bethune, Marie-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2314-2321</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The purpose of this study was to characterize the antiviral activity, cytotoxicity, and mechanism of action of TMC114, a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI).  TMC114 exhibited potent anti-HIV activity with a 50% effective concn. (EC50) of 1 to 5 nM and a 90% effective concn. of 2.7 to 13 nM.  TMC114 exhibited no cytotoxicity at concns. up to 100 μM (selectivity index, >20,000).  All viruses in a panel of 19 recombinant clin. isolates carrying multiple protease mutations and demonstrating resistance to an av. of five other PIs, were susceptible to TMC114, defined as a fold change in EC50 of <4.  TMC114 was also effective against the majority of 1501 PI-resistant recombinant viruses derived from recent clin. samples, with EC50s of <10 nM for 75% of the samples.  In sequential passage expts. using HIV-1 LAI, two mutations (R41T and K70E) were selected.  One selected virus showed a 10-fold redn. in susceptibility to TMC114, but <10-fold redns. in susceptibility to the current PIs (atazanavir was not assessed), except saquinavir.  However, when the selected mutations were introduced into a lab. strain by site-directed mutagenesis, they had no effect on susceptibility to TMC114 or other PIs.  There was no evidence of antagonism between TMC114 and any currently available PIs or reverse transcriptase inhibitors.  Combinations with ritonavir, nelfinavir, and amprenavir showed some evidence of synergy.  These results suggest that TMC114 is a potential candidate for the treatment of both naive and PI-experienced patients with HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb3029R5vTU7Vg90H21EOLACvtfcHk0lhlQobFWfUd8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrs%253D&md5=2257492f3a092600688a4abcac54435e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.6.2314-2321.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.6.2314-2321.2005%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMeyer%26aufirst%3DS.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DJochmans%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dde%2BBethune%26aufirst%3DM.-P.%26atitle%3DTMC114%252C%2520a%2520Novel%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Protease%2520Inhibitor%2520Active%2520against%2520Protease%2520Inhibitor-Resistant%2520Viruses%252C%2520Including%2520a%2520Broad%2520Range%2520of%2520Clinical%2520Isolates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2314%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Lefebvre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Resilience to Resistance of HIV-1 Protease Inhibitors: Profile of Darunavir</span> <span class="citation_source-journal">AIDS Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=18820715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADC%252BD1cnjtVOqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=131-142&author=E.+Lefebvreauthor=C.+A.+Schiffer&title=Resilience+to+Resistance+of+HIV-1+Protease+Inhibitors%3A+Profile+of+Darunavir"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir</span></div><div class="casAuthors">Lefebvre Eric; Schiffer Celia A</div><div class="citationInfo"><span class="NLM_cas:title">AIDS reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-42</span>
        ISSN:<span class="NLM_cas:issn">1139-6121</span>.
    </div><div class="casAbstract">The current effectiveness of HAART in the management of HIV infection is compromised by the emergence of extensively cross-resistant strains of HIV-1, requiring a significant need for new therapeutic agents.  Due to its crucial role in viral maturation and therefore HIV-1 replication and infectivity, the HIV-1 protease continues to be a major development target for antiretroviral therapy.  However, new protease inhibitors must have higher thresholds to the development of resistance and cross-resistance.  Research has demonstrated that the binding characteristics between a protease inhibitor and the active site of the HIV-1 protease are key factors in the development of resistance.  More specifically, the way in which a protease inhibitor fits within the substrate consensus volume, or "substrate envelope", appears to be critical.  The currently available inhibitors are not only smaller than the native substrates, but also have a different shape.  This difference in shape underlies observed patterns of resistance because primary drug-resistant mutations often arise at positions in the protease where the inhibitors protrude beyond the substrate envelope but are still in contact with the enzyme.  Since all currently available protease inhibitors occupy a similar space (in spite of their structural differences) in the active site of the enzyme, the specific positions where the inhibitors protrude and contact the enzyme correspond to the locations where most mutations occur that give rise to multidrug-resistant HIV-1 strains.  Detailed investigation of the structure, thermodynamics, and dynamics of the active site of the protease enzyme is enabling the identification of new protease inhibitors that more closely fit within the substrate envelope and therefore decrease the risk of drug resistance developing.  The features of darunavir, the latest FDA-approved protease inhibitor, include its high binding affinity (Kd = 4.5 x 10-12 M) for the protease active site, the presence of hydrogen bonds with the backbone, and its ability to fit closely within the substrate envelope (or consensus volume).  Darunavir is potent against both wild-type and protease inhibitor-resistant viruses in vitro, including a broad range of over 4,000 clinical isolates.  Additionally, in vitro selection studies with wild-type HIV-1 strains have shown that resistance to darunavir develops much more slowly and is more difficult to generate than for existing protease inhibitors.  Clinical studies have shown that darunavir administered with low-dose ritonavir (darunavir/ritonavir) provides highly potent viral suppression (including significant decreases in HIV viral load in patients with documented protease inhibitor resistance) together with favorable tolerability.  In conclusion, as a result of its high binding affinity for and overall fit within the active site of HIV-1 protease, darunavir has a higher genetic barrier to the development of resistance and better clinical efficacy against multidrug-resistant HIV relative to current protease inhibitors.  The observed efficacy, safety and tolerability of darunavir in highly treatment-experienced patients makes darunavir an important new therapeutic option for HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRReWcDTR8Wad0Q2ypr7jHkfW6udTcc2eae-T9c47yEd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnjtVOqsA%253D%253D&md5=f86f996c06f6432434694c1e38ec58d5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLefebvre%26aufirst%3DE.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DResilience%2520to%2520Resistance%2520of%2520HIV-1%2520Protease%2520Inhibitors%253A%2520Profile%2520of%2520Darunavir%26jtitle%3DAIDS%2520Rev.%26date%3D2008%26volume%3D10%26spage%3D131%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapsal, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar7001232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFyhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=78-86&author=A.+K.+Ghoshauthor=B.+D.+Chapsalauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Design+of+HIV+Protease+Inhibitors+Targeting+Protein+Backbone%3A+An+Effective+Strategy+for+Combating+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance</span></div><div class="casAuthors">Ghosh, Arun K.; Chapsal, Bruno D.; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-86</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery of HIV protease inhibitors (PIs) followed by their incorporation into highly active antiretroviral therapy (HAART) was a major turning point for the management of HIV/AIDS.  However, the rapid emergence of drug resistance has become a major concern.  Our structure-based design of HIV-1 PIs that can specifically interact with the enzyme backbone atoms has led to the development of compds. with unprecedented potency and drug-resistance profiles.  Particularly notable is the development of a stereochem. defined bis(tetrahydrofuranyl)urethane as the non-peptidic P2 ligand.  Incorporation of this ligand has provided a variety of exceedingly potent HIV-1 PIs with superior activity against multi-PI-resistant variants relative to other FDA-approved PIs.  Darunavir, a PI recently approved for the treatment of drug-resistant HIV, directly resulted from this strategy.  Our detailed protein-darunavir X-ray crystal structures have clearly demonstrated extensive interactions with the protein backbone in the enzyme active site.  This present design concept targeting the protein backbone may serve as a powerful strategy to combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZCuOKomAEbVg90H21EOLACvtfcHk0ljEo333ZnIw_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFyhsbo%253D&md5=a8ee6f368273a5fece6ebbaf9bafc750</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Far7001232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far7001232%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DChapsal%26aufirst%3DB.%2BD.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DDesign%2520of%2520HIV%2520Protease%2520Inhibitors%2520Targeting%2520Protein%2520Backbone%253A%2520An%2520Effective%2520Strategy%2520for%2520Combating%2520Drug%2520Resistance%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D78%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Tie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boross, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaddis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span> </span><span class="NLM_article-title">High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-Peptide Inhibitor (UIC-94017) Active against Multi-Drug-Resistant Clinical Strains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1016%2Fj.jmb.2004.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15066436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVeltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2004&pages=341-352&author=Y.+Tieauthor=P.+I.+Borossauthor=Y.-F.+Wangauthor=L.+Gaddisauthor=A.+K.+Hussainauthor=S.+Leshchenkoauthor=A.+K.+Ghoshauthor=J.+M.+Louisauthor=R.+W.+Harrisonauthor=I.+T.+Weber&title=High+Resolution+Crystal+Structures+of+HIV-1+Protease+with+a+Potent+Non-Peptide+Inhibitor+%28UIC-94017%29+Active+against+Multi-Drug-Resistant+Clinical+Strains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical Strains</span></div><div class="casAuthors">Tie, Yunfeng; Boross, Peter I.; Wang, Yuan-Fang; Gaddis, Laquasha; Hussain, Azhar K.; Leshchenko, Sofiya; Ghosh, Arun K.; Louis, John M.; Harrison, Robert W.; Weber, Irene T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-352</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The compd. UIC-94017 (TMC-114) is a second-generation HIV protease inhibitor with improved pharmacokinetics that is chem. related to the clin. inhibitor amprenavir.  UIC-94017 is a broad-spectrum potent inhibitor active against HIV-1 clin. isolates with minimal cytotoxicity.  We have detd. the high-resoln. crystal structures of UIC-94017 in complexes with wild-type HIV-1 protease (PR) and mutant proteases PRV82A and PRI84V that are common in drug-resistant HIV.  The structures were refined at resolns. of 1.10 - 1.53 Å.  The crystal structures of PR and PRI84V with UIC-94017 ternary complexes show that the inhibitor binds to the protease in two overlapping positions, while the PRV82A complex had one ordered inhibitor.  In all three structures, UIC-94017 forms hydrogen bonds with the conserved main-chain atoms of Asp29 and Asp30 of the protease.  These interactions are proposed to be crit. for the potency of this compd. against HIV isolates that are resistant to multiple protease inhibitors.  Other small differences were obsd. in the interactions of the mutants with UIC-94017 as compared to PR.  PRV82A showed differences in the position of the main-chain atoms of residue 82 compared to PR structure that better accommodated the inhibitor.  Finally, the 1.10 Å resoln. structure of PRV82A with UIC-94017 showed an unusual distribution of electron d. for the catalytic aspartate residues, which is discussed in relation to the reaction mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHW51Not1WA7Vg90H21EOLACvtfcHk0lj9ZqCSm6Zcew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVeltL0%253D&md5=82ecc0bb118a886b254ac579ffe9c5fc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DTie%26aufirst%3DY.%26aulast%3DBoross%26aufirst%3DP.%2BI.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGaddis%26aufirst%3DL.%26aulast%3DHussain%26aufirst%3DA.%2BK.%26aulast%3DLeshchenko%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DLouis%26aufirst%3DJ.%2BM.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26atitle%3DHigh%2520Resolution%2520Crystal%2520Structures%2520of%2520HIV-1%2520Protease%2520with%2520a%2520Potent%2520Non-Peptide%2520Inhibitor%2520%2528UIC-94017%2529%2520Active%2520against%2520Multi-Drug-Resistant%2520Clinical%2520Strains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D338%26spage%3D341%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">King, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabu-Jeyabalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalivaika, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bethune, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Structural and Thermodynamic Basis for the Binding of TMC114 a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">12012</span><span class="NLM_x">–</span> <span class="NLM_lpage">12021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FJVI.78.21.12012-12021.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15479840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVKlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=12012-12021&author=N.+M.+Kingauthor=M.+Prabu-Jeyabalanauthor=E.+A.+Nalivaikaauthor=P.+Wigerinckauthor=M.-P.+de+Bethuneauthor=C.+A.+Schiffer&title=Structural+and+Thermodynamic+Basis+for+the+Binding+of+TMC114+a+Next-Generation+Human+Immunodeficiency+Virus+Type+1+Protease+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor</span></div><div class="casAuthors">King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Wigerinck, Piet; de Bethune, Marie-Pierre; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12012-12021</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild-type (wt.) and multidrug-resistant (MDR) viruses in vitro as well as in vivo.  Although chem. similar to amprenavir (APV), the potency of TMC114 is substantially greater.  To examine the basis for this potency, we solved crystal structures of TMC114 complexed with wt. HIV-1 protease and TMC114 and APV complexed with an MDR (L63P, V82T, and I84V) protease variant.  In addn., we detd. the corresponding binding thermodn. by isothermal titrn. calorimetry.  TMC114 binds approx. 2 orders of magnitude more tightly to the wt. enzyme (Kd = 4.5×10-12 M) than APV (Kd = 3.9×10-10 M).  Our x-ray data (resoln. ranging from 2.2 to 1.2 Å) reveal strong interactions between the bis-tetrahydrofuranyl urethane moiety of TMC114 and main-chain atoms of D29 and D30.  These interactions appear largely responsible for TMC114's very favorable binding enthalpy to the wt. protease (-12.1 kcal/mol).  However, TMC114 binding to the MDR HIV-1 protease is reduced by a factor of 13.3, whereas the APV binding const. is reduced only by a factor of 5.1.  However, even with the redn. in binding affinity to the MDR HIV protease, TMC114 still binds with an affinity that is more than 1.5 orders of magnitude tighter than the first-generation inhibitors.  Both APV and TMC114 fit predominantly within the substrate envelope, a property that may be assocd. with decreased susceptibility to drug-resistant mutations relative to that of first-generation inhibitors.  Overall, TMC114's potency against MDR viruses is likely a combination of its extremely high affinity and close fit within the substrate envelope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRCtpDBSgPLVg90H21EOLACvtfcHk0lj9ZqCSm6Zcew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVKlsbw%253D&md5=dbe410a8b7dc6a5078c312e90f24a538</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.21.12012-12021.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.21.12012-12021.2004%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DN.%2BM.%26aulast%3DPrabu-Jeyabalan%26aufirst%3DM.%26aulast%3DNalivaika%26aufirst%3DE.%2BA.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dde%2BBethune%26aufirst%3DM.-P.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DStructural%2520and%2520Thermodynamic%2520Basis%2520for%2520the%2520Binding%2520of%2520TMC114%2520a%2520Next-Generation%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Protease%2520Inhibitor%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D12012%26epage%3D12021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kovalevsky, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span> </span><span class="NLM_article-title">Ultra-High Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1016%2Fj.jmb.2006.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=16962136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFSitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2006&pages=161-173&author=A.+Y.+Kovalevskyauthor=F.+Liuauthor=S.+Leshchenkoauthor=A.+K.+Ghoshauthor=J.+M.+Louisauthor=R.+W.+Harrisonauthor=I.+T.+Weber&title=Ultra-High+Resolution+Crystal+Structure+of+HIV-1+Protease+Mutant+Reveals+Two+Binding+Sites+for+Clinical+Inhibitor+TMC114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114</span></div><div class="casAuthors">Kovalevsky, Andrey Y.; Liu, Fengling; Leshchenko, Sofiya; Ghosh, Arun K.; Louis, John M.; Harrison, Robert W.; Weber, Irene T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-173</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">TMC114 (darunavir) is a promising clin. inhibitor of HIV-1 protease (PR) for treatment of drug resistant HIV/AIDS.  We report the ultra-high 0.84 Å resoln. crystal structure of the TMC114 complex with PR contg. the drug-resistant mutation V32I (PRV32I), and the 1.22 Å resoln. structure of a complex with PRM46L.  These structures show TMC114 bound at two distinct sites, one in the active-site cavity and the second on the surface of one of the flexible flaps in the PR dimer.  Remarkably, TMC114 binds at these two sites simultaneously in two diastereomers related by inversion of the sulfonamide nitrogen.  Moreover, the flap site is shaped to accommodate the diastereomer with the S-enantiomeric nitrogen rather than the one with the R-enantiomeric nitrogen.  The existence of the second binding site and two diastereomers suggest a mechanism for the high effectiveness of TMC114 on drug-resistant HIV and the potential design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8m58MkQUwabVg90H21EOLACvtfcHk0lho7z3i59203Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFSitLY%253D&md5=16353639fe7af398614b0078c396cb6d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2006.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2006.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DKovalevsky%26aufirst%3DA.%2BY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLeshchenko%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DLouis%26aufirst%3DJ.%2BM.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26atitle%3DUltra-High%2520Resolution%2520Crystal%2520Structure%2520of%2520HIV-1%2520Protease%2520Mutant%2520Reveals%2520Two%2520Binding%2520Sites%2520for%2520Clinical%2520Inhibitor%2520TMC114%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D363%26spage%3D161%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Amano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leschenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boross, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">A Novel Bis-tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multi-PI-Resistant Human Immunodeficiency Virus in Vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=2143-2155&author=M.+Amanoauthor=Y.+Kohauthor=D.+Dasauthor=J.+Liauthor=S.+Leschenkoauthor=Y.-F.+Wangauthor=P.+I.+Borossauthor=I.+T.+Weberauthor=A.+K.+Ghoshauthor=H.+Mitsuya&title=A+Novel+Bis-tetrahydrofuranylurethane-Containing+Nonpeptidic+Protease+Inhibitor+%28PI%29%2C+GRL-98065%2C+Is+Potent+against+Multi-PI-Resistant+Human+Immunodeficiency+Virus+in+Vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLeschenko%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DBoross%26aufirst%3DP.%2BI.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DA%2520Novel%2520Bis-tetrahydrofuranylurethane-Containing%2520Nonpeptidic%2520Protease%2520Inhibitor%2520%2528PI%2529%252C%2520GRL-98065%252C%2520Is%2520Potent%2520against%2520Multi-PI-Resistant%2520Human%2520Immunodeficiency%2520Virus%2520in%2520Vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D2143%26epage%3D2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nakashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masayuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogasawara, K.</span><span> </span><span class="NLM_article-title">Chiral Preparation of Polyoxygenated Cyclopentanoids</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1055%2Fs-2000-6271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=817-823&author=H.+Nakashimaauthor=S.+Masayukiauthor=T.+Taniguchiauthor=K.+Ogasawara&title=Chiral+Preparation+of+Polyoxygenated+Cyclopentanoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-6271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-6271%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DMasayuki%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOgasawara%26aufirst%3DK.%26atitle%3DChiral%2520Preparation%2520of%2520Polyoxygenated%2520Cyclopentanoids%26jtitle%3DSynthesis%26date%3D2000%26volume%3D6%26spage%3D817%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Laumen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M. P.</span><span> </span><span class="NLM_article-title">A Facile Chemoenzymatic Route to Optically Pure Building Blocks for Cyclopentanoid Natural Products</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1039%2Fc39860001298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADyaL2sXosVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&pages=1298-1299&author=K.+Laumenauthor=M.+P.+Schneider&title=A+Facile+Chemoenzymatic+Route+to+Optically+Pure+Building+Blocks+for+Cyclopentanoid+Natural+Products"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">A facile chemoenzymic route to optically pure building blocks for cyclopentanoid natural products</span></div><div class="casAuthors">Laumen, Kurt; Schneider, Manfred P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1298-9</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Enantioselective hydrolysis of cis-3,5-diacetoxycyclopent-1-ene by lipases gave (1R,4S)-4-acetoxycyclopent-2-en-1-ol (I) enantioselectively in 76-90% yield and 91-97% enantiomeric excess.  I is a central chiral building block for cyclopentanoid natural products; several cyclopentanoid synthons, e.g. (R)-4-hydroxycyclopent-2-en-1-one, were prepd. from I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3axL7eZ_irVg90H21EOLACvtfcHk0lho7z3i59203Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXosVahtQ%253D%253D&md5=49c2dd3ff74c88e671ff98d80b591c06</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1039%2Fc39860001298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39860001298%26sid%3Dliteratum%253Aachs%26aulast%3DLaumen%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DM.%2BP.%26atitle%3DA%2520Facile%2520Chemoenzymatic%2520Route%2520to%2520Optically%2520Pure%2520Building%2520Blocks%2520for%2520Cyclopentanoid%2520Natural%2520Products%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1986%26spage%3D1298%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Ishihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span> </span><span class="NLM_article-title">An Extremely Simple, Convenient, and Selective Method for Acylating Primary Alcohols in the Presence of Secondary Alcohols</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3791</span><span class="NLM_x">–</span> <span class="NLM_lpage">3793</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00067a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=3791-3793&author=K.+Ishiharaauthor=H.+Kuriharaauthor=H.+Yamamoto&title=An+Extremely+Simple%2C+Convenient%2C+and+Selective+Method+for+Acylating+Primary+Alcohols+in+the+Presence+of+Secondary+Alcohols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo00067a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00067a005%26sid%3Dliteratum%253Aachs%26aulast%3DIshihara%26aufirst%3DK.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DH.%26atitle%3DAn%2520Extremely%2520Simple%252C%2520Convenient%252C%2520and%2520Selective%2520Method%2520for%2520Acylating%2520Primary%2520Alcohols%2520in%2520the%2520Presence%2520of%2520Secondary%2520Alcohols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1993%26volume%3D58%26spage%3D3791%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Nara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span> </span><span class="NLM_article-title">Stereochemical Studies—LVII Synthesis of Optically Active Compounds by the Novel Use of Meso-Compounds—1. Efficient Synthesis of Two Structural Types of Optically Pure Prostaglandin Intermediates</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3161</span><span class="NLM_x">–</span> <span class="NLM_lpage">3170</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1980&pages=3161-3170&author=M.+Naraauthor=S.+Terashimaauthor=S.+Yamada&title=Stereochemical+Studies%E2%80%94LVII+Synthesis+of+Optically+Active+Compounds+by+the+Novel+Use+of+Meso-Compounds%E2%80%941.+Efficient+Synthesis+of+Two+Structural+Types+of+Optically+Pure+Prostaglandin+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DM.%26aulast%3DTerashima%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DStereochemical%2520Studies%25E2%2580%2594LVII%2520Synthesis%2520of%2520Optically%2520Active%2520Compounds%2520by%2520the%2520Novel%2520Use%2520of%2520Meso-Compounds%25E2%2580%25941.%2520Efficient%2520Synthesis%2520of%2520Two%2520Structural%2520Types%2520of%2520Optically%2520Pure%2520Prostaglandin%2520Intermediates%26jtitle%3DTetrahedron%26date%3D1980%26volume%3D36%26spage%3D3161%26epage%3D3170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Moriarty, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, B. R.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, I.</span><span> </span><span class="NLM_article-title">Capture of Electron-Deficient Species with Aryl Halides. New Syntheses of Hypervalent Iodonium Ylides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">–</span> <span class="NLM_lpage">1378</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00291a044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=1985&pages=1375-1378&author=R.+M.+Moriartyauthor=B.+R.+Baileyauthor=O.+Prakashauthor=I.+Prakash&title=Capture+of+Electron-Deficient+Species+with+Aryl+Halides.+New+Syntheses+of+Hypervalent+Iodonium+Ylides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja00291a044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00291a044%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26aulast%3DBailey%26aufirst%3DB.%2BR.%26aulast%3DPrakash%26aufirst%3DO.%26aulast%3DPrakash%26aufirst%3DI.%26atitle%3DCapture%2520of%2520Electron-Deficient%2520Species%2520with%2520Aryl%2520Halides.%2520New%2520Syntheses%2520of%2520Hypervalent%2520Iodonium%2520Ylides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1985%26volume%3D107%26spage%3D1375%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Müller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allenbach, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardinelli, G.</span><span> </span><span class="NLM_article-title">On the Enantioselectivity of Transition Metal-Catalyzed 1,3-Cycloadditions of 2-Diazocyclohexane-1,3-diones</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">3164</span><span class="NLM_x">–</span> <span class="NLM_lpage">3178</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2003&pages=3164-3178&author=P.+M%C3%BCllerauthor=Y.+F.+Allenbachauthor=G.+Bernardinelli&title=On+the+Enantioselectivity+of+Transition+Metal-Catalyzed+1%2C3-Cycloadditions+of+2-Diazocyclohexane-1%2C3-diones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DAllenbach%26aufirst%3DY.%2BF.%26aulast%3DBernardinelli%26aufirst%3DG.%26atitle%3DOn%2520the%2520Enantioselectivity%2520of%2520Transition%2520Metal-Catalyzed%25201%252C3-Cycloadditions%2520of%25202-Diazocyclohexane-1%252C3-diones%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2003%26volume%3D86%26spage%3D3164%26epage%3D3178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Ferrie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reymond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdevielle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossy, J.</span><span> </span><span class="NLM_article-title">Formal Chemoselective Synthesis of Leucascandrolide A</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2461</span><span class="NLM_x">–</span> <span class="NLM_lpage">2464</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol070670a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=2461-2464&author=L.+Ferrieauthor=S.+Reymondauthor=P.+Capdevielleauthor=J.+Cossy&title=Formal+Chemoselective+Synthesis+of+Leucascandrolide+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fol070670a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol070670a%26sid%3Dliteratum%253Aachs%26aulast%3DFerrie%26aufirst%3DL.%26aulast%3DReymond%26aufirst%3DS.%26aulast%3DCapdevielle%26aufirst%3DP.%26aulast%3DCossy%26aufirst%3DJ.%26atitle%3DFormal%2520Chemoselective%2520Synthesis%2520of%2520Leucascandrolide%2520A%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D2461%26epage%3D2464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tsantali, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takakis, I. M.</span><span> </span><span class="NLM_article-title">Expeditious Copper-Catalyzed Conjugate 1,4-Addition of Bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to α,β-Cycloalkenones and Subsequent Tranformations</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">6455</span><span class="NLM_x">–</span> <span class="NLM_lpage">6458</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo034350q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=6455-6458&author=G.+G.+Tsantaliauthor=I.+M.+Takakis&title=Expeditious+Copper-Catalyzed+Conjugate+1%2C4-Addition+of+Bromo%5B2-%281%2C3-dioxolan-2-yl%29ethyl%5Dmagnesium+to+%CE%B1%2C%CE%B2-Cycloalkenones+and+Subsequent+Tranformations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo034350q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034350q%26sid%3Dliteratum%253Aachs%26aulast%3DTsantali%26aufirst%3DG.%2BG.%26aulast%3DTakakis%26aufirst%3DI.%2BM.%26atitle%3DExpeditious%2520Copper-Catalyzed%2520Conjugate%25201%252C4-Addition%2520of%2520Bromo%255B2-%25281%252C3-dioxolan-2-yl%2529ethyl%255Dmagnesium%2520to%2520%25CE%25B1%252C%25CE%25B2-Cycloalkenones%2520and%2520Subsequent%2520Tranformations%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D6455%26epage%3D6458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Shen, Z.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geo, G.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, T.-P.</span><span> </span><span class="NLM_article-title">Indium-Copper and Indium-Silver Mediated Barbier Grignard Type Alkylation Reaction of Aldehydes Using Unactivated Alkyl Halides in Water</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">3922</span><span class="NLM_x">–</span> <span class="NLM_lpage">3924</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo8000589" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=3922-3924&author=Z.-L.+Shenauthor=G.-L.+Geoauthor=T.-P.+Loh&title=Indium-Copper+and+Indium-Silver+Mediated+Barbier+Grignard+Type+Alkylation+Reaction+of+Aldehydes+Using+Unactivated+Alkyl+Halides+in+Water"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjo8000589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo8000589%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DZ.-L.%26aulast%3DGeo%26aufirst%3DG.-L.%26aulast%3DLoh%26aufirst%3DT.-P.%26atitle%3DIndium-Copper%2520and%2520Indium-Silver%2520Mediated%2520Barbier%2520Grignard%2520Type%2520Alkylation%2520Reaction%2520of%2520Aldehydes%2520Using%2520Unactivated%2520Alkyl%2520Halides%2520in%2520Water%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D3922%26epage%3D3924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leschenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noetzel, M.</span><span> </span><span class="NLM_article-title">Stereoselective Photochemical 1,3-Dioxolane Addition to 5-Alkoxymethyl-2(5<i>H</i>)-furanone: Synthesis of Bis-tetrahydrofuranyl Ligand for HIV Protease Inhibitor UIC-94017 (TMC-114)</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">7822</span><span class="NLM_x">–</span> <span class="NLM_lpage">7829</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo049156y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=7822-7829&author=A.+K.+Ghoshauthor=S.+Leschenkoauthor=M.+Noetzel&title=Stereoselective+Photochemical+1%2C3-Dioxolane+Addition+to+5-Alkoxymethyl-2%285H%29-furanone%3A+Synthesis+of+Bis-tetrahydrofuranyl+Ligand+for+HIV+Protease+Inhibitor+UIC-94017+%28TMC-114%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo049156y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049156y%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DLeschenko%26aufirst%3DS.%26aulast%3DNoetzel%26aufirst%3DM.%26atitle%3DStereoselective%2520Photochemical%25201%252C3-Dioxolane%2520Addition%2520to%25205-Alkoxymethyl-2%25285H%2529-furanone%253A%2520Synthesis%2520of%2520Bis-tetrahydrofuranyl%2520Ligand%2520for%2520HIV%2520Protease%2520Inhibitor%2520UIC-94017%2520%2528TMC-114%2529%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D7822%26epage%3D7829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Toth, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, G. R.</span><span> </span><span class="NLM_article-title">A Simple Continuous Fluorometric Assay for HIV Protease</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1111%2Fj.1399-3011.1990.tb00994.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=2090647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADyaK3MXhvVSrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1990&pages=544-550&author=M.+V.+Tothauthor=G.+R.+Marshall&title=A+Simple+Continuous+Fluorometric+Assay+for+HIV+Protease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A simple, continuous fluorometric assay for HIV protease</span></div><div class="casAuthors">Toth, Mihaly V.; Marshall, Garland R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-50</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">Novel fluorogenic substrates for human immunodeficiency virus (HIV) aspartic protease were developed based on the principle of fluorescence energy transfer.  Starting from a p24/p15 cleavage site-derived hexapeptide substrate, Ac-Thr-Ile-Nle-Nle-Gln-Arg-NH2, incorporation of 2-aminobenzoic acid in place of the Ac group as the donor and p-nitrophenylalanine at the P1' position as acceptor gave the intramolecularly quenched fluorogenic substrate.  Cleavage of the substrate by HIV protease released the fluorescent N-terminal tripeptide from its close apposition to the quenching nitrobenzyl group, resulting in enhanced fluorescence.  An automated assay based on 96-well microtiter plates and a fluorometric plate reader were developed, which allowed high throughput of compds. in the search for HIV protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQqXZE66Ff9rVg90H21EOLACvtfcHk0ljd_jSx1bJSSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvVSrur8%253D&md5=dd889560b9da071462f0f07723802392</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1990.tb00994.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1990.tb00994.x%26sid%3Dliteratum%253Aachs%26aulast%3DToth%26aufirst%3DM.%2BV.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26atitle%3DA%2520Simple%2520Continuous%2520Fluorometric%2520Assay%2520for%2520HIV%2520Protease%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1990%26volume%3D36%26spage%3D544%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">MMFF VII. Characterization of MMFF94, MMFF94s, and Other Widely Available Force Fields for Conformational Energies and for Intermolecular-Interaction Energies and Geometries</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=730-748&author=T.+A.+Halgren&title=MMFF+VII.+Characterization+of+MMFF94%2C+MMFF94s%2C+and+Other+Widely+Available+Force+Fields+for+Conformational+Energies+and+for+Intermolecular-Interaction+Energies+and+Geometries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DMMFF%2520VII.%2520Characterization%2520of%2520MMFF94%252C%2520MMFF94s%252C%2520and%2520Other%2520Widely%2520Available%2520Force%2520Fields%2520for%2520Conformational%2520Energies%2520and%2520for%2520Intermolecular-Interaction%2520Energies%2520and%2520Geometries%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1999%26volume%3D20%26spage%3D730%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Hodgson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marriot, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisedale, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span> </span><span class="NLM_article-title">Isomerisations of Cycloalkene- and Bicycloalkene-Derived Achiral Epoxides by Enantioselective α-Deprotonation</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_fpage">2151</span><span class="NLM_x">–</span> <span class="NLM_lpage">2161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=2151-2161&author=D.+M.+Hodgsonauthor=G.+P.+Leeauthor=R.+E.+Marriotauthor=A.+J.+Thompsonauthor=R.+Wisedaleauthor=J.+Witherington&title=Isomerisations+of+Cycloalkene-+and+Bicycloalkene-Derived+Achiral+Epoxides+by+Enantioselective+%CE%B1-Deprotonation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DLee%26aufirst%3DG.%2BP.%26aulast%3DMarriot%26aufirst%3DR.%2BE.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DWisedale%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DIsomerisations%2520of%2520Cycloalkene-%2520and%2520Bicycloalkene-Derived%2520Achiral%2520Epoxides%2520by%2520Enantioselective%2520%25CE%25B1-Deprotonation%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1998%26spage%3D2151%26epage%3D2161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':[],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 62 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiao Guo, Yang Wu, Gongqiang Li, <span class="NLM_string-name hlFld-ContribAuthor">Ji-Bao Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Redox-Triggered Ruthenium-Catalyzed Remote C–H Acylation with Primary Alcohols. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (21)
                                     , 12987-12995. <a href="https://doi.org/10.1021/acscatal.0c03343" title="DOI URL">https://doi.org/10.1021/acscatal.0c03343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c03343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c03343%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DRedox-Triggered%252BRuthenium-Catalyzed%252BRemote%252BC%2525E2%252580%252593H%252BAcylation%252Bwith%252BPrimary%252BAlcohols%26aulast%3DGuo%26aufirst%3DXiao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31072020%26date%3D08102020%26date%3D23102020%26volume%3D10%26issue%3D21%26spage%3D12987%26epage%3D12995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Linah N. Rusere, Gordon J. Lockbaum, Mina Henes, Sook-Kyung Lee, Ean Spielvogel, Desaboini Nageswara Rao, Klajdi Kosovrasti, Ellen A. Nalivaika, Ronald Swanstrom, Nese Kurt Yilmaz, Celia A. Schiffer, <span class="NLM_string-name hlFld-ContribAuthor">Akbar Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8296-8313. <a href="https://doi.org/10.1021/acs.jmedchem.0c00529" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00529%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BAnalysis%252Bof%252BPotent%252BHybrid%252BHIV-1%252BProtease%252BInhibitors%252BContaining%252BBis-tetrahydrofuran%252Bin%252Ba%252BPseudosymmetric%252BDipeptide%252BIsostere%26aulast%3DRusere%26aufirst%3DLinah%2BN.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31032020%26date%3D03082020%26date%3D16072020%26volume%3D63%26issue%3D15%26spage%3D8296%26epage%3D8313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mei Zhu, Yue Dou, Ling Ma, Biao Dong, Fan Zhang, Guoning Zhang, Juxian Wang, Jinming Zhou, Shan Cen, <span class="NLM_string-name hlFld-ContribAuthor">Yucheng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1196-1204. <a href="https://doi.org/10.1021/acsmedchemlett.0c00043" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00043%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BHIV-1%252BProtease%252BInhibitors%252Bwith%252BMorpholine%252Bas%252Bthe%252BP2%252BLigand%252Bto%252BEnhance%252BActivity%252Bagainst%252BDRV-Resistant%252BVariants%26aulast%3DZhu%26aufirst%3DMei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27012020%26date%3D31032020%26date%3D02042020%26date%3D31032020%26volume%3D11%26issue%3D6%26spage%3D1196%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arun K. Ghosh, <span class="NLM_string-name hlFld-ContribAuthor">William L. Robinson</span>. </span><span class="cited-content_cbyCitation_article-title">A Photochemical Route to Optically Active Hexahydro-4H-furopyranol, a High-Affinity P2 Ligand for HIV-1 Protease Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (15)
                                     , 9801-9805. <a href="https://doi.org/10.1021/acs.joc.9b01361" title="DOI URL">https://doi.org/10.1021/acs.joc.9b01361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b01361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b01361%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BPhotochemical%252BRoute%252Bto%252BOptically%252BActive%252BHexahydro-4H-furopyranol%25252C%252Ba%252BHigh-Affinity%252BP2%252BLigand%252Bfor%252BHIV-1%252BProtease%252BInhibitors%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22052019%26date%3D16072019%26volume%3D84%26issue%3D15%26spage%3D9801%26epage%3D9805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arun K. Ghosh, Jacqueline N. Williams, Rachel Y. Ho, Hannah M. Simpson, Shin-ichiro Hattori, Hironori Hayashi, Johnson Agniswamy, Yuan-Fang Wang, Irene T. Weber, <span class="NLM_string-name hlFld-ContribAuthor">Hiroaki Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure–Activity Studies and Biological and X-ray Structural Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9722-9737. <a href="https://doi.org/10.1021/acs.jmedchem.8b01227" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01227%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BPotent%252BHIV-1%252BProtease%252BInhibitors%252BContaining%252BBicyclic%252BOxazolidinone%252BScaffold%252Bas%252Bthe%252BP2%252BLigands%25253A%252BStructure%2525E2%252580%252593Activity%252BStudies%252Band%252BBiological%252Band%252BX-ray%252BStructural%252BStudies%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03082018%26date%3D24102018%26volume%3D61%26issue%3D21%26spage%3D9722%26epage%3D9737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arun K. Ghosh, Prasanth R. Nyalapatla, Satish Kovela, Kalapala Venkateswara Rao, Margherita Brindisi, Heather L. Osswald, Masayuki Amano, Manabu Aoki, Johnson Agniswamy, Yuan-Fang Wang, Irene T. Weber, <span class="NLM_string-name hlFld-ContribAuthor">Hiroaki Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure–Activity Studies, Biological and X-ray Structural Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4561-4577. <a href="https://doi.org/10.1021/acs.jmedchem.8b00298" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00298%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BHighly%252BPotent%252BHIV-1%252BProtease%252BInhibitors%252BContaining%252BTricyclic%252BFused%252BRing%252BSystems%252Bas%252BNovel%252BP2%252BLigands%25253A%252BStructure%2525E2%252580%252593Activity%252BStudies%25252C%252BBiological%252Band%252BX-ray%252BStructural%252BAnalysis%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21022018%26date%3D15052018%26volume%3D61%26issue%3D10%26spage%3D4561%26epage%3D4577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Kalapala Venkateswara  Rao</span>, <span class="hlFld-ContribAuthor ">Prasanth R.  Nyalapatla</span>, <span class="hlFld-ContribAuthor ">Heather L.  Osswald</span>, <span class="hlFld-ContribAuthor ">Cuthbert D.  Martyr</span>, <span class="hlFld-ContribAuthor ">Manabu  Aoki</span>, <span class="hlFld-ContribAuthor ">Hironori  Hayashi</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Haydar  Bulut</span>, <span class="hlFld-ContribAuthor ">Debananda  Das</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, and <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (10)
                                     , 4267-4278. <a href="https://doi.org/10.1021/acs.jmedchem.7b00172" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00172</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00172%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BDevelopment%252Bof%252BHighly%252BPotent%252BHIV-1%252BProtease%252BInhibitors%252Bwith%252Ba%252BCrown-Like%252BOxotricyclic%252BCore%252Bas%252Bthe%252BP2-Ligand%252BTo%252BCombat%252BMultidrug-Resistant%252BHIV%252BVariants%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D02022017%26date%3D18042017%26date%3D25052017%26volume%3D60%26issue%3D10%26spage%3D4267%26epage%3D4278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Han  Chen</span>, <span class="hlFld-ContribAuthor ">Xue-Li  Sun</span>, <span class="hlFld-ContribAuthor ">Hua-Shi  Guan</span>, and <span class="hlFld-ContribAuthor ">Yan-Kai  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Diversity-Oriented One-Pot Synthesis to Construct Functionalized Chroman-2-one Derivatives and Other Heterocyclic Compounds. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (9)
                                     , 4774-4783. <a href="https://doi.org/10.1021/acs.joc.7b00461" title="DOI URL">https://doi.org/10.1021/acs.joc.7b00461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b00461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b00461%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDiversity-Oriented%252BOne-Pot%252BSynthesis%252Bto%252BConstruct%252BFunctionalized%252BChroman-2-one%252BDerivatives%252Band%252BOther%252BHeterocyclic%252BCompounds%26aulast%3DChen%26aufirst%3DYing-Han%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D26022017%26date%3D24042017%26date%3D05052017%26date%3D19042017%26volume%3D82%26issue%3D9%26spage%3D4774%26epage%3D4783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Heather L.  Osswald</span>, and <span class="hlFld-ContribAuthor ">Gary  Prato</span>  . </span><span class="cited-content_cbyCitation_article-title">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (11)
                                     , 5172-5208. <a href="https://doi.org/10.1021/acs.jmedchem.5b01697" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01697%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BHIV-1%252BProtease%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHIV%25252FAIDS%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D30102015%26date%3D22012016%26date%3D09062016%26volume%3D59%26issue%3D11%26spage%3D5172%26epage%3D5208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nuno R.  Candeias</span>, <span class="hlFld-ContribAuthor ">Roberta  Paterna</span>, and <span class="hlFld-ContribAuthor ">Pedro M. P.  Gois</span>  . </span><span class="cited-content_cbyCitation_article-title">Homologation Reaction of Ketones with Diazo Compounds. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (5)
                                     , 2937-2981. <a href="https://doi.org/10.1021/acs.chemrev.5b00381" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00381%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DHomologation%252BReaction%252Bof%252BKetones%252Bwith%252BDiazo%252BCompounds%26aulast%3DCandeias%26aufirst%3DNuno%2BR.%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D30062015%26date%3D08022016%26date%3D09032016%26volume%3D116%26issue%3D5%26spage%3D2937%26epage%3D2981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Xufen  Yu</span>, <span class="hlFld-ContribAuthor ">Heather L.  Osswald</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Masayuki  Amano</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, and <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of Potent HIV-1 Protease Inhibitors with Modified P1-Biphenyl Ligands: Synthesis, Biological Evaluation, and Enzyme–Inhibitor X-ray Structural Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (13)
                                     , 5334-5343. <a href="https://doi.org/10.1021/acs.jmedchem.5b00676" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00676%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252BPotent%252BHIV-1%252BProtease%252BInhibitors%252Bwith%252BModified%252BP1-Biphenyl%252BLigands%25253A%252BSynthesis%25252C%252BBiological%252BEvaluation%25252C%252Band%252BEnzyme%2525E2%252580%252593Inhibitor%252BX-ray%252BStructural%252BStudies%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D01052015%26date%3D24062015%26date%3D09072015%26volume%3D58%26issue%3D13%26spage%3D5334%26epage%3D5343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span> and <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>  . </span><span class="cited-content_cbyCitation_article-title">Organic Carbamates in Drug Design and Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (7)
                                     , 2895-2940. <a href="https://doi.org/10.1021/jm501371s" title="DOI URL">https://doi.org/10.1021/jm501371s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501371s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501371s%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOrganic%252BCarbamates%252Bin%252BDrug%252BDesign%252Band%252BMedicinal%252BChemistry%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D04092014%26date%3D07012015%26date%3D09042015%26volume%3D58%26issue%3D7%26spage%3D2895%26epage%3D2940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soumendra Nath  Das</span>, <span class="hlFld-ContribAuthor ">Arpan  Chowdhury</span>, <span class="hlFld-ContribAuthor ">Neha  Tripathi</span>, <span class="hlFld-ContribAuthor ">Prithwish K.  Jana</span>, and <span class="hlFld-ContribAuthor ">Sukhendu B  Mandal</span>  . </span><span class="cited-content_cbyCitation_article-title">Exploitation of in Situ Generated Sugar-Based Olefin Keto-Nitrones: Synthesis of Carbocycles, Heterocycles, and Nucleoside Derivatives. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>80 </em>
                                    (2)
                                     , 1136-1148. <a href="https://doi.org/10.1021/jo502672x" title="DOI URL">https://doi.org/10.1021/jo502672x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo502672x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo502672x%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DExploitation%252Bof%252Bin%252BSitu%252BGenerated%252BSugar-Based%252BOlefin%252BKeto-Nitrones%25253A%252BSynthesis%252Bof%252BCarbocycles%25252C%252BHeterocycles%25252C%252Band%252BNucleoside%252BDerivatives%26aulast%3DDas%26aufirst%3DSoumendra%2BNath%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D24112014%26date%3D30122014%26date%3D16012015%26date%3D16122014%26volume%3D80%26issue%3D2%26spage%3D1136%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanghratna  Kasare</span>, <span class="hlFld-ContribAuthor ">Siddheshwar K.  Bankar</span>, and <span class="hlFld-ContribAuthor ">S. S. V.  Ramasastry</span>  . </span><span class="cited-content_cbyCitation_article-title">Expeditious Metal-Free Access to Functionalized Polycyclic Acetals under Mild Aqueous Conditions. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2014,</strong> <em>16 </em>
                                    (16)
                                     , 4284-4287. <a href="https://doi.org/10.1021/ol501986f" title="DOI URL">https://doi.org/10.1021/ol501986f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol501986f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol501986f%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DExpeditious%252BMetal-Free%252BAccess%252Bto%252BFunctionalized%252BPolycyclic%252BAcetals%252Bunder%252BMild%252BAqueous%252BConditions%26aulast%3DKasare%26aufirst%3DSanghratna%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D10072014%26date%3D30072014%26date%3D15082014%26volume%3D16%26issue%3D16%26spage%3D4284%26epage%3D4287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen  Hanessian</span> and <span class="hlFld-ContribAuthor ">Amit Kumar  Chattopadhyay</span>  . </span><span class="cited-content_cbyCitation_article-title">Iminium Ion–Enamine Cascade Cyclizations: Facile Access to Structurally Diverse Azacyclic Compounds and Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2014,</strong> <em>16 </em>
                                    (1)
                                     , 232-235. <a href="https://doi.org/10.1021/ol403229q" title="DOI URL">https://doi.org/10.1021/ol403229q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol403229q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol403229q%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIminium%252BIon%2525E2%252580%252593Enamine%252BCascade%252BCyclizations%25253A%252BFacile%252BAccess%252Bto%252BStructurally%252BDiverse%252BAzacyclic%252BCompounds%252Band%252BNatural%252BProducts%26aulast%3DHanessian%26aufirst%3DStephen%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D08112013%26date%3D16122013%26date%3D03012014%26volume%3D16%26issue%3D1%26spage%3D232%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofeng  Ma</span>, <span class="hlFld-ContribAuthor ">Qin  Tang</span>, <span class="hlFld-ContribAuthor ">Jun  Ke</span>, <span class="hlFld-ContribAuthor ">Xinglong  Yang</span>, <span class="hlFld-ContribAuthor ">Jichao  Zhang</span>, and <span class="hlFld-ContribAuthor ">Huawu  Shao</span>  . </span><span class="cited-content_cbyCitation_article-title">InCl3 Catalyzed Highly Diastereoselective [3 + 2] Cycloaddition of 1,2-Cyclopropanated Sugars with Aldehydes: A Straightforward Synthesis of Persubstituted Bis-Tetrahydrofurans and Perhydrofuro[2,3-b]pyrans. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2013,</strong> <em>15 </em>
                                    (20)
                                     , 5170-5173. <a href="https://doi.org/10.1021/ol402192f" title="DOI URL">https://doi.org/10.1021/ol402192f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol402192f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol402192f%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DInCl3%252BCatalyzed%252BHighly%252BDiastereoselective%252B%25255B3%252B%25252B%252B2%25255D%252BCycloaddition%252Bof%252B1%25252C2-Cyclopropanated%252BSugars%252Bwith%252BAldehydes%25253A%252BA%252BStraightforward%252BSynthesis%252Bof%252BPersubstituted%252BBis-Tetrahydrofurans%252Band%252BPerhydrofuro%25255B2%25252C3-b%25255Dpyrans%26aulast%3DMa%26aufirst%3DXiaofeng%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D02082013%26date%3D04102013%26date%3D18102013%26volume%3D15%26issue%3D20%26spage%3D5170%26epage%3D5173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Garth L.  Parham</span>, <span class="hlFld-ContribAuthor ">Cuthbert D.  Martyr</span>, <span class="hlFld-ContribAuthor ">Prasanth R.  Nyalapatla</span>, <span class="hlFld-ContribAuthor ">Heather L.  Osswald</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Masayuki  Amano</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, and <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>  . </span><span class="cited-content_cbyCitation_article-title">Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P2 Ligands: Design, Synthesis, and Protein–Ligand X-ray Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (17)
                                     , 6792-6802. <a href="https://doi.org/10.1021/jm400768f" title="DOI URL">https://doi.org/10.1021/jm400768f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400768f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400768f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHighly%252BPotent%252BHIV-1%252BProtease%252BInhibitors%252Bwith%252BNovel%252BTricyclic%252BP2%252BLigands%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BProtein%2525E2%252580%252593Ligand%252BX-ray%252BStudies%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D18042013%26date%3D15082013%26date%3D12092013%26volume%3D56%26issue%3D17%26spage%3D6792%26epage%3D6802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maloy Kumar  Parai</span>, <span class="hlFld-ContribAuthor ">David J.  Huggins</span>, <span class="hlFld-ContribAuthor ">Hong  Cao</span>, <span class="hlFld-ContribAuthor ">Madhavi N. L.  Nalam</span>, <span class="hlFld-ContribAuthor ">Akbar  Ali</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>, <span class="hlFld-ContribAuthor ">Bruce  Tidor</span>, and <span class="hlFld-ContribAuthor ">Tariq M.  Rana</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological and Structural Evaluations of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (14)
                                     , 6328-6341. <a href="https://doi.org/10.1021/jm300238h" title="DOI URL">https://doi.org/10.1021/jm300238h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300238h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300238h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252Band%252BStructural%252BEvaluations%252Bof%252BNovel%252BHIV-1%252BProtease%252BInhibitors%252BTo%252BCombat%252BDrug%252BResistance%26aulast%3DParai%26aufirst%3DMaloy%2BKumar%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D23022012%26date%3D13072012%26date%3D26072012%26date%3D18062012%26volume%3D55%26issue%3D14%26spage%3D6328%26epage%3D6341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A.  DeGoey</span>, <span class="hlFld-ContribAuthor ">David J.  Grampovnik</span>, <span class="hlFld-ContribAuthor ">Hui-Ju  Chen</span>, <span class="hlFld-ContribAuthor ">William J.  Flosi</span>, <span class="hlFld-ContribAuthor ">Larry L.  Klein</span>, <span class="hlFld-ContribAuthor ">Tatyana  Dekhtyar</span>, <span class="hlFld-ContribAuthor ">Vincent  Stoll</span>, <span class="hlFld-ContribAuthor ">Mulugeta  Mamo</span>, <span class="hlFld-ContribAuthor ">Akhteruzzaman  Molla</span>, and <span class="hlFld-ContribAuthor ">Dale J.  Kempf</span>  . </span><span class="cited-content_cbyCitation_article-title">P1-Substituted Symmetry-Based Human Immunodeficiency Virus Protease Inhibitors with Potent Antiviral Activity against Drug-Resistant Viruses. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (20)
                                     , 7094-7104. <a href="https://doi.org/10.1021/jm201109t" title="DOI URL">https://doi.org/10.1021/jm201109t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201109t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201109t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DP1-Substituted%252BSymmetry-Based%252BHuman%252BImmunodeficiency%252BVirus%252BProtease%252BInhibitors%252Bwith%252BPotent%252BAntiviral%252BActivity%252Bagainst%252BDrug-Resistant%252BViruses%26aulast%3DDeGoey%26aufirst%3DDavid%2BA.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D26052011%26date%3D21092011%26date%3D27102011%26date%3D07092011%26volume%3D54%26issue%3D20%26spage%3D7094%26epage%3D7104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katherine A.  Davies</span> and <span class="hlFld-ContribAuthor ">Jeremy E.  Wulff</span>  . </span><span class="cited-content_cbyCitation_article-title">Marrying Iterative Synthesis to Cascading Radical Cyclization: 6-endo/5-exo Radical Cascade across Bis-Vinyl Ethers. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2011,</strong> <em>13 </em>
                                    (20)
                                     , 5552-5555. <a href="https://doi.org/10.1021/ol202286q" title="DOI URL">https://doi.org/10.1021/ol202286q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol202286q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol202286q%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DMarrying%252BIterative%252BSynthesis%252Bto%252BCascading%252BRadical%252BCyclization%25253A%252B6-endo%25252F5-exo%252BRadical%252BCascade%252Bacross%252BBis-Vinyl%252BEthers%26aulast%3DDavies%26aufirst%3DKatherine%2BA.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D23082011%26date%3D15092011%26date%3D21102011%26volume%3D13%26issue%3D20%26spage%3D5552%26epage%3D5555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Bruno D.  Chapsal</span>, <span class="hlFld-ContribAuthor ">Garth L.  Parham</span>, <span class="hlFld-ContribAuthor ">Melinda  Steffey</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Masayuki  Amano</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, and <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P2-Ligands: Synthesis, Biological Evaluation, and Protein–Ligand X-ray Crystal Structure. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (16)
                                     , 5890-5901. <a href="https://doi.org/10.1021/jm200649p" title="DOI URL">https://doi.org/10.1021/jm200649p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm200649p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm200649p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252BHIV-1%252BProtease%252BInhibitors%252Bwith%252BC3-Substituted%252BHexahydrocyclopentafuranyl%252BUrethanes%252Bas%252BP2-Ligands%25253A%252BSynthesis%25252C%252BBiological%252BEvaluation%25252C%252Band%252BProtein%2525E2%252580%252593Ligand%252BX-ray%252BCrystal%252BStructure%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2011%26date%3D2011%26date%3D2011%26date%3D20052011%26date%3D29072011%26date%3D25082011%26volume%3D54%26issue%3D16%26spage%3D5890%26epage%3D5901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sagar S.  Thorat</span>, <span class="hlFld-ContribAuthor ">Ravindar  Kontham</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for the synthesis of furo-pyranones and their application in the total synthesis of related natural products. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (9)
                                     , 2110-2162. <a href="https://doi.org/10.1039/D0QO01421D" title="DOI URL">https://doi.org/10.1039/D0QO01421D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO01421D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO01421D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DStrategies%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bfuro-pyranones%252Band%252Btheir%252Bapplication%252Bin%252Bthe%252Btotal%252Bsynthesis%252Bof%252Brelated%252Bnatural%252Bproducts%26aulast%3DThorat%26aufirst%3DSagar%2BS.%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D9%26spage%3D2110%26epage%3D2162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengjin  Wu</span>, <span class="hlFld-ContribAuthor ">Leifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Ji</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">David A.  Nicewicz</span>, <span class="hlFld-ContribAuthor ">Jiean  Chen</span>, <span class="hlFld-ContribAuthor ">Yong  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Synthesis of Bicyclic Acetals via Visible Light Catalysis. </span><span class="cited-content_cbyCitation_journal-name">iScience</span><span> <strong>2020,</strong> <em>23 </em>
                                    (8)
                                     , 101395. <a href="https://doi.org/10.1016/j.isci.2020.101395" title="DOI URL">https://doi.org/10.1016/j.isci.2020.101395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.isci.2020.101395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.isci.2020.101395%26sid%3Dliteratum%253Aachs%26jtitle%3DiScience%26atitle%3DDirect%252BSynthesis%252Bof%252BBicyclic%252BAcetals%252Bvia%252BVisible%252BLight%252BCatalysis%26aulast%3DWu%26aufirst%3DFengjin%26date%3D2020%26volume%3D23%26issue%3D8%26spage%3D101395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moritz  Hönig</span>, <span class="hlFld-ContribAuthor ">Erick M.  Carreira</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis and Structural Revision of a Harziane Diterpenoid. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (3)
                                     , 1208-1212. <a href="https://doi.org/10.1002/ange.201912982" title="DOI URL">https://doi.org/10.1002/ange.201912982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201912982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201912982%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DTotal%252BSynthesis%252Band%252BStructural%252BRevision%252Bof%252Ba%252BHarziane%252BDiterpenoid%26aulast%3DH%25C3%25B6nig%26aufirst%3DMoritz%26date%3D2020%26date%3D2019%26volume%3D132%26issue%3D3%26spage%3D1208%26epage%3D1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moritz  Hönig</span>, <span class="hlFld-ContribAuthor ">Erick M.  Carreira</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis and Structural Revision of a Harziane Diterpenoid. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (3)
                                     , 1192-1196. <a href="https://doi.org/10.1002/anie.201912982" title="DOI URL">https://doi.org/10.1002/anie.201912982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201912982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201912982%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DTotal%252BSynthesis%252Band%252BStructural%252BRevision%252Bof%252Ba%252BHarziane%252BDiterpenoid%26aulast%3DH%25C3%25B6nig%26aufirst%3DMoritz%26date%3D2020%26date%3D2019%26volume%3D59%26issue%3D3%26spage%3D1192%26epage%3D1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yujia  Tian</span>, <span class="hlFld-ContribAuthor ">Shengde  Zhang</span>, <span class="hlFld-ContribAuthor ">Hongyan  Yin</span>, <span class="hlFld-ContribAuthor ">Aixia  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative structure-activity relationship (QSAR) models and their applicability domain analysis on HIV-1 protease inhibitors by machine learning methods. </span><span class="cited-content_cbyCitation_journal-name">Chemometrics and Intelligent Laboratory Systems</span><span> <strong>2020,</strong> <em>196 </em>, 103888. <a href="https://doi.org/10.1016/j.chemolab.2019.103888" title="DOI URL">https://doi.org/10.1016/j.chemolab.2019.103888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chemolab.2019.103888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chemolab.2019.103888%26sid%3Dliteratum%253Aachs%26jtitle%3DChemometrics%2520and%2520Intelligent%2520Laboratory%2520Systems%26atitle%3DQuantitative%252Bstructure-activity%252Brelationship%252B%252528QSAR%252529%252Bmodels%252Band%252Btheir%252Bapplicability%252Bdomain%252Banalysis%252Bon%252BHIV-1%252Bprotease%252Binhibitors%252Bby%252Bmachine%252Blearning%252Bmethods%26aulast%3DTian%26aufirst%3DYujia%26date%3D2020%26volume%3D196%26spage%3D103888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei  Zhu</span>, <span class="hlFld-ContribAuthor ">Ling  Ma</span>, <span class="hlFld-ContribAuthor ">Huiyu  Zhou</span>, <span class="hlFld-ContribAuthor ">Biao  Dong</span>, <span class="hlFld-ContribAuthor ">Yujia  Wang</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Jinming  Zhou</span>, <span class="hlFld-ContribAuthor ">Guoning  Zhang</span>, <span class="hlFld-ContribAuthor ">Juxian  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Liang</span>, <span class="hlFld-ContribAuthor ">Shan  Cen</span>, <span class="hlFld-ContribAuthor ">Yucheng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111866. <a href="https://doi.org/10.1016/j.ejmech.2019.111866" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111866%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPreliminary%252BSAR%252Band%252Bbiological%252Bevaluation%252Bof%252Bpotent%252BHIV-1%252Bprotease%252Binhibitors%252Bwith%252Bpyrimidine%252Bbases%252Bas%252Bnovel%252BP2%252Bligands%252Bto%252Benhance%252Bactivity%252Bagainst%252BDRV-resistant%252BHIV-1%252Bvariants%26aulast%3DZhu%26aufirst%3DMei%26date%3D2020%26volume%3D185%26spage%3D111866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chandrashekhar  Voshavar</span>. </span><span class="cited-content_cbyCitation_article-title">Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (18)
                                     , 1571-1598. <a href="https://doi.org/10.2174/1568026619666190619115243" title="DOI URL">https://doi.org/10.2174/1568026619666190619115243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190619115243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190619115243%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DProtease%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BHIV%25252FAIDS%25253A%252BRecent%252BAdvances%252Band%252BFuture%252BChallenges%26aulast%3DVoshavar%26aufirst%3DChandrashekhar%26date%3D2019%26volume%3D19%26issue%3D18%26spage%3D1571%26epage%3D1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. M.  Chalanchi</span>, <span class="hlFld-ContribAuthor ">A.  Ebrahimi</span>, <span class="hlFld-ContribAuthor ">A.  Nowroozi</span>. </span><span class="cited-content_cbyCitation_article-title">Theoretical insight to intermolecular hydrogen bond interactions between methyl N-(2-pyridyl) carbamate and acetic acid: substituent effects, cooperativity and energy decomposition analysis. </span><span class="cited-content_cbyCitation_journal-name">Bulgarian Chemical Communications</span><span> <strong>2019,</strong> <em>51 </em>
                                    (2)
                                     , 224-233. <a href="https://doi.org/10.34049/bcc.51.2.4896" title="DOI URL">https://doi.org/10.34049/bcc.51.2.4896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.34049/bcc.51.2.4896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.34049%2Fbcc.51.2.4896%26sid%3Dliteratum%253Aachs%26jtitle%3DBulgarian%2520Chemical%2520Communications%26atitle%3DTheoretical%252Binsight%252Bto%252Bintermolecular%252Bhydrogen%252Bbond%252Binteractions%252Bbetween%252Bmethyl%252BN-%2525282-pyridyl%252529%252Bcarbamate%252Band%252Bacetic%252Bacid%25253A%252Bsubstituent%252Beffects%25252C%252Bcooperativity%252Band%252Benergy%252Bdecomposition%252Banalysis%26aulast%3DChalanchi%26aufirst%3DS.%2BM.%26date%3D2019%26date%3D2019%26volume%3D51%26issue%3D2%26spage%3D224%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>. </span><span class="cited-content_cbyCitation_article-title">Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>7 </em>
                                    (8)
                                     , 1448-1466. <a href="https://doi.org/10.1002/ajoc.201800255" title="DOI URL">https://doi.org/10.1002/ajoc.201800255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201800255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201800255%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DNature%252BInspired%252BMolecular%252BDesign%25253A%252BStereoselective%252BSynthesis%252Bof%252BBicyclic%252Band%252BPolycyclic%252BEthers%252Bfor%252BPotent%252BHIV-1%252BProtease%252BInhibitors%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D8%26spage%3D1448%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Kalapala Venkateswara  Rao</span>, <span class="hlFld-ContribAuthor ">Prasanth R.  Nyalapatla</span>, <span class="hlFld-ContribAuthor ">Satish  Kovela</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>, <span class="hlFld-ContribAuthor ">Heather L.  Osswald</span>, <span class="hlFld-ContribAuthor ">Bhavanam  Sekhara Reddy</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Manabu  Aoki</span>, <span class="hlFld-ContribAuthor ">Shin-ichiro  Hattori</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Highly Potent, Dual-Acting and Central-Nervous-System-Penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-Resistant HIV-1 Variants. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (8)
                                     , 803-815. <a href="https://doi.org/10.1002/cmdc.201700824" title="DOI URL">https://doi.org/10.1002/cmdc.201700824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700824%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Bof%252BHighly%252BPotent%25252C%252BDual-Acting%252Band%252BCentral-Nervous-System-Penetrating%252BHIV-1%252BProtease%252BInhibitors%252Bwith%252BExcellent%252BPotency%252Bagainst%252BMultidrug-Resistant%252BHIV-1%252BVariants%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D8%26spage%3D803%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Hao  You</span>, <span class="hlFld-ContribAuthor ">Ying-Han  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao-Na  Wu</span>, <span class="hlFld-ContribAuthor ">Yan-Kai  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Lactols in Asymmetric Sequential Organo- and Gold-Catalysis: Synthesis of Densely Functionalized Epimeric Bicyclic O,O-Acetals. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2017,</strong> <em>359 </em>
                                    (24)
                                     , 4260-4266. <a href="https://doi.org/10.1002/adsc.201701071" title="DOI URL">https://doi.org/10.1002/adsc.201701071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201701071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201701071%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DLactols%252Bin%252BAsymmetric%252BSequential%252BOrgano-%252Band%252BGold-Catalysis%25253A%252BSynthesis%252Bof%252BDensely%252BFunctionalized%252BEpimeric%252BBicyclic%252BO%25252CO-Acetals%26aulast%3DYou%26aufirst%3DZhi-Hao%26date%3D2017%26date%3D2017%26volume%3D359%26issue%3D24%26spage%3D4260%26epage%3D4266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoguang  Bai</span>, <span class="hlFld-ContribAuthor ">Zhiheng  Yang</span>, <span class="hlFld-ContribAuthor ">Mei  Zhu</span>, <span class="hlFld-ContribAuthor ">Biao  Dong</span>, <span class="hlFld-ContribAuthor ">Lei  Zhou</span>, <span class="hlFld-ContribAuthor ">Guoning  Zhang</span>, <span class="hlFld-ContribAuthor ">Juxian  Wang</span>, <span class="hlFld-ContribAuthor ">Yucheng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of potent HIV-1 protease inhibitors with ( S )-tetrahydrofuran-tertiary amine-acetamide as P2−ligand: Structure−activity studies and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>137 </em>, 30-44. <a href="https://doi.org/10.1016/j.ejmech.2017.05.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpotent%252BHIV-1%252Bprotease%252Binhibitors%252Bwith%252B%252528%252BS%252B%252529-tetrahydrofuran-tertiary%252Bamine-acetamide%252Bas%252BP2%2525E2%252588%252592ligand%25253A%252BStructure%2525E2%252588%252592activity%252Bstudies%252Band%252Bbiological%252Bevaluation%26aulast%3DBai%26aufirst%3DXiaoguang%26date%3D2017%26volume%3D137%26spage%3D30%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Anindya  Sarkar</span>. </span><span class="cited-content_cbyCitation_article-title">An enantioselective enzymatic desymmetrization route to hexahydro-4H-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (33)
                                     , 3230-3233. <a href="https://doi.org/10.1016/j.tetlet.2017.07.010" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.07.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.07.010%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAn%252Benantioselective%252Benzymatic%252Bdesymmetrization%252Broute%252Bto%252Bhexahydro-4H-furopyranol%25252C%252Ba%252Bhigh-affinity%252Bligand%252Bfor%252BHIV-1%252Bprotease%252Binhibitors%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2017%26volume%3D58%26issue%3D33%26spage%3D3230%26epage%3D3233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. I.  Boev</span>, <span class="hlFld-ContribAuthor ">A. I.  Moskalenko</span>, <span class="hlFld-ContribAuthor ">S. L.  Belopukhov</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective synthesis of tri- and tetrasubstituted tetrahydropyrans from syn- and anti-1-R-2-(4-bromophenyl)-5-methylhex-4-en-1-ols and some chemical transformations of the products. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>53 </em>
                                    (7)
                                     , 1044-1052. <a href="https://doi.org/10.1134/S1070428017070144" title="DOI URL">https://doi.org/10.1134/S1070428017070144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428017070144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428017070144%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereoselective%252Bsynthesis%252Bof%252Btri-%252Band%252Btetrasubstituted%252Btetrahydropyrans%252Bfrom%252Bsyn-%252Band%252Banti-1-R-2-%2525284-bromophenyl%252529-5-methylhex-4-en-1-ols%252Band%252Bsome%252Bchemical%252Btransformations%252Bof%252Bthe%252Bproducts%26aulast%3DBoev%26aufirst%3DV.%2BI.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D7%26spage%3D1044%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. I.  Boev</span>, <span class="hlFld-ContribAuthor ">A. I.  Moskalenko</span>, <span class="hlFld-ContribAuthor ">S. L.  Belopukhov</span>, <span class="hlFld-ContribAuthor ">G. N.  Nikonova</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective synthesis of 2-aryl-4-en-1-ols, promising synthons for the preparation of oxygen heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>53 </em>
                                    (2)
                                     , 169-177. <a href="https://doi.org/10.1134/S1070428017020051" title="DOI URL">https://doi.org/10.1134/S1070428017020051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428017020051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428017020051%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereoselective%252Bsynthesis%252Bof%252B2-aryl-4-en-1-ols%25252C%252Bpromising%252Bsynthons%252Bfor%252Bthe%252Bpreparation%252Bof%252Boxygen%252Bheterocycles%26aulast%3DBoev%26aufirst%3DV.%2BI.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D2%26spage%3D169%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonal  Dubey</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on HIV-1 Protease and its Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 221-261. <a href="https://doi.org/10.1016/B978-0-12-809712-0.00009-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-809712-0.00009-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809712-0.00009-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809712-0.00009-5%26sid%3Dliteratum%253Aachs%26atitle%3DStudies%252Bon%252BHIV-1%252BProtease%252Band%252Bits%252BInhibitors%26aulast%3DDubey%26aufirst%3DSonal%26date%3D2017%26spage%3D221%26epage%3D261%26pub%3DElsevier%26atitle%3DViral%252BProteases%252Band%252BTheir%252BInhibitors%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Narasimha M.  Midde</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Patters</span>, <span class="hlFld-ContribAuthor ">PSS  Rao</span>, <span class="hlFld-ContribAuthor ">Theodore J.  Cory</span>, <span class="hlFld-ContribAuthor ">Santosh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Investigational protease inhibitors as antiretroviral therapies. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2016,</strong> <em>25 </em>
                                    (10)
                                     , 1189-1200. <a href="https://doi.org/10.1080/13543784.2016.1212837" title="DOI URL">https://doi.org/10.1080/13543784.2016.1212837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2016.1212837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2016.1212837%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInvestigational%252Bprotease%252Binhibitors%252Bas%252Bantiretroviral%252Btherapies%26aulast%3DMidde%26aufirst%3DNarasimha%2BM.%26date%3D2016%26date%3D2016%26volume%3D25%26issue%3D10%26spage%3D1189%26epage%3D1200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md Ataul  Islam</span>, <span class="hlFld-ContribAuthor ">Tahir S.  Pillay</span>. </span><span class="cited-content_cbyCitation_article-title">Simplified molecular input line entry system-based descriptors in QSAR modeling for HIV-protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemometrics and Intelligent Laboratory Systems</span><span> <strong>2016,</strong> <em>153 </em>, 67-74. <a href="https://doi.org/10.1016/j.chemolab.2016.02.008" title="DOI URL">https://doi.org/10.1016/j.chemolab.2016.02.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chemolab.2016.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chemolab.2016.02.008%26sid%3Dliteratum%253Aachs%26jtitle%3DChemometrics%2520and%2520Intelligent%2520Laboratory%2520Systems%26atitle%3DSimplified%252Bmolecular%252Binput%252Bline%252Bentry%252Bsystem-based%252Bdescriptors%252Bin%252BQSAR%252Bmodeling%252Bfor%252BHIV-protease%252Binhibitors%26aulast%3DIslam%26aufirst%3DMd%2BAtaul%26date%3D2016%26volume%3D153%26spage%3D67%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Jun  Takayama</span>, <span class="hlFld-ContribAuthor ">Luke A.  Kassekert</span>, <span class="hlFld-ContribAuthor ">Jean-Rene  Ella-Menye</span>, <span class="hlFld-ContribAuthor ">Sofiya  Yashchuk</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Manabu  Aoki</span>, <span class="hlFld-ContribAuthor ">Masayuki  Amano</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (21)
                                     , 4903-4909. <a href="https://doi.org/10.1016/j.bmcl.2015.05.052" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.05.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.05.052%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Bdesign%25252C%252Bsynthesis%25252C%252BX-ray%252Bstudies%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BHIV-1%252Bprotease%252Binhibitors%252Bcontaining%252Bisophthalamide-derived%252BP2-ligands%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2015%26volume%3D25%26issue%3D21%26spage%3D4903%26epage%3D4909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wei</span>, <span class="hlFld-ContribAuthor ">Jinlong  Li</span>, <span class="hlFld-ContribAuthor ">Zeming  Chen</span>, <span class="hlFld-ContribAuthor ">Fengwei  Wang</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Huang</span>, <span class="hlFld-ContribAuthor ">Zhangyong  Hong</span>, <span class="hlFld-ContribAuthor ">Jianping  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>101 </em>, 409-418. <a href="https://doi.org/10.1016/j.ejmech.2015.06.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.06.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.06.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultistage%252Bvirtual%252Bscreening%252Band%252Bidentification%252Bof%252Bnovel%252BHIV-1%252Bprotease%252Binhibitors%252Bby%252Bintegrating%252BSVM%25252C%252Bshape%25252C%252Bpharmacophore%252Band%252Bdocking%252Bmethods%26aulast%3DWei%26aufirst%3DYu%26date%3D2015%26volume%3D101%26spage%3D409%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md Ataul  Islam</span>, <span class="hlFld-ContribAuthor ">Tahir S.  Pillay</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2015,</strong> <em>56 </em>, 20-30. <a href="https://doi.org/10.1016/j.jmgm.2014.11.015" title="DOI URL">https://doi.org/10.1016/j.jmgm.2014.11.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2014.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2014.11.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DExploration%252Bof%252Bthe%252Bstructural%252Brequirements%252Bof%252BHIV-protease%252Binhibitors%252Busing%252Bpharmacophore%25252C%252Bvirtual%252Bscreening%252Band%252Bmolecular%252Bdocking%252Bapproaches%252Bfor%252Blead%252Bidentification%26aulast%3DIslam%26aufirst%3DMd%2BAtaul%26date%3D2015%26volume%3D56%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Cuthbert D.  Martyr</span>, <span class="hlFld-ContribAuthor ">Luke A.  Kassekert</span>, <span class="hlFld-ContribAuthor ">Prasanth R.  Nyalapatla</span>, <span class="hlFld-ContribAuthor ">Melinda  Steffey</span>, <span class="hlFld-ContribAuthor ">Johnson  Agniswamy</span>, <span class="hlFld-ContribAuthor ">Yuan-Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, <span class="hlFld-ContribAuthor ">Masayuki  Amano</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2015,</strong> <em>13 </em>
                                    (48)
                                     , 11607-11621. <a href="https://doi.org/10.1039/C5OB01930C" title="DOI URL">https://doi.org/10.1039/C5OB01930C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5OB01930C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5OB01930C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252BX-ray%252Bstructural%252Bstudies%252Bof%252BHIV-1%252Bprotease%252Binhibitors%252Bcontaining%252Bsubstituted%252Bfused-tetrahydropyranyl%252Btetrahydrofuran%252Bas%252BP2-ligands%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2015%26date%3D2015%26volume%3D13%26issue%3D48%26spage%3D11607%26epage%3D11621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashit K.  Ganguly</span>, <span class="hlFld-ContribAuthor ">Sesha S.  Alluri</span>, <span class="hlFld-ContribAuthor ">Chih-Hung  Wang</span>, <span class="hlFld-ContribAuthor ">Alyssa  Antropow</span>, <span class="hlFld-ContribAuthor ">Alex  White</span>, <span class="hlFld-ContribAuthor ">Danielle  Caroccia</span>, <span class="hlFld-ContribAuthor ">Dipshikha  Biswas</span>, <span class="hlFld-ContribAuthor ">Eunhee  Kang</span>, <span class="hlFld-ContribAuthor ">Li-Kang  Zhang</span>, <span class="hlFld-ContribAuthor ">Steven S.  Carroll</span>, <span class="hlFld-ContribAuthor ">Christine  Burlein</span>, <span class="hlFld-ContribAuthor ">John  Fay</span>, <span class="hlFld-ContribAuthor ">Peter  Orth</span>, <span class="hlFld-ContribAuthor ">Corey  Strickland</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization of cyclic sulfonamide based novel HIV-1 protease inhibitors to picomolar affinities guided by X-ray crystallographic analysis. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2014,</strong> <em>70 </em>
                                    (18)
                                     , 2894-2904. <a href="https://doi.org/10.1016/j.tet.2014.03.038" title="DOI URL">https://doi.org/10.1016/j.tet.2014.03.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2014.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2014.03.038%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DStructural%252Boptimization%252Bof%252Bcyclic%252Bsulfonamide%252Bbased%252Bnovel%252BHIV-1%252Bprotease%252Binhibitors%252Bto%252Bpicomolar%252Baffinities%252Bguided%252Bby%252BX-ray%252Bcrystallographic%252Banalysis%26aulast%3DGanguly%26aufirst%3DAshit%2BK.%26date%3D2014%26volume%3D70%26issue%3D18%26spage%3D2894%26epage%3D2904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofeng  Ma</span>, <span class="hlFld-ContribAuthor ">Jichao  Zhang</span>, <span class="hlFld-ContribAuthor ">Qin  Tang</span>, <span class="hlFld-ContribAuthor ">Jun  Ke</span>, <span class="hlFld-ContribAuthor ">Wei  Zou</span>, <span class="hlFld-ContribAuthor ">Huawu  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Stereospecific [3+2] cycloaddition of 1,2-cyclopropanated sugars and ketones catalyzed by SnCl
              4
              : an efficient synthesis of multi-substituted perhydrofuro[2,3-b]furans and perhydrofuro[2,3-b]pyrans. </span><span class="cited-content_cbyCitation_journal-name">Chem. Commun.</span><span> <strong>2014,</strong> <em>50 </em>
                                    (26)
                                     , 3505-3508. <a href="https://doi.org/10.1039/C3CC48963A" title="DOI URL">https://doi.org/10.1039/C3CC48963A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C3CC48963A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC3CC48963A%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Commun.%26atitle%3DStereospecific%252B%25255B3%25252B2%25255D%252Bcycloaddition%252Bof%252B1%25252C2-cyclopropanated%252Bsugars%252Band%252Bketones%252Bcatalyzed%252Bby%252BSnCl%252B4%252B%25253A%252Ban%252Befficient%252Bsynthesis%252Bof%252Bmulti-substituted%252Bperhydrofuro%25255B2%25252C3-b%25255Dfurans%252Band%252Bperhydrofuro%25255B2%25252C3-b%25255Dpyrans%26aulast%3DMa%26aufirst%3DXiaofeng%26date%3D2014%26date%3D2014%26volume%3D50%26issue%3D26%26spage%3D3505%26epage%3D3508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofeng  Ma</span>, <span class="hlFld-ContribAuthor ">Qin  Tang</span>, <span class="hlFld-ContribAuthor ">Jun  Ke</span>, <span class="hlFld-ContribAuthor ">Jichao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinglong  Yang</span>, <span class="hlFld-ContribAuthor ">Xudong  Shen</span>, <span class="hlFld-ContribAuthor ">Huawu  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">A neighboring group participation strategy: direct and highly diastereoselective synthesis of 2-substituted and 2,2-bisubstituted perhydrofuro[2,3-b]pyran derivatives. </span><span class="cited-content_cbyCitation_journal-name">Org. Biomol. Chem.</span><span> <strong>2014,</strong> <em>12 </em>
                                    (37)
                                     , 7381-7388. <a href="https://doi.org/10.1039/C4OB00642A" title="DOI URL">https://doi.org/10.1039/C4OB00642A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4OB00642A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4OB00642A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26atitle%3DA%252Bneighboring%252Bgroup%252Bparticipation%252Bstrategy%25253A%252Bdirect%252Band%252Bhighly%252Bdiastereoselective%252Bsynthesis%252Bof%252B2-substituted%252Band%252B2%25252C2-bisubstituted%252Bperhydrofuro%25255B2%25252C3-b%25255Dpyran%252Bderivatives%26aulast%3DMa%26aufirst%3DXiaofeng%26date%3D2014%26date%3D2014%26volume%3D12%26issue%3D37%26spage%3D7381%26epage%3D7388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Santosh Kumar  Alamsetti</span>, <span class="hlFld-ContribAuthor ">Andreas K. Å.  Persson</span>, <span class="hlFld-ContribAuthor ">Tuo  Jiang</span>, <span class="hlFld-ContribAuthor ">Jan-E.  Bäckvall</span>. </span><span class="cited-content_cbyCitation_article-title">Scalable Synthesis of Oxazolones from Propargylic Alcohols through Multistep Palladium(II) Catalysis: β-Selective Oxidative Heck Coupling of Cyclic Sulfonyl Enamides and Aryl Boroxines. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2013,</strong> <em>125 </em>
                                    (51)
                                     , 13990-13995. <a href="https://doi.org/10.1002/ange.201307471" title="DOI URL">https://doi.org/10.1002/ange.201307471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201307471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201307471%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DScalable%252BSynthesis%252Bof%252BOxazolones%252Bfrom%252BPropargylic%252BAlcohols%252Bthrough%252BMultistep%252BPalladium%252528II%252529%252BCatalysis%25253A%252B%2525CE%2525B2-Selective%252BOxidative%252BHeck%252BCoupling%252Bof%252BCyclic%252BSulfonyl%252BEnamides%252Band%252BAryl%252BBoroxines%26aulast%3DAlamsetti%26aufirst%3DSantosh%2BKumar%26date%3D2013%26date%3D2013%26volume%3D125%26issue%3D51%26spage%3D13990%26epage%3D13995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Santosh Kumar  Alamsetti</span>, <span class="hlFld-ContribAuthor ">Andreas K. Å.  Persson</span>, <span class="hlFld-ContribAuthor ">Tuo  Jiang</span>, <span class="hlFld-ContribAuthor ">Jan-E.  Bäckvall</span>. </span><span class="cited-content_cbyCitation_article-title">Scalable Synthesis of Oxazolones from Propargylic Alcohols through Multistep Palladium(II) Catalysis: β-Selective Oxidative Heck Coupling of Cyclic Sulfonyl Enamides and Aryl Boroxines. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2013,</strong> <em>52 </em>
                                    (51)
                                     , 13745-13750. <a href="https://doi.org/10.1002/anie.201307471" title="DOI URL">https://doi.org/10.1002/anie.201307471</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201307471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201307471%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DScalable%252BSynthesis%252Bof%252BOxazolones%252Bfrom%252BPropargylic%252BAlcohols%252Bthrough%252BMultistep%252BPalladium%252528II%252529%252BCatalysis%25253A%252B%2525CE%2525B2-Selective%252BOxidative%252BHeck%252BCoupling%252Bof%252BCyclic%252BSulfonyl%252BEnamides%252Band%252BAryl%252BBoroxines%26aulast%3DAlamsetti%26aufirst%3DSantosh%2BKumar%26date%3D2013%26date%3D2013%26volume%3D52%26issue%3D51%26spage%3D13745%26epage%3D13750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madhavi N.L.  Nalam</span>, <span class="hlFld-ContribAuthor ">Akbar  Ali</span>, <span class="hlFld-ContribAuthor ">G.S. Kiran Kumar  Reddy</span>, <span class="hlFld-ContribAuthor ">Hong  Cao</span>, <span class="hlFld-ContribAuthor ">Saima G.  Anjum</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Nese Kurt  Yilmaz</span>, <span class="hlFld-ContribAuthor ">Bruce  Tidor</span>, <span class="hlFld-ContribAuthor ">Tariq M.  Rana</span>, <span class="hlFld-ContribAuthor ">Celia A.  Schiffer</span>. </span><span class="cited-content_cbyCitation_article-title">Substrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biology</span><span> <strong>2013,</strong> <em>20 </em>
                                    (9)
                                     , 1116-1124. <a href="https://doi.org/10.1016/j.chembiol.2013.07.014" title="DOI URL">https://doi.org/10.1016/j.chembiol.2013.07.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2013.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2013.07.014%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biology%26atitle%3DSubstrate%252BEnvelope-Designed%252BPotent%252BHIV-1%252BProtease%252BInhibitors%252Bto%252BAvoid%252BDrug%252BResistance%26aulast%3DNalam%26aufirst%3DMadhavi%25C2%25A0N.L.%26date%3D2013%26volume%3D20%26issue%3D9%26spage%3D1116%26epage%3D1124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Likai  Xia</span>, <span class="hlFld-ContribAuthor ">Yong Rok  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient One-Pot Synthesis of Multi-Substituted Dihydrofurans by Ruthenium(II)-Catalyzed [3+2] Cycloaddition of Cyclic or Acyclic Diazodicarbonyl Compounds with Olefins. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2013,</strong> <em>355 </em>
                                    (11-12)
                                     , 2361-2374. <a href="https://doi.org/10.1002/adsc.201300245" title="DOI URL">https://doi.org/10.1002/adsc.201300245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201300245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201300245%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DEfficient%252BOne-Pot%252BSynthesis%252Bof%252BMulti-Substituted%252BDihydrofurans%252Bby%252BRuthenium%252528II%252529-Catalyzed%252B%25255B3%25252B2%25255D%2525E2%252580%252589Cycloaddition%252Bof%252BCyclic%252Bor%252BAcyclic%252BDiazodicarbonyl%252BCompounds%252Bwith%252BOlefins%26aulast%3DXia%26aufirst%3DLikai%26date%3D2013%26date%3D2013%26volume%3D355%26issue%3D11-12%26spage%3D2361%26epage%3D2374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mitesh  Patel</span>, <span class="hlFld-ContribAuthor ">Nanda K  Mandava</span>, <span class="hlFld-ContribAuthor ">Ramya Krishna  Vadlapatla</span>, <span class="hlFld-ContribAuthor ">Ashim K  Mitra</span>. </span><span class="cited-content_cbyCitation_article-title">Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Patent Analyst</span><span> <strong>2013,</strong> <em>2 </em>
                                    (4)
                                     , 513-538. <a href="https://doi.org/10.4155/ppa.13.33" title="DOI URL">https://doi.org/10.4155/ppa.13.33</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/ppa.13.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fppa.13.33%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Patent%2520Analyst%26atitle%3DRecent%252Bpatents%252Band%252Bemerging%252Btherapeutics%252Bfor%252BHIV%252Binfections%25253A%252Ba%252Bfocus%252Bon%252Bprotease%252Binhibitors%26aulast%3DPatel%26aufirst%3DMitesh%26date%3D2013%26volume%3D2%26issue%3D4%26spage%3D513%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shashidhar N.  Rao</span>, <span class="hlFld-ContribAuthor ">Govardhan A.  Balaji</span>, <span class="hlFld-ContribAuthor ">Vitukudi N.  Balaji</span>. </span><span class="cited-content_cbyCitation_article-title">Docking and 3-D QSAR studies on the binding of tetrahydropyrimid-2-one HIV-1 protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2013,</strong> <em>1042 </em>, 86-103. <a href="https://doi.org/10.1016/j.molstruc.2013.03.022" title="DOI URL">https://doi.org/10.1016/j.molstruc.2013.03.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2013.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2013.03.022%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DDocking%252Band%252B3-D%252BQSAR%252Bstudies%252Bon%252Bthe%252Bbinding%252Bof%252Btetrahydropyrimid-2-one%252BHIV-1%252Bprotease%252Binhibitors%26aulast%3DRao%26aufirst%3DShashidhar%2BN.%26date%3D2013%26volume%3D1042%26spage%3D86%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Bruno D.  Chapsal</span>. </span><span class="cited-content_cbyCitation_article-title">Design of the anti-HIV protease inhibitor darunavir. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 355-384. <a href="https://doi.org/10.1016/B978-0-12-397176-0.00013-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-397176-0.00013-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-397176-0.00013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-397176-0.00013-3%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Bof%252Bthe%252Banti-HIV%252Bprotease%252Binhibitor%252Bdarunavir%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2013%26spage%3D355%26epage%3D384%26pub%3DElsevier%26atitle%3DIntroduction%252Bto%252BBiological%252Band%252BSmall%252BMolecule%252BDrug%252BResearch%252Band%252BDevelopment%26date%3D2013%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofeng  Ma</span>, <span class="hlFld-ContribAuthor ">Qin  Tang</span>, <span class="hlFld-ContribAuthor ">Jun  Ke</span>, <span class="hlFld-ContribAuthor ">Jichao  Zhang</span>, <span class="hlFld-ContribAuthor ">Cong  Wang</span>, <span class="hlFld-ContribAuthor ">Haibo  Wang</span>, <span class="hlFld-ContribAuthor ">Yuxue  Li</span>, <span class="hlFld-ContribAuthor ">Huawu  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Straightforward and highly diastereoselective synthesis of 2,2-di-substituted perhydrofuro[2,3-b]pyran (and furan) derivatives promoted by BiCl3. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2013,</strong> <em>49 </em>
                                    (63)
                                     , 7085. <a href="https://doi.org/10.1039/c3cc42292e" title="DOI URL">https://doi.org/10.1039/c3cc42292e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3cc42292e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3cc42292e%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DStraightforward%252Band%252Bhighly%252Bdiastereoselective%252Bsynthesis%252Bof%252B2%25252C2-di-substituted%252Bperhydrofuro%25255B2%25252C3-b%25255Dpyran%252B%252528and%252Bfuran%252529%252Bderivatives%252Bpromoted%252Bby%252BBiCl3%26aulast%3DMa%26aufirst%3DXiaofeng%26date%3D2013%26volume%3D49%26issue%3D63%26spage%3D7085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Divya  Yadav</span>, <span class="hlFld-ContribAuthor ">Sarvesh  Paliwal</span>, <span class="hlFld-ContribAuthor ">Rakesh  Yadav</span>, <span class="hlFld-ContribAuthor ">Mahima  Pal</span>, <span class="hlFld-ContribAuthor ">Anubhuti  Pandey</span>, . </span><span class="cited-content_cbyCitation_article-title">Identification of Novel HIV 1- Protease Inhibitors: Application of Ligand and Structure Based Pharmacophore Mapping and Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2012,</strong> <em>7 </em>
                                    (11)
                                     , e48942. <a href="https://doi.org/10.1371/journal.pone.0048942" title="DOI URL">https://doi.org/10.1371/journal.pone.0048942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0048942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0048942%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DIdentification%252Bof%252BNovel%252BHIV%252B1-%252BProtease%252BInhibitors%25253A%252BApplication%252Bof%252BLigand%252Band%252BStructure%252BBased%252BPharmacophore%252BMapping%252Band%252BVirtual%252BScreening%26aulast%3DYadav%26aufirst%3DDivya%26date%3D2012%26date%3D2012%26volume%3D7%26issue%3D11%26spage%3De48942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arup  Roy</span>, <span class="hlFld-ContribAuthor ">Gangadhar J.  Sanjayan</span>. </span><span class="cited-content_cbyCitation_article-title">Sugar–amino acid cyclic conjugates as novel conformationally constrained hydroxyethylamine transition-state isosteres. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2012,</strong> <em>53 </em>
                                    (26)
                                     , 3361-3363. <a href="https://doi.org/10.1016/j.tetlet.2012.04.086" title="DOI URL">https://doi.org/10.1016/j.tetlet.2012.04.086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2012.04.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2012.04.086%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSugar%2525E2%252580%252593amino%252Bacid%252Bcyclic%252Bconjugates%252Bas%252Bnovel%252Bconformationally%252Bconstrained%252Bhydroxyethylamine%252Btransition-state%252Bisosteres%26aulast%3DRoy%26aufirst%3DArup%26date%3D2012%26volume%3D53%26issue%3D26%26spage%3D3361%26epage%3D3363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianwei  Yan</span>, <span class="hlFld-ContribAuthor ">Ning  Huang</span>, <span class="hlFld-ContribAuthor ">Shukun  Li</span>, <span class="hlFld-ContribAuthor ">Liu-Meng  Yang</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Xing</span>, <span class="hlFld-ContribAuthor ">Yong-Tang  Zheng</span>, <span class="hlFld-ContribAuthor ">Youhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (5)
                                     , 1976-1979. <a href="https://doi.org/10.1016/j.bmcl.2012.01.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.01.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.01.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bamprenavir-based%252BP1-substituted%252Bbi-aryl%252Bderivatives%252Bas%252Bultra-potent%252BHIV-1%252Bprotease%252Binhibitors%26aulast%3DYan%26aufirst%3DJianwei%26date%3D2012%26volume%3D22%26issue%3D5%26spage%3D1976%26epage%3D1979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">David D.  Anderson</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Verstärkung der Bindung an das Proteinrückgrat - ein fruchtbares Konzept gegen die Arzneimittelresistenz von HIV. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2012,</strong> <em>124 </em>
                                    (8)
                                     , 1812-1838. <a href="https://doi.org/10.1002/ange.201102762" title="DOI URL">https://doi.org/10.1002/ange.201102762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201102762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201102762%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DVerst%2525C3%2525A4rkung%252Bder%252BBindung%252Ban%252Bdas%252BProteinr%2525C3%2525BCckgrat%252B-%252Bein%252Bfruchtbares%252BKonzept%252Bgegen%252Bdie%252BArzneimittelresistenz%252Bvon%252BHIV%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2012%26date%3D2012%26volume%3D124%26issue%3D8%26spage%3D1812%26epage%3D1838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">David D.  Anderson</span>, <span class="hlFld-ContribAuthor ">Irene T.  Weber</span>, <span class="hlFld-ContribAuthor ">Hiroaki  Mitsuya</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancing Protein Backbone Binding-A Fruitful Concept for Combating Drug-Resistant HIV. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2012,</strong> <em>51 </em>
                                    (8)
                                     , 1778-1802. <a href="https://doi.org/10.1002/anie.201102762" title="DOI URL">https://doi.org/10.1002/anie.201102762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201102762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201102762%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DEnhancing%252BProtein%252BBackbone%252BBinding-A%252BFruitful%252BConcept%252Bfor%252BCombating%252BDrug-Resistant%252BHIV%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2012%26date%3D2012%26volume%3D51%26issue%3D8%26spage%3D1778%26epage%3D1802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K  Ghosh</span>, <span class="hlFld-ContribAuthor ">David D  Anderson</span>. </span><span class="cited-content_cbyCitation_article-title">Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2011,</strong> <em>3 </em>
                                    (9)
                                     , 1181-1197. <a href="https://doi.org/10.4155/fmc.11.68" title="DOI URL">https://doi.org/10.4155/fmc.11.68</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.11.68&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.11.68%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DTetrahydrofuran%25252C%252Btetrahydropyran%25252C%252Btriazoles%252Band%252Brelated%252Bheterocyclic%252Bderivatives%252Bas%252BHIV%252Bprotease%252Binhibitors%26aulast%3DGhosh%26aufirst%3DArun%2BK%26date%3D2011%26volume%3D3%26issue%3D9%26spage%3D1181%26epage%3D1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Per  Öhrngren</span>, <span class="hlFld-ContribAuthor ">Xiongyu  Wu</span>, <span class="hlFld-ContribAuthor ">Magnus  Persson</span>, <span class="hlFld-ContribAuthor ">Jenny K.  Ekegren</span>, <span class="hlFld-ContribAuthor ">Hans  Wallberg</span>, <span class="hlFld-ContribAuthor ">Lotta  Vrang</span>, <span class="hlFld-ContribAuthor ">Åsa  Rosenquist</span>, <span class="hlFld-ContribAuthor ">Bertil  Samuelsson</span>, <span class="hlFld-ContribAuthor ">Torsten  Unge</span>, <span class="hlFld-ContribAuthor ">Mats  Larhed</span>. </span><span class="cited-content_cbyCitation_article-title">HIV-1 protease inhibitors with a tertiary alcohol containing transition-state mimic and various P2 and P1′ substituents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2011,</strong> <em>2 </em>
                                    (8)
                                     , 701. <a href="https://doi.org/10.1039/c1md00077b" title="DOI URL">https://doi.org/10.1039/c1md00077b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c1md00077b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc1md00077b%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DHIV-1%252Bprotease%252Binhibitors%252Bwith%252Ba%252Btertiary%252Balcohol%252Bcontaining%252Btransition-state%252Bmimic%252Band%252Bvarious%252BP2%252Band%252BP1%2525E2%252580%2525B2%252Bsubstituents%26aulast%3D%25C3%2596hrngren%26aufirst%3DPer%26date%3D2011%26volume%3D2%26issue%3D8%26spage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sangram S.  Kale</span>, <span class="hlFld-ContribAuthor ">Sanjay T.  Chavan</span>, <span class="hlFld-ContribAuthor ">Sushma G.  Sabharwal</span>, <span class="hlFld-ContribAuthor ">Vedavati G.  Puranik</span>, <span class="hlFld-ContribAuthor ">Gangadhar J.  Sanjayan</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic amino acid-carbohydrate-conjugates as conformationally restricted hydroxyethylamine (HEA) transition-state isosteres. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2011,</strong> <em>9 </em>
                                    (21)
                                     , 7300. <a href="https://doi.org/10.1039/c1ob06215h" title="DOI URL">https://doi.org/10.1039/c1ob06215h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c1ob06215h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc1ob06215h%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DBicyclic%252Bamino%252Bacid-carbohydrate-conjugates%252Bas%252Bconformationally%252Brestricted%252Bhydroxyethylamine%252B%252528HEA%252529%252Btransition-state%252Bisosteres%26aulast%3DKale%26aufirst%3DSangram%2BS.%26date%3D2011%26volume%3D9%26issue%3D21%26spage%3D7300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of inhibitors <b>1</b>−<b>3</b> and <b>35a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Ligand (−)-<b>7</b> and Its Respective Enantiomer (+)-<b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Furocyclohexanol P<sub>2</sub> Ligand (−)-<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Ligands (−)-<b>18</b> and (−)-<b>19</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Hexahydrofuro[3,4-<i>b</i>]pyran-4-ol Ligand <b>25</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Hexahydrofuro[2,3-<i>b</i>]pyran-5-ol Ligand <b>30</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Activated Mixed Carbonates <b>31a</b>−<b>g</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Syntheses of Inhibitors <b>35a</b>−<b>g</b>, <b>36</b>, and <b>37</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/medium/jm-2010-012787_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Stereoview of inhibitor <b>35a</b> modeled into the active site of HIV-1 protease and superimposed on the X-ray crystal structure of <b>1b</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I7E">3I7E</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-2/jm1012787/production/images/large/jm-2010-012787_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm1012787&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Conway, B.</span><span> </span><span class="NLM_article-title">HAART in Treatment-Experienced Patients in the 21st Century: The Audacity of Hope</span> <span class="citation_source-journal">Future Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.2217%2F17460794.4.1.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWju7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=39-41&author=B.+Conway&title=HAART+in+Treatment-Experienced+Patients+in+the+21st+Century%3A+The+Audacity+of+Hope"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HAART in treatment-experienced patients in the 21st century: the audacity of hope</span></div><div class="casAuthors">Conway, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Future Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-41</span>CODEN:
                <span class="NLM_cas:coden">FVUIAM</span>;
        ISSN:<span class="NLM_cas:issn">1746-0794</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Evaluation of: Steigbigel RT, Cooper DA, Kumar PN et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection.  N. Engl. J. Med. 359, 339-354 (2008).  Over the past decade the use of highly active antiretroviral therapy (HAART) has led to a significant increase in life expectancy, at least in drug-naive subjects.  More recently, data generated in the BENCHMRK studies has extended this benefit to treatment-experienced patients, with over 60% of such individuals achieving maximal virol. suppression when treated with the integrase inhibitor raltegravir.  If it is combined with darunavir and etravirine (as was done in the TRIO study), this benefit may be extended to over 90% of these patients.  Similar results may also be achieved using maraviroc, an orally administered chemokine receptor antagonist.  Unless new issues of long-term toxicity or drug resistance arise, we are now in a position to offer new hope to heavily treatment-experienced individuals living with HIV in a way that could not have been possible as recently as 2 or 3 years ago.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5FG4TflFKXrVg90H21EOLACvtfcHk0lhPC5yOyOaRzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWju7rL&md5=f8d6765fecadd3ecb16c0fcc70c6b4a7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2217%2F17460794.4.1.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460794.4.1.39%26sid%3Dliteratum%253Aachs%26aulast%3DConway%26aufirst%3DB.%26atitle%3DHAART%2520in%2520Treatment-Experienced%2520Patients%2520in%2520the%252021st%2520Century%253A%2520The%2520Audacity%2520of%2520Hope%26jtitle%3DFuture%2520Virol.%26date%3D2009%26volume%3D4%26spage%3D39%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Bartlett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMasi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moxham, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseau, F.</span><span> </span><span class="NLM_article-title">Overview on the Effectiveness of Triple Combination Therapy in Antiretroviral-Naive HIV-1 Infected Adults</span> <span class="citation_source-journal">AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1369</span><span class="NLM_x">–</span> <span class="NLM_lpage">1377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=1369-1377&author=J.+A.+Bartlettauthor=R.+DeMasiauthor=J.+Quinnauthor=C.+Moxhamauthor=F.+Rousseau&title=Overview+on+the+Effectiveness+of+Triple+Combination+Therapy+in+Antiretroviral-Naive+HIV-1+Infected+Adults"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DJ.%2BA.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DQuinn%26aufirst%3DJ.%26aulast%3DMoxham%26aufirst%3DC.%26aulast%3DRousseau%26aufirst%3DF.%26atitle%3DOverview%2520on%2520the%2520Effectiveness%2520of%2520Triple%2520Combination%2520Therapy%2520in%2520Antiretroviral-Naive%2520HIV-1%2520Infected%2520Adults%26jtitle%3DAIDS%26date%3D2001%26volume%3D15%26spage%3D1369%26epage%3D1377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Walensky, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paltiel, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Losina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercincavage, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schackman, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sax, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedberg, K. A.</span><span> </span><span class="NLM_article-title">The Survival Benefits of AIDS Treatment in the United States</span> <span class="citation_source-journal">J. Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1086%2F505147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=16741877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADC%252BD28zivVaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2006&pages=11-19&author=R.+P.+Walenskyauthor=A.+D.+Paltielauthor=E.+Losinaauthor=L.+M.+Mercincavageauthor=B.+R.+Schackmanauthor=P.+E.+Saxauthor=M.+C.+Weinsteinauthor=K.+A.+Freedberg&title=The+Survival+Benefits+of+AIDS+Treatment+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The survival benefits of AIDS treatment in the United States</span></div><div class="casAuthors">Walensky Rochelle P; Paltiel A David; Losina Elena; Mercincavage Lauren M; Schackman Bruce R; Sax Paul E; Weinstein Milton C; Freedberg Kenneth A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-9</span>
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    </div><div class="casAbstract">BACKGROUND:  As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States.  METHODS:  We defined eras corresponding to advances in standards of human immunodeficiency virus (HIV) disease care, including opportunistic infection prophylaxis, treatment with ART, and the prevention of mother-to-child transmission (pMTCT) of HIV.  Per-person survival benefits for each era were determined using a mathematical simulation model.  Published estimates provided the number of adult patients with new diagnoses of AIDS who were receiving care in the United States from 1989 to 2003.  RESULTS:  Compared with survival associated with untreated HIV disease, per-person survival increased 0.26 years with Pneumocystis jiroveci pneumonia prophylaxis alone.  Four eras of increasingly effective ART in addition to prophylaxis resulted in per-person survival increases of 7.81, 11.05, 11.57, and 13.33 years, compared with the absence of treatment.  Treatment for patients with AIDS in care in the United States since 1989 yielded a total survival benefit of 2.8 million years. pMTCT averted nearly 2900 infant infections, equivalent to 137,000 additional years of survival benefit.  CONCLUSIONS:  At least 3.0 million years of life have been saved in the United States as a direct result of care of patients with AIDS, highlighting the significant advances made in HIV disease treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7NsMYkLu_6zEC-75aqa5AfW6udTcc2ebzJ_-XAFebFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28zivVaksg%253D%253D&md5=31288a5957b51c0aa1908bf7350b67cb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1086%2F505147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F505147%26sid%3Dliteratum%253Aachs%26aulast%3DWalensky%26aufirst%3DR.%2BP.%26aulast%3DPaltiel%26aufirst%3DA.%2BD.%26aulast%3DLosina%26aufirst%3DE.%26aulast%3DMercincavage%26aufirst%3DL.%2BM.%26aulast%3DSchackman%26aufirst%3DB.%2BR.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DWeinstein%26aufirst%3DM.%2BC.%26aulast%3DFreedberg%26aufirst%3DK.%2BA.%26atitle%3DThe%2520Survival%2520Benefits%2520of%2520AIDS%2520Treatment%2520in%2520the%2520United%2520States%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2006%26volume%3D194%26spage%3D11%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Sepkowitz, K. A.</span><span> </span><span class="NLM_article-title">AIDS: The First 20 Years</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1764</span><span class="NLM_x">–</span> <span class="NLM_lpage">1772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1056%2FNEJM200106073442306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=11396444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADC%252BD3MzivVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1764-1772&author=K.+A.+Sepkowitz&title=AIDS%3A+The+First+20+Years"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">AIDS--the first 20 years</span></div><div class="casAuthors">Sepkowitz K A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1764-72</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTov3XdeSk_JhBrI9DTGjC0fW6udTcc2ebzJ_-XAFebFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MzivVehsg%253D%253D&md5=1048e8fdcd1919e7adb1c095749d7692</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJM200106073442306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200106073442306%26sid%3Dliteratum%253Aachs%26aulast%3DSepkowitz%26aufirst%3DK.%2BA.%26atitle%3DAIDS%253A%2520The%2520First%252020%2520Years%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1764%26epage%3D1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Palella, F. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorman, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loveless, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuhrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satten, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aschman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmberg, S. D.</span><span> </span><span class="NLM_article-title">Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">853</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1056%2FNEJM199803263381301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=9516219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADyaK1c7mslyjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=1998&pages=853-860&author=F.+J.+Palellaauthor=K.+M.+Delaneyauthor=A.+C.+Moormanauthor=M.+O.+Lovelessauthor=J.+Fuhrerauthor=G.+A.+Sattenauthor=D.+J.+Aschmanauthor=S.+D.+Holmberg&title=Declining+Morbidity+and+Mortality+among+Patients+with+Advanced+Human+Immunodeficiency+Virus+Infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators</span></div><div class="casAuthors">Palella F J Jr; Delaney K M; Moorman A C; Loveless M O; Fuhrer J; Satten G A; Aschman D J; Holmberg S D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">853-60</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND AND METHODS:  National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS).  To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997.  RESULTS:  Mortality among the patients declined from 29.4 per 100 person-years in the first quarter of 1995 to 8.8 per 100 in the second quarter of 1997.  There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV.  The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997.  In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality.  Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit.  Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid.  CONCLUSIONS:  The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS6uVwzPlrzo4IRAdBLKY41fW6udTcc2eZ4Vo5I1WQWgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7mslyjuw%253D%253D&md5=63bd6978cc957517f4bcfae251adc3ef</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM199803263381301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199803263381301%26sid%3Dliteratum%253Aachs%26aulast%3DPalella%26aufirst%3DF.%2BJ.%26aulast%3DDelaney%26aufirst%3DK.%2BM.%26aulast%3DMoorman%26aufirst%3DA.%2BC.%26aulast%3DLoveless%26aufirst%3DM.%2BO.%26aulast%3DFuhrer%26aufirst%3DJ.%26aulast%3DSatten%26aufirst%3DG.%2BA.%26aulast%3DAschman%26aufirst%3DD.%2BJ.%26aulast%3DHolmberg%26aufirst%3DS.%2BD.%26atitle%3DDeclining%2520Morbidity%2520and%2520Mortality%2520among%2520Patients%2520with%2520Advanced%2520Human%2520Immunodeficiency%2520Virus%2520Infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1998%26volume%3D338%26spage%3D853%26epage%3D860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">De Clercq, E.</span><span> </span><span class="NLM_article-title">Anti-HIV Drugs: 25 Compounds Approved within 25 Years after the Discovery of HIV</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1016%2Fj.ijantimicag.2008.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=19108994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=307-320&author=E.+De+Clercq&title=Anti-HIV+Drugs%3A+25+Compounds+Approved+within+25+Years+after+the+Discovery+of+HIV"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative etiol. agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compds. have been formally approved for clin. use in the treatment of AIDS.  These compds. fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse transcriptase inhibitors (NtRTIs: tenofovir); non-nucleoside reverse transcriptase inhibitors (NNRTIs: nevirapine, delavirdine, efavirenz and etravirine); protease inhibitors (PIs: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir); cell entry inhibitors [fusion inhibitors (FIs: enfuvirtide) and co-receptor inhibitors (CRIs: maraviroc)]; and integrase inhibitors (INIs: raltegravir).  These compds. should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsT6dqAjvKIrVg90H21EOLACvtfcHk0ljdoyNhgrJ4HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKgs7g%253D&md5=6d8263455e9c912d353ef2ea230a5e15</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2008.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2008.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAnti-HIV%2520Drugs%253A%252025%2520Compounds%2520Approved%2520within%252025%2520Years%2520after%2520the%2520Discovery%2520of%2520HIV%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2009%26spage%3D307%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Pillay, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhaskaran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurriaans, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masquelier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gifford, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balotta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rezza, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Mendoza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poggensee, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, K.</span><span> </span><span class="NLM_article-title">The Impact of Transmitted Drug Resistance on the Natural History of HIV Infection and Response to First-Line Therapy</span> <span class="citation_source-journal">AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=21-28&author=D.+Pillayauthor=K.+Bhaskaranauthor=S.+Jurriaansauthor=M.+Prinsauthor=B.+Masquelierauthor=F.+Dabisauthor=R.+Giffordauthor=C.+Nielsenauthor=C.+Pedersenauthor=C.+Balottaauthor=G.+Rezzaauthor=M.+Ortizauthor=C.+de+Mendozaauthor=C.+Kuchererauthor=G.+Poggenseeauthor=J.+Gillauthor=K.+Porter&title=The+Impact+of+Transmitted+Drug+Resistance+on+the+Natural+History+of+HIV+Infection+and+Response+to+First-Line+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPillay%26aufirst%3DD.%26aulast%3DBhaskaran%26aufirst%3DK.%26aulast%3DJurriaans%26aufirst%3DS.%26aulast%3DPrins%26aufirst%3DM.%26aulast%3DMasquelier%26aufirst%3DB.%26aulast%3DDabis%26aufirst%3DF.%26aulast%3DGifford%26aufirst%3DR.%26aulast%3DNielsen%26aufirst%3DC.%26aulast%3DPedersen%26aufirst%3DC.%26aulast%3DBalotta%26aufirst%3DC.%26aulast%3DRezza%26aufirst%3DG.%26aulast%3DOrtiz%26aufirst%3DM.%26aulast%3Dde%2BMendoza%26aufirst%3DC.%26aulast%3DKucherer%26aufirst%3DC.%26aulast%3DPoggensee%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DJ.%26aulast%3DPorter%26aufirst%3DK.%26atitle%3DThe%2520Impact%2520of%2520Transmitted%2520Drug%2520Resistance%2520on%2520the%2520Natural%2520History%2520of%2520HIV%2520Infection%2520and%2520Response%2520to%2520First-Line%2520Therapy%26jtitle%3DAIDS%26date%3D2006%26volume%3D20%26spage%3D21%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Grabar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Corfec, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allavena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlureau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dupont, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro-Peray, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poizot-Martin, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costagliola, D.</span><span> </span><span class="NLM_article-title">Factors Associated with Clinical and Virological Failure in Patients Receiving a Triple Therapy Including a Protease Inhibitor</span> <span class="citation_source-journal">AIDS</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1097%2F00002030-200001280-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=10708284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvFWmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2000&pages=141-149&author=S.+Grabarauthor=C.+Pradierauthor=E.+Le+Corfecauthor=R.+Lancarauthor=C.+Allavenaauthor=M.+Bentataauthor=P.+Berlureauauthor=C.+Dupontauthor=P.+Fabbro-Perayauthor=I.+Poizot-Martinauthor=D.+Costagliola&title=Factors+Associated+with+Clinical+and+Virological+Failure+in+Patients+Receiving+a+Triple+Therapy+Including+a+Protease+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor</span></div><div class="casAuthors">Grabar, Sophie; Pradier, Christian; Le Corfec, Emmanuelle; Lancar, Remi; Allavena, Clotilde; Bentata, Michelle; Berlureau, Patricia; Dupont, Caroline; Fabbro-Peray, Pascale; Poizot-Martin, Isabelle; Costagliola, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The aim of this study was to det. the predictors of virol. and clin. failure in patients receiving a protease inhibitor as part of triple therapy.  From the French Hospital Database on HIV, 1402 protease inhibitor-naive patients starting a highly active antiretroviral therapy regimen with ritonavir, saquinavir-hard gel capsule (hgc) or indinavir between July 1996 and Mar. 1997, and with measured HIV RNA at baseline and at 12 mo, were studied for progression to a new AIDS-defining event (ADE) or death.  Virol. failure was defined as plasma HIV RNA > 1000 copies/mL at 12 mo.  Multivariate analyses were performed using Cox models for clin. outcomes and logistic regression for virol. outcomes.  During a median follow-up of 14.1 mo, 94 (6.7%) patients experienced an ADE or died.  At 12 mo, 700 patients (49.9%) had virol. failure.  In the multivariate anal., baseline CD4 cell count and viral load were found to be independent predictors of both virol. and clin. failure.  Neither the type of the first protease inhibitor taken nor previous antiretroviral therapy experience was assocd. with risk of clin. progression.  For virol. failure, the use of saquinavir-hgc was assocd. with a significant 1.96-fold increase in risk compared with indinavir; pre-treated patients were at higher risk than antiretroviral therapy-naive patients.  In this study with large samples of patients, the use of saquinavir-hgc was assocd. with higher risk of virol. failure at 12 mo than were ritonavir and indinavir; no differences between protease inhibitors were found for clin. progression.  As biases cannot be excluded, a longer duration of follow-up will be necessary to answer the question of whether the results are really discrepant or simply reflect the delay between virol. failure and clin. manifestations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnZr0XLVQAIbVg90H21EOLACvtfcHk0ljVJiOaT3B1RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvFWmsLg%253D&md5=e805e2d951c8c8e9172c9121b5dddb5a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1097%2F00002030-200001280-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002030-200001280-00009%26sid%3Dliteratum%253Aachs%26aulast%3DGrabar%26aufirst%3DS.%26aulast%3DPradier%26aufirst%3DC.%26aulast%3DLe%2BCorfec%26aufirst%3DE.%26aulast%3DLancar%26aufirst%3DR.%26aulast%3DAllavena%26aufirst%3DC.%26aulast%3DBentata%26aufirst%3DM.%26aulast%3DBerlureau%26aufirst%3DP.%26aulast%3DDupont%26aufirst%3DC.%26aulast%3DFabbro-Peray%26aufirst%3DP.%26aulast%3DPoizot-Martin%26aufirst%3DI.%26aulast%3DCostagliola%26aufirst%3DD.%26atitle%3DFactors%2520Associated%2520with%2520Clinical%2520and%2520Virological%2520Failure%2520in%2520Patients%2520Receiving%2520a%2520Triple%2520Therapy%2520Including%2520a%2520Protease%2520Inhibitor%26jtitle%3DAIDS%26date%3D2000%26volume%3D14%26spage%3D141%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Little, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daar, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markowitz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koup, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellors, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connick, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitcomb, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmann, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richman, D. D.</span><span> </span><span class="NLM_article-title">Antiretroviral-Drug Resistance among Patients Recently Infected with HIV</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1056%2FNEJMoa013552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=12167680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFKrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=385-394&author=S.+J.+Littleauthor=S.+Holteauthor=J.+P.+Routyauthor=E.+S.+Daarauthor=M.+Markowitzauthor=A.+C.+Collierauthor=R.+A.+Koupauthor=J.+W.+Mellorsauthor=E.+Connickauthor=B.+Conwayauthor=M.+Kilbyauthor=L.+Wangauthor=J.+M.+Whitcombauthor=N.+S.+Hellmannauthor=D.+D.+Richman&title=Antiretroviral-Drug+Resistance+among+Patients+Recently+Infected+with+HIV"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral-drug resistance among patients recently infected with HIV</span></div><div class="casAuthors">Little, Susan J.; Holte, Sarah; Routy, Jean-Pierre; Daar, Eric S.; Markowitz, Marty; Collier, Ann C.; Koup, Richard A.; Mellors, John W.; Connick, Elizabeth; Conway, Brian; Kilby, Michael; Wang, Lei; Whitcomb, Jeannette M.; Hellmann, Nicholas S.; Richman, Douglas D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">385-394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estd. at 1 to 11 %.  We performed a retrospective anal. of susceptibility to antiretroviral drugs before treatment and drug-resistance mutations in HIV in plasma samples from 377 subjects with primary HIV infection who had not yet received treatment and who were identified between May 1995 and June 2000 in 10 North American cities.  Responses to treatment could be evaluated in 202 subjects.  Over the five-year period, the frequency of transmitted drug resistance increased significantly.  The frequency of high-level resistance to one or more drugs (indicated by a value of more than 10 for the ratio of the 50 % inhibitory concn. [IC50] for the subject's virus to the IC50 for a drug-sensitive ref. virus) increased from 3.4 % during the period from 1995 to 1998 to 12.4 % during the period from 1999 to 2000 (P = 0.002), and the frequency of multidrug resistance increased from 1.1 % to 6.2 % (P = 0.01).  The frequency of resistance mutations detected by sequence anal. increased from 8.0 % to 22.7 % (P<0.001), and the frequency of multidrug resistance detected by sequence anal. increased from 3.8 % to 10.2 % (P = 0.05).  Among subjects infected with drug-resistant virus, the time to viral suppression after the initiation of antiretroviral therapy was longer (P = 0.05), and the time to virol. failure was shorter (P = 0.05).  The proportion of new HIV infections that involve drug-resistant virus is increasing in North America.  Initial antiretroviral therapy is more likely to fail in patients who are infected with drug-resistant virus.  Testing for resistance to drugs before therapy begins is now indicated even for recently infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMYtEft2HLLVg90H21EOLACvtfcHk0ljVJiOaT3B1RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFKrt78%253D&md5=e0210630dd7ce7ee727b51342e51ad7f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa013552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa013552%26sid%3Dliteratum%253Aachs%26aulast%3DLittle%26aufirst%3DS.%2BJ.%26aulast%3DHolte%26aufirst%3DS.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DDaar%26aufirst%3DE.%2BS.%26aulast%3DMarkowitz%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DA.%2BC.%26aulast%3DKoup%26aufirst%3DR.%2BA.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DConnick%26aufirst%3DE.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DKilby%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWhitcomb%26aufirst%3DJ.%2BM.%26aulast%3DHellmann%26aufirst%3DN.%2BS.%26aulast%3DRichman%26aufirst%3DD.%2BD.%26atitle%3DAntiretroviral-Drug%2520Resistance%2520among%2520Patients%2520Recently%2520Infected%2520with%2520HIV%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D385%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Grant, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hecht, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmerdam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liegler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petropoulos, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellmann, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Busch, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, J. O.</span><span> </span><span class="NLM_article-title">Time Trends in Primary HIV-1 Drug Resistance among Recently Infected Persons</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2002&pages=181-188&author=R.+M.+Grantauthor=F.+M.+Hechtauthor=M.+Warmerdamauthor=L.+Liuauthor=T.+Lieglerauthor=C.+J.+Petropoulosauthor=N.+S.+Hellmannauthor=M.+Chesneyauthor=M.+P.+Buschauthor=J.+O.+Kahn&title=Time+Trends+in+Primary+HIV-1+Drug+Resistance+among+Recently+Infected+Persons"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DR.%2BM.%26aulast%3DHecht%26aufirst%3DF.%2BM.%26aulast%3DWarmerdam%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLiegler%26aufirst%3DT.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DHellmann%26aufirst%3DN.%2BS.%26aulast%3DChesney%26aufirst%3DM.%26aulast%3DBusch%26aufirst%3DM.%2BP.%26aulast%3DKahn%26aufirst%3DJ.%2BO.%26atitle%3DTime%2520Trends%2520in%2520Primary%2520HIV-1%2520Drug%2520Resistance%2520among%2520Recently%2520Infected%2520Persons%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2002%26volume%3D288%26spage%3D181%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Hue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gifford, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernhill, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillay, D.</span><span> </span><span class="NLM_article-title">On behalf of the UK Collaborative Group on HIV Drug Resistance. Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naive Individuals</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">2645</span><span class="NLM_x">–</span> <span class="NLM_lpage">2654</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FJVI.01556-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=19158238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2rtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2009&pages=2645-2654&author=S.+Hueauthor=R.+J.+Giffordauthor=D.+Dunnauthor=E.+Fernhillauthor=D.+Pillay&title=On+behalf+of+the+UK+Collaborative+Group+on+HIV+Drug+Resistance.+Demonstration+of+Sustained+Drug-Resistant+Human+Immunodeficiency+Virus+Type+1+Lineages+Circulating+among+Treatment-Naive+Individuals"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals</span></div><div class="casAuthors">Hue, Stephane; Gifford, Robert J.; Dunn, David; Fernhill, Esther; Pillay, Deenan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2645-2654</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Transmission of human immunodeficiency virus (HIV) drug resistance is well-recognized and compromises response to first-line therapy.  However, the population dynamics of transmitted resistance remains unclear, although previous models have assumed that such transmission reflects direct infection from treated individuals.  We investigated whether population-based phylogenetic analyses would uncover lineages of resistant viruses circulating in untreated individuals.  Through the phylogenetic anal. of 14,061 HIV type 1 (HIV-1) pol gene sequences generated in the United Kingdom from both treatment-naive and -experienced individuals, we identified five treatment-independent viral clusters contg. mutations conferring cross-resistance to antiretroviral drugs prescribed today in the United Kingdom.  These viral lineages represent sustainable reservoirs of resistance among new HIV infections, independent of treatment.  Dated phylogenies reconstructed through Bayesian Markov chain Monte Carlo inference indicated that these reservoirs originated between 1997 and 2003 and have persisted in the HIV-infected population for up to 8 years.  Since our cohort does not represent all infected individuals within the United Kingdom, our results are likely to underestimate the no. and size of the resistant reservoirs circulating among drug-naive patients.  The existence of sustained reservoirs of resistance in the absence of treatment has the capacity to threaten the long-term efficacy of antiretroviral therapy and suggests there is a limit to the decline of transmitted drug resistance.  Given the current decrease in resistance transmitted from treated individuals, a greater proportion of resistance is likely to come from drug-naive lineages.  These findings provide new insights for the planning and management of treatment programs in resource-rich and developing countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5IXepn13UVrVg90H21EOLACvtfcHk0lg-YyRrh_ztXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2rtb0%253D&md5=5d1b3046cfd58bb7d10aa410d7aca28c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FJVI.01556-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01556-08%26sid%3Dliteratum%253Aachs%26aulast%3DHue%26aufirst%3DS.%26aulast%3DGifford%26aufirst%3DR.%2BJ.%26aulast%3DDunn%26aufirst%3DD.%26aulast%3DFernhill%26aufirst%3DE.%26aulast%3DPillay%26aufirst%3DD.%26atitle%3DOn%2520behalf%2520of%2520the%2520UK%2520Collaborative%2520Group%2520on%2520HIV%2520Drug%2520Resistance.%2520Demonstration%2520of%2520Sustained%2520Drug-Resistant%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Lineages%2520Circulating%2520among%2520Treatment-Naive%2520Individuals%26jtitle%3DJ.%2520Virol.%26date%3D2009%26volume%3D83%26spage%3D2645%26epage%3D2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lucas, G. M.</span><span> </span><span class="NLM_article-title">Antiretroviral Adherence, Drug Resistance, Viral Fitness and HIV Disease Progression: A Tangled Web Is Woven</span> <span class="citation_source-journal">J. Antimicrob. Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1093%2Fjac%2Fdki042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15722389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFWiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=413-416&author=G.+M.+Lucas&title=Antiretroviral+Adherence%2C+Drug+Resistance%2C+Viral+Fitness+and+HIV+Disease+Progression%3A+A+Tangled+Web+Is+Woven"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven</span></div><div class="casAuthors">Lucas, Gregory M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-416</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The clin. goals of HIV treatment are optimally accomplished through consistent high-level adherence to highly active antiretroviral therapy (HAART) and durable suppression of the viral load.  However, as a result of the need for lifelong therapy and HIV's prodigious replication rate and error-prone reverse transcriptase, varying amts. of antiretroviral drug resistance are common in treated individuals.  Medication adherence is linked to the development of drug resistance, although not by a simple linear relationship.  Recent studies have suggested that extensive drug resistance is not a major determinant of HIV disease progression and death.  Rather, failure to access care and discontinuation of or non-adherence with therapy are arguably the most important factors assocd. with HIV disease progression in the HAART era.  Other data indicate that continued therapy in the setting of extensive drug resistance and the inability to achieve viral suppression can provide continued clin. benefit.  Such benefit may be mediated, at least partially, by redns. in viral fitness assocd. with drug resistance mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMJxPoNSUilLVg90H21EOLACvtfcHk0lg-YyRrh_ztXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFWiurw%253D&md5=b18d174da77a7cfb6e7f14af3e36d28f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdki042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdki042%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DG.%2BM.%26atitle%3DAntiretroviral%2520Adherence%252C%2520Drug%2520Resistance%252C%2520Viral%2520Fitness%2520and%2520HIV%2520Disease%2520Progression%253A%2520A%2520Tangled%2520Web%2520Is%2520Woven%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2005%26volume%3D55%26spage%3D413%26epage%3D416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Spaltenstein, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazmierski, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samano, V.</span><span> </span><span class="NLM_article-title">Discovery of Next Generation Inhibitors of HIV Protease</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1589</span><span class="NLM_x">–</span> <span class="NLM_lpage">1607</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.2174%2F156802605775009694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=16375744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD28XislSlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1589-1607&author=A.+Spaltensteinauthor=W.+M.+Kazmierskiauthor=J.+F.+Millerauthor=V.+Samano&title=Discovery+of+Next+Generation+Inhibitors+of+HIV+Protease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of next generation inhibitors of HIV protease</span></div><div class="casAuthors">Spaltenstein, Andrew; Kazmierski, Wieslaw M.; Miller, John F.; Samano, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1589-1607</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Due to factors such as resistance and long-term side effects as well as dosing regimen-related adherence issues, HIV therapy is a constantly moving target.  HIV-1 protease inhibitors had an immediate and dramatic impact on the outcome of HIV/AIDS when launched in late 1995, and the search for new and improved next generation mols. has been under way in many labs.  At GlaxoSmithKline (GSK) and Vertex Pharmaceuticals, this effort focused on 2 key issues, patient compliance and viral resistance.  Using a water-solubilizing prodrug approach, the pill burden in delivering a protease inhibitor, Amprenavir, was dramatically decreased.  By eliminating the large amts. of excipients necessary for the original soft-gel formulation, Fosamprenavir (Lexiva/Telzir) delivers the clin. efficacious dose of Amprenavir with 2 compact tablets per dose, compared to 8 gel capsules.  The efforts to overcome viral resistance to 1st generation protease inhibitors by further elaborating the SAR of the Amprenavir and related scaffolds led to successive and dramatic improvements in wild-type antiviral potencies, and ultimately to the discovery of ultra-potent mols. with very favorable overall resistance profiles.  The selection of GW640385 (Brecanavir - USAN approved only) as a clin. candidate and its progression into current phase 2 dose ranging studies represents the culmination of the effort toward the next generation protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplhByH_w0_47Vg90H21EOLACvtfcHk0lgWBQBUDlSLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislSlsLs%253D&md5=5bf9ffbed174a9cd87b109d7e45410a8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F156802605775009694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802605775009694%26sid%3Dliteratum%253Aachs%26aulast%3DSpaltenstein%26aufirst%3DA.%26aulast%3DKazmierski%26aufirst%3DW.%2BM.%26aulast%3DMiller%26aufirst%3DJ.%2BF.%26aulast%3DSamano%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520Next%2520Generation%2520Inhibitors%2520of%2520HIV%2520Protease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1589%26epage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumaragurubaran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Bis-tetrahydrofuran: A Privileged Ligand for Darunavir and a New Generation of HIV-Protease Inhibitors That Combat Drug-Resistance</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">939</span><span class="NLM_x">–</span> <span class="NLM_lpage">950</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=939-950&author=A.+K.+Ghoshauthor=P.+R.+Sridharauthor=N.+Kumaragurubaranauthor=Y.+Kohauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Bis-tetrahydrofuran%3A+A+Privileged+Ligand+for+Darunavir+and+a+New+Generation+of+HIV-Protease+Inhibitors+That+Combat+Drug-Resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DSridhar%26aufirst%3DP.%2BR.%26aulast%3DKumaragurubaran%26aufirst%3DN.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DBis-tetrahydrofuran%253A%2520A%2520Privileged%2520Ligand%2520for%2520Darunavir%2520and%2520a%2520New%2520Generation%2520of%2520HIV-Protease%2520Inhibitors%2520That%2520Combat%2520Drug-Resistance%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D939%26epage%3D950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovalevsky, A. Yu.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedekind, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grum-Tokars, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatanaga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5252</span><span class="NLM_x">–</span> <span class="NLM_lpage">5261</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060561m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1Wqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5252-5261&author=A.+K.+Ghoshauthor=P.+R.+Sridharauthor=S.+Leshchenkoauthor=A.+K.+Hussainauthor=J.+Liauthor=A.+Yu.+Kovalevskyauthor=D.+E.+Waltersauthor=J.+E.+Wedekindauthor=V.+Grum-Tokarsauthor=D.+Dasauthor=Y.+Kohauthor=K.+Maedaauthor=H.+Gatanagaauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Structure-Based+Design+of+Novel+HIV-1+Protease+Inhibitors+To+Combat+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance</span></div><div class="casAuthors">Ghosh, Arun K.; Sridhar, Perali Ramu; Leshchenko, Sofiya; Hussain, Azhar K.; Li, Jianfeng; Kovalevsky, Andrey Yu.; Walters, D. Eric; Wedekind, Joseph E.; Grum-Tokars, Valerie; Das, Debananda; Koh, Yasuhiro; Maeda, Kenji; Gatanaga, Hiroyuki; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5252-5261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based design and synthesis of novel HIV protease inhibitors are described.  The inhibitors are designed specifically to interact with the backbone of HIV protease active site to combat drug resistance.  Inhibitor (I) has exhibited exceedingly potent enzyme inhibitory and antiviral potency.  Furthermore, this inhibitor maintains impressive potency against a wide spectrum of HIV including a variety of multi-PI-resistant clin. strains.  The inhibitors incorporated a stereochem. defined 5-hexahydrocyclopenta[b]furanyl urethane as the P2-ligand into the (R)-(hydroxyethylamino)sulfonamide isostere.  Optically active (3aS,5R,6aR)-5-hydroxy-hexahydrocyclopenta[b]furan was prepd. by an enzymic asymmetrization of meso-diacetate with acetyl cholinesterase, radical cyclization, and Lewis acid-catalyzed anomeric redn. as the key steps.  A protein-ligand x-ray crystal structure of inhibitor I-bound HIV-1 protease (1.35 Å resoln.) revealed extensive interactions in the HIV protease active site including strong hydrogen bonding interactions with the backbone.  This design strategy may lead to novel inhibitors that can combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdf3BkHGYz7rVg90H21EOLACvtfcHk0lgWBQBUDlSLAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1Wqu7Y%253D&md5=a82e762625bf1dd78bbe129a1b426560</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm060561m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060561m%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DSridhar%26aufirst%3DP.%2BR.%26aulast%3DLeshchenko%26aufirst%3DS.%26aulast%3DHussain%26aufirst%3DA.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKovalevsky%26aufirst%3DA.%2BYu.%26aulast%3DWalters%26aufirst%3DD.%2BE.%26aulast%3DWedekind%26aufirst%3DJ.%2BE.%26aulast%3DGrum-Tokars%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DGatanaga%26aufirst%3DH.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DStructure-Based%2520Design%2520of%2520Novel%2520HIV-1%2520Protease%2520Inhibitors%2520To%2520Combat%2520Drug%2520Resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5252%26epage%3D5261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldridge, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agniswamy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miguel, S. G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Probing Multidrug-Resistance/Protein−Ligand Interaction with New Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1850</span><span class="NLM_x">–</span> <span class="NLM_lpage">1854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1850-1854&author=A.+K.+Ghoshauthor=C.-X.+Xuauthor=K.+V.+Raoauthor=A.+Baldridgeauthor=J.+Agniswamyauthor=Y.-F.+Wangauthor=I.+T.+Weberauthor=M.+Aokiauthor=S.+G.+P.+Miguelauthor=M.+Amanoauthor=H.+Mitsuya&title=Probing+Multidrug-Resistance%2FProtein%E2%88%92Ligand+Interaction+with+New+Oxatricyclic+Designed+Ligands+in+HIV-1+Protease+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DXu%26aufirst%3DC.-X.%26aulast%3DRao%26aufirst%3DK.%2BV.%26aulast%3DBaldridge%26aufirst%3DA.%26aulast%3DAgniswamy%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DMiguel%26aufirst%3DS.%2BG.%2BP.%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DProbing%2520Multidrug-Resistance%252FProtein%25E2%2588%2592Ligand%2520Interaction%2520with%2520New%2520Oxatricyclic%2520Designed%2520Ligands%2520in%2520HIV-1%2520Protease%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1850%26epage%3D1854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>FDA News Release, June 23, 2006: FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News+Release%2C+June+23%2C+2006%3A+FDA+Approves+New+HIV+Treatment+for+Patients+Who+Do+Not+Respond+to+Existing+Drugs.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2F2006%2Fucm108676.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="note"><p class="first last">On October 21, 2008, FDA expanded approval to Prezista (darunavir), coadministered with ritonavir and with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-naive adult patients. In addition to the traditional approval, a new dosing regimen for treatment-naive adult patients was approved.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilcer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devasamudram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kincaid, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boross, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volarath, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaddis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Novel Bis-tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus in Vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3123</span><span class="NLM_x">–</span> <span class="NLM_lpage">3129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FAAC.47.10.3123-3129.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=14506019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVWmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=3123-3129&author=Y.+Kohauthor=H.+Nakataauthor=K.+Maedaauthor=H.+Ogataauthor=G.+Bilcerauthor=T.+Devasamudramauthor=J.+F.+Kincaidauthor=P.+Borossauthor=Y.-F.+Wangauthor=Y.+Tieauthor=P.+Volarathauthor=L.+Gaddisauthor=R.+W.+Harrisonauthor=I.+T.+Weberauthor=A.+K.+Ghoshauthor=H.+Mitsuya&title=Novel+Bis-tetrahydrofuranylurethane-Containing+Nonpeptidic+Protease+Inhibitor+%28PI%29+UIC-94017+%28TMC114%29+with+Potent+Activity+against+Multi-PI-Resistant+Human+Immunodeficiency+Virus+in+Vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro</span></div><div class="casAuthors">Koh, Yasuhiro; Nakata, Hirotomo; Maeda, Kenji; Ogata, Hiromi; Bilcer, Geoffrey; Devasamudram, Thippeswamy; Kincaid, John F.; Boross, Peter; Wang, Yuan-Fang; Tie, Yunfeng; Volarath, Patra; Gaddis, Laquasha; Harrison, Robert W.; Weber, Irene T.; Ghosh, Arun K.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3123-3129</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) contg. a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against lab. HIV-1 strains and primary clin. isolates (50% inhibitory concn. [IC50], ∼0.003 μM; IC90, ∼0.009 μM) with minimal cytotoxicity (50% cytotoxic concn. for CD4+ MT-2 cells, 74 μM).  UIC-94017 blocked the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concns. up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to amprenavir (IC50, 0.22 μM).  UIC-94017 was also potent against multi-PI-resistant clin. HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents.  Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants.  Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxs09jTg7yoLVg90H21EOLACvtfcHk0lh21XVf3vy-Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVWmsbo%253D&md5=b6b08cabb983eec9e2cc5d7e2bcd16ae</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.10.3123-3129.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.10.3123-3129.2003%26sid%3Dliteratum%253Aachs%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DBilcer%26aufirst%3DG.%26aulast%3DDevasamudram%26aufirst%3DT.%26aulast%3DKincaid%26aufirst%3DJ.%2BF.%26aulast%3DBoross%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DTie%26aufirst%3DY.%26aulast%3DVolarath%26aufirst%3DP.%26aulast%3DGaddis%26aufirst%3DL.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DNovel%2520Bis-tetrahydrofuranylurethane-Containing%2520Nonpeptidic%2520Protease%2520Inhibitor%2520%2528PI%2529%2520UIC-94017%2520%2528TMC114%2529%2520with%2520Potent%2520Activity%2520against%2520Multi-PI-Resistant%2520Human%2520Immunodeficiency%2520Virus%2520in%2520Vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D3123%26epage%3D3129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">De Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azijn, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surleraux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochmans, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauwels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bethune, M.-P.</span><span> </span><span class="NLM_article-title">TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2314</span><span class="NLM_x">–</span> <span class="NLM_lpage">2321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FAAC.49.6.2314-2321.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15917527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=2314-2321&author=S.+De+Meyerauthor=H.+Azijnauthor=D.+Surlerauxauthor=D.+Jochmansauthor=A.+Tahriauthor=R.+Pauwelsauthor=P.+Wigerinckauthor=M.-P.+de+Bethune&title=TMC114%2C+a+Novel+Human+Immunodeficiency+Virus+Type+1+Protease+Inhibitor+Active+against+Protease+Inhibitor-Resistant+Viruses%2C+Including+a+Broad+Range+of+Clinical+Isolates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates</span></div><div class="casAuthors">De Meyer, Sandra; Azijn, Hilde; Surleraux, Dominique; Jochmans, Dirk; Tahri, Abdellah; Pauwels, Rudi; Wigerinck, Piet; de Bethune, Marie-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2314-2321</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The purpose of this study was to characterize the antiviral activity, cytotoxicity, and mechanism of action of TMC114, a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI).  TMC114 exhibited potent anti-HIV activity with a 50% effective concn. (EC50) of 1 to 5 nM and a 90% effective concn. of 2.7 to 13 nM.  TMC114 exhibited no cytotoxicity at concns. up to 100 μM (selectivity index, >20,000).  All viruses in a panel of 19 recombinant clin. isolates carrying multiple protease mutations and demonstrating resistance to an av. of five other PIs, were susceptible to TMC114, defined as a fold change in EC50 of <4.  TMC114 was also effective against the majority of 1501 PI-resistant recombinant viruses derived from recent clin. samples, with EC50s of <10 nM for 75% of the samples.  In sequential passage expts. using HIV-1 LAI, two mutations (R41T and K70E) were selected.  One selected virus showed a 10-fold redn. in susceptibility to TMC114, but <10-fold redns. in susceptibility to the current PIs (atazanavir was not assessed), except saquinavir.  However, when the selected mutations were introduced into a lab. strain by site-directed mutagenesis, they had no effect on susceptibility to TMC114 or other PIs.  There was no evidence of antagonism between TMC114 and any currently available PIs or reverse transcriptase inhibitors.  Combinations with ritonavir, nelfinavir, and amprenavir showed some evidence of synergy.  These results suggest that TMC114 is a potential candidate for the treatment of both naive and PI-experienced patients with HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb3029R5vTU7Vg90H21EOLACvtfcHk0lh21XVf3vy-Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFCgsrs%253D&md5=2257492f3a092600688a4abcac54435e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.6.2314-2321.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.6.2314-2321.2005%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMeyer%26aufirst%3DS.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DSurleraux%26aufirst%3DD.%26aulast%3DJochmans%26aufirst%3DD.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dde%2BBethune%26aufirst%3DM.-P.%26atitle%3DTMC114%252C%2520a%2520Novel%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Protease%2520Inhibitor%2520Active%2520against%2520Protease%2520Inhibitor-Resistant%2520Viruses%252C%2520Including%2520a%2520Broad%2520Range%2520of%2520Clinical%2520Isolates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D2314%26epage%3D2321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Lefebvre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Resilience to Resistance of HIV-1 Protease Inhibitors: Profile of Darunavir</span> <span class="citation_source-journal">AIDS Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=18820715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A280%3ADC%252BD1cnjtVOqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=131-142&author=E.+Lefebvreauthor=C.+A.+Schiffer&title=Resilience+to+Resistance+of+HIV-1+Protease+Inhibitors%3A+Profile+of+Darunavir"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir</span></div><div class="casAuthors">Lefebvre Eric; Schiffer Celia A</div><div class="citationInfo"><span class="NLM_cas:title">AIDS reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-42</span>
        ISSN:<span class="NLM_cas:issn">1139-6121</span>.
    </div><div class="casAbstract">The current effectiveness of HAART in the management of HIV infection is compromised by the emergence of extensively cross-resistant strains of HIV-1, requiring a significant need for new therapeutic agents.  Due to its crucial role in viral maturation and therefore HIV-1 replication and infectivity, the HIV-1 protease continues to be a major development target for antiretroviral therapy.  However, new protease inhibitors must have higher thresholds to the development of resistance and cross-resistance.  Research has demonstrated that the binding characteristics between a protease inhibitor and the active site of the HIV-1 protease are key factors in the development of resistance.  More specifically, the way in which a protease inhibitor fits within the substrate consensus volume, or "substrate envelope", appears to be critical.  The currently available inhibitors are not only smaller than the native substrates, but also have a different shape.  This difference in shape underlies observed patterns of resistance because primary drug-resistant mutations often arise at positions in the protease where the inhibitors protrude beyond the substrate envelope but are still in contact with the enzyme.  Since all currently available protease inhibitors occupy a similar space (in spite of their structural differences) in the active site of the enzyme, the specific positions where the inhibitors protrude and contact the enzyme correspond to the locations where most mutations occur that give rise to multidrug-resistant HIV-1 strains.  Detailed investigation of the structure, thermodynamics, and dynamics of the active site of the protease enzyme is enabling the identification of new protease inhibitors that more closely fit within the substrate envelope and therefore decrease the risk of drug resistance developing.  The features of darunavir, the latest FDA-approved protease inhibitor, include its high binding affinity (Kd = 4.5 x 10-12 M) for the protease active site, the presence of hydrogen bonds with the backbone, and its ability to fit closely within the substrate envelope (or consensus volume).  Darunavir is potent against both wild-type and protease inhibitor-resistant viruses in vitro, including a broad range of over 4,000 clinical isolates.  Additionally, in vitro selection studies with wild-type HIV-1 strains have shown that resistance to darunavir develops much more slowly and is more difficult to generate than for existing protease inhibitors.  Clinical studies have shown that darunavir administered with low-dose ritonavir (darunavir/ritonavir) provides highly potent viral suppression (including significant decreases in HIV viral load in patients with documented protease inhibitor resistance) together with favorable tolerability.  In conclusion, as a result of its high binding affinity for and overall fit within the active site of HIV-1 protease, darunavir has a higher genetic barrier to the development of resistance and better clinical efficacy against multidrug-resistant HIV relative to current protease inhibitors.  The observed efficacy, safety and tolerability of darunavir in highly treatment-experienced patients makes darunavir an important new therapeutic option for HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRReWcDTR8Wad0Q2ypr7jHkfW6udTcc2eZu_w8S-2mwH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnjtVOqsA%253D%253D&md5=f86f996c06f6432434694c1e38ec58d5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLefebvre%26aufirst%3DE.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DResilience%2520to%2520Resistance%2520of%2520HIV-1%2520Protease%2520Inhibitors%253A%2520Profile%2520of%2520Darunavir%26jtitle%3DAIDS%2520Rev.%26date%3D2008%26volume%3D10%26spage%3D131%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapsal, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar7001232" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFyhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2008&pages=78-86&author=A.+K.+Ghoshauthor=B.+D.+Chapsalauthor=I.+T.+Weberauthor=H.+Mitsuya&title=Design+of+HIV+Protease+Inhibitors+Targeting+Protein+Backbone%3A+An+Effective+Strategy+for+Combating+Drug+Resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating Drug Resistance</span></div><div class="casAuthors">Ghosh, Arun K.; Chapsal, Bruno D.; Weber, Irene T.; Mitsuya, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-86</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The discovery of HIV protease inhibitors (PIs) followed by their incorporation into highly active antiretroviral therapy (HAART) was a major turning point for the management of HIV/AIDS.  However, the rapid emergence of drug resistance has become a major concern.  Our structure-based design of HIV-1 PIs that can specifically interact with the enzyme backbone atoms has led to the development of compds. with unprecedented potency and drug-resistance profiles.  Particularly notable is the development of a stereochem. defined bis(tetrahydrofuranyl)urethane as the non-peptidic P2 ligand.  Incorporation of this ligand has provided a variety of exceedingly potent HIV-1 PIs with superior activity against multi-PI-resistant variants relative to other FDA-approved PIs.  Darunavir, a PI recently approved for the treatment of drug-resistant HIV, directly resulted from this strategy.  Our detailed protein-darunavir X-ray crystal structures have clearly demonstrated extensive interactions with the protein backbone in the enzyme active site.  This present design concept targeting the protein backbone may serve as a powerful strategy to combat drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZCuOKomAEbVg90H21EOLACvtfcHk0lhUoKEW_QcRAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFyhsbo%253D&md5=a8ee6f368273a5fece6ebbaf9bafc750</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Far7001232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far7001232%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DChapsal%26aufirst%3DB.%2BD.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DDesign%2520of%2520HIV%2520Protease%2520Inhibitors%2520Targeting%2520Protein%2520Backbone%253A%2520An%2520Effective%2520Strategy%2520for%2520Combating%2520Drug%2520Resistance%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2008%26volume%3D41%26spage%3D78%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Tie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boross, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaddis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span> </span><span class="NLM_article-title">High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-Peptide Inhibitor (UIC-94017) Active against Multi-Drug-Resistant Clinical Strains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1016%2Fj.jmb.2004.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15066436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVeltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2004&pages=341-352&author=Y.+Tieauthor=P.+I.+Borossauthor=Y.-F.+Wangauthor=L.+Gaddisauthor=A.+K.+Hussainauthor=S.+Leshchenkoauthor=A.+K.+Ghoshauthor=J.+M.+Louisauthor=R.+W.+Harrisonauthor=I.+T.+Weber&title=High+Resolution+Crystal+Structures+of+HIV-1+Protease+with+a+Potent+Non-Peptide+Inhibitor+%28UIC-94017%29+Active+against+Multi-Drug-Resistant+Clinical+Strains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical Strains</span></div><div class="casAuthors">Tie, Yunfeng; Boross, Peter I.; Wang, Yuan-Fang; Gaddis, Laquasha; Hussain, Azhar K.; Leshchenko, Sofiya; Ghosh, Arun K.; Louis, John M.; Harrison, Robert W.; Weber, Irene T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-352</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The compd. UIC-94017 (TMC-114) is a second-generation HIV protease inhibitor with improved pharmacokinetics that is chem. related to the clin. inhibitor amprenavir.  UIC-94017 is a broad-spectrum potent inhibitor active against HIV-1 clin. isolates with minimal cytotoxicity.  We have detd. the high-resoln. crystal structures of UIC-94017 in complexes with wild-type HIV-1 protease (PR) and mutant proteases PRV82A and PRI84V that are common in drug-resistant HIV.  The structures were refined at resolns. of 1.10 - 1.53 Å.  The crystal structures of PR and PRI84V with UIC-94017 ternary complexes show that the inhibitor binds to the protease in two overlapping positions, while the PRV82A complex had one ordered inhibitor.  In all three structures, UIC-94017 forms hydrogen bonds with the conserved main-chain atoms of Asp29 and Asp30 of the protease.  These interactions are proposed to be crit. for the potency of this compd. against HIV isolates that are resistant to multiple protease inhibitors.  Other small differences were obsd. in the interactions of the mutants with UIC-94017 as compared to PR.  PRV82A showed differences in the position of the main-chain atoms of residue 82 compared to PR structure that better accommodated the inhibitor.  Finally, the 1.10 Å resoln. structure of PRV82A with UIC-94017 showed an unusual distribution of electron d. for the catalytic aspartate residues, which is discussed in relation to the reaction mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHW51Not1WA7Vg90H21EOLACvtfcHk0lhUoKEW_QcRAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVeltL0%253D&md5=82ecc0bb118a886b254ac579ffe9c5fc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DTie%26aufirst%3DY.%26aulast%3DBoross%26aufirst%3DP.%2BI.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGaddis%26aufirst%3DL.%26aulast%3DHussain%26aufirst%3DA.%2BK.%26aulast%3DLeshchenko%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DLouis%26aufirst%3DJ.%2BM.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26atitle%3DHigh%2520Resolution%2520Crystal%2520Structures%2520of%2520HIV-1%2520Protease%2520with%2520a%2520Potent%2520Non-Peptide%2520Inhibitor%2520%2528UIC-94017%2529%2520Active%2520against%2520Multi-Drug-Resistant%2520Clinical%2520Strains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D338%26spage%3D341%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">King, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabu-Jeyabalan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nalivaika, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigerinck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bethune, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffer, C. A.</span><span> </span><span class="NLM_article-title">Structural and Thermodynamic Basis for the Binding of TMC114 a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">12012</span><span class="NLM_x">–</span> <span class="NLM_lpage">12021</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1128%2FJVI.78.21.12012-12021.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=15479840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVKlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=12012-12021&author=N.+M.+Kingauthor=M.+Prabu-Jeyabalanauthor=E.+A.+Nalivaikaauthor=P.+Wigerinckauthor=M.-P.+de+Bethuneauthor=C.+A.+Schiffer&title=Structural+and+Thermodynamic+Basis+for+the+Binding+of+TMC114+a+Next-Generation+Human+Immunodeficiency+Virus+Type+1+Protease+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor</span></div><div class="casAuthors">King, Nancy M.; Prabu-Jeyabalan, Moses; Nalivaika, Ellen A.; Wigerinck, Piet; de Bethune, Marie-Pierre; Schiffer, Celia A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12012-12021</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild-type (wt.) and multidrug-resistant (MDR) viruses in vitro as well as in vivo.  Although chem. similar to amprenavir (APV), the potency of TMC114 is substantially greater.  To examine the basis for this potency, we solved crystal structures of TMC114 complexed with wt. HIV-1 protease and TMC114 and APV complexed with an MDR (L63P, V82T, and I84V) protease variant.  In addn., we detd. the corresponding binding thermodn. by isothermal titrn. calorimetry.  TMC114 binds approx. 2 orders of magnitude more tightly to the wt. enzyme (Kd = 4.5×10-12 M) than APV (Kd = 3.9×10-10 M).  Our x-ray data (resoln. ranging from 2.2 to 1.2 Å) reveal strong interactions between the bis-tetrahydrofuranyl urethane moiety of TMC114 and main-chain atoms of D29 and D30.  These interactions appear largely responsible for TMC114's very favorable binding enthalpy to the wt. protease (-12.1 kcal/mol).  However, TMC114 binding to the MDR HIV-1 protease is reduced by a factor of 13.3, whereas the APV binding const. is reduced only by a factor of 5.1.  However, even with the redn. in binding affinity to the MDR HIV protease, TMC114 still binds with an affinity that is more than 1.5 orders of magnitude tighter than the first-generation inhibitors.  Both APV and TMC114 fit predominantly within the substrate envelope, a property that may be assocd. with decreased susceptibility to drug-resistant mutations relative to that of first-generation inhibitors.  Overall, TMC114's potency against MDR viruses is likely a combination of its extremely high affinity and close fit within the substrate envelope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRCtpDBSgPLVg90H21EOLACvtfcHk0lhUoKEW_QcRAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVKlsbw%253D&md5=dbe410a8b7dc6a5078c312e90f24a538</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.21.12012-12021.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.21.12012-12021.2004%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DN.%2BM.%26aulast%3DPrabu-Jeyabalan%26aufirst%3DM.%26aulast%3DNalivaika%26aufirst%3DE.%2BA.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3Dde%2BBethune%26aufirst%3DM.-P.%26aulast%3DSchiffer%26aufirst%3DC.%2BA.%26atitle%3DStructural%2520and%2520Thermodynamic%2520Basis%2520for%2520the%2520Binding%2520of%2520TMC114%2520a%2520Next-Generation%2520Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Protease%2520Inhibitor%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D12012%26epage%3D12021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kovalevsky, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leshchenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span> </span><span class="NLM_article-title">Ultra-High Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">173</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1016%2Fj.jmb.2006.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=16962136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFSitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2006&pages=161-173&author=A.+Y.+Kovalevskyauthor=F.+Liuauthor=S.+Leshchenkoauthor=A.+K.+Ghoshauthor=J.+M.+Louisauthor=R.+W.+Harrisonauthor=I.+T.+Weber&title=Ultra-High+Resolution+Crystal+Structure+of+HIV-1+Protease+Mutant+Reveals+Two+Binding+Sites+for+Clinical+Inhibitor+TMC114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Ultra-high Resolution Crystal Structure of HIV-1 Protease Mutant Reveals Two Binding Sites for Clinical Inhibitor TMC114</span></div><div class="casAuthors">Kovalevsky, Andrey Y.; Liu, Fengling; Leshchenko, Sofiya; Ghosh, Arun K.; Louis, John M.; Harrison, Robert W.; Weber, Irene T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-173</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">TMC114 (darunavir) is a promising clin. inhibitor of HIV-1 protease (PR) for treatment of drug resistant HIV/AIDS.  We report the ultra-high 0.84 Å resoln. crystal structure of the TMC114 complex with PR contg. the drug-resistant mutation V32I (PRV32I), and the 1.22 Å resoln. structure of a complex with PRM46L.  These structures show TMC114 bound at two distinct sites, one in the active-site cavity and the second on the surface of one of the flexible flaps in the PR dimer.  Remarkably, TMC114 binds at these two sites simultaneously in two diastereomers related by inversion of the sulfonamide nitrogen.  Moreover, the flap site is shaped to accommodate the diastereomer with the S-enantiomeric nitrogen rather than the one with the R-enantiomeric nitrogen.  The existence of the second binding site and two diastereomers suggest a mechanism for the high effectiveness of TMC114 on drug-resistant HIV and the potential design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8m58MkQUwabVg90H21EOLACvtfcHk0lh5_isrjxhOig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFSitLY%253D&md5=16353639fe7af398614b0078c396cb6d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2006.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2006.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DKovalevsky%26aufirst%3DA.%2BY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLeshchenko%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DLouis%26aufirst%3DJ.%2BM.%26aulast%3DHarrison%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26atitle%3DUltra-High%2520Resolution%2520Crystal%2520Structure%2520of%2520HIV-1%2520Protease%2520Mutant%2520Reveals%2520Two%2520Binding%2520Sites%2520for%2520Clinical%2520Inhibitor%2520TMC114%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2006%26volume%3D363%26spage%3D161%26epage%3D173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Amano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leschenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boross, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsuya, H.</span><span> </span><span class="NLM_article-title">A Novel Bis-tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multi-PI-Resistant Human Immunodeficiency Virus in Vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=2143-2155&author=M.+Amanoauthor=Y.+Kohauthor=D.+Dasauthor=J.+Liauthor=S.+Leschenkoauthor=Y.-F.+Wangauthor=P.+I.+Borossauthor=I.+T.+Weberauthor=A.+K.+Ghoshauthor=H.+Mitsuya&title=A+Novel+Bis-tetrahydrofuranylurethane-Containing+Nonpeptidic+Protease+Inhibitor+%28PI%29%2C+GRL-98065%2C+Is+Potent+against+Multi-PI-Resistant+Human+Immunodeficiency+Virus+in+Vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAmano%26aufirst%3DM.%26aulast%3DKoh%26aufirst%3DY.%26aulast%3DDas%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLeschenko%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DBoross%26aufirst%3DP.%2BI.%26aulast%3DWeber%26aufirst%3DI.%2BT.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DA%2520Novel%2520Bis-tetrahydrofuranylurethane-Containing%2520Nonpeptidic%2520Protease%2520Inhibitor%2520%2528PI%2529%252C%2520GRL-98065%252C%2520Is%2520Potent%2520against%2520Multi-PI-Resistant%2520Human%2520Immunodeficiency%2520Virus%2520in%2520Vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D2143%26epage%3D2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Nakashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masayuki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogasawara, K.</span><span> </span><span class="NLM_article-title">Chiral Preparation of Polyoxygenated Cyclopentanoids</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1055%2Fs-2000-6271" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=817-823&author=H.+Nakashimaauthor=S.+Masayukiauthor=T.+Taniguchiauthor=K.+Ogasawara&title=Chiral+Preparation+of+Polyoxygenated+Cyclopentanoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1055%2Fs-2000-6271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2000-6271%26sid%3Dliteratum%253Aachs%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DMasayuki%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOgasawara%26aufirst%3DK.%26atitle%3DChiral%2520Preparation%2520of%2520Polyoxygenated%2520Cyclopentanoids%26jtitle%3DSynthesis%26date%3D2000%26volume%3D6%26spage%3D817%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Laumen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M. P.</span><span> </span><span class="NLM_article-title">A Facile Chemoenzymatic Route to Optically Pure Building Blocks for Cyclopentanoid Natural Products</span> <span class="citation_source-journal">J. Chem. Soc., Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1039%2Fc39860001298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADyaL2sXosVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&pages=1298-1299&author=K.+Laumenauthor=M.+P.+Schneider&title=A+Facile+Chemoenzymatic+Route+to+Optically+Pure+Building+Blocks+for+Cyclopentanoid+Natural+Products"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">A facile chemoenzymic route to optically pure building blocks for cyclopentanoid natural products</span></div><div class="casAuthors">Laumen, Kurt; Schneider, Manfred P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Chemical Communications</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1298-9</span>CODEN:
                <span class="NLM_cas:coden">JCCCAT</span>;
        ISSN:<span class="NLM_cas:issn">0022-4936</span>.
    </div><div class="casAbstract">Enantioselective hydrolysis of cis-3,5-diacetoxycyclopent-1-ene by lipases gave (1R,4S)-4-acetoxycyclopent-2-en-1-ol (I) enantioselectively in 76-90% yield and 91-97% enantiomeric excess.  I is a central chiral building block for cyclopentanoid natural products; several cyclopentanoid synthons, e.g. (R)-4-hydroxycyclopent-2-en-1-one, were prepd. from I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3axL7eZ_irVg90H21EOLACvtfcHk0lglh5DMUTPZjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXosVahtQ%253D%253D&md5=49c2dd3ff74c88e671ff98d80b591c06</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1039%2Fc39860001298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc39860001298%26sid%3Dliteratum%253Aachs%26aulast%3DLaumen%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DM.%2BP.%26atitle%3DA%2520Facile%2520Chemoenzymatic%2520Route%2520to%2520Optically%2520Pure%2520Building%2520Blocks%2520for%2520Cyclopentanoid%2520Natural%2520Products%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Chem.%2520Commun.%26date%3D1986%26spage%3D1298%26epage%3D1299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Ishihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span> </span><span class="NLM_article-title">An Extremely Simple, Convenient, and Selective Method for Acylating Primary Alcohols in the Presence of Secondary Alcohols</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3791</span><span class="NLM_x">–</span> <span class="NLM_lpage">3793</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00067a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1993&pages=3791-3793&author=K.+Ishiharaauthor=H.+Kuriharaauthor=H.+Yamamoto&title=An+Extremely+Simple%2C+Convenient%2C+and+Selective+Method+for+Acylating+Primary+Alcohols+in+the+Presence+of+Secondary+Alcohols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo00067a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00067a005%26sid%3Dliteratum%253Aachs%26aulast%3DIshihara%26aufirst%3DK.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DH.%26atitle%3DAn%2520Extremely%2520Simple%252C%2520Convenient%252C%2520and%2520Selective%2520Method%2520for%2520Acylating%2520Primary%2520Alcohols%2520in%2520the%2520Presence%2520of%2520Secondary%2520Alcohols%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1993%26volume%3D58%26spage%3D3791%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Nara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span> </span><span class="NLM_article-title">Stereochemical Studies—LVII Synthesis of Optically Active Compounds by the Novel Use of Meso-Compounds—1. Efficient Synthesis of Two Structural Types of Optically Pure Prostaglandin Intermediates</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3161</span><span class="NLM_x">–</span> <span class="NLM_lpage">3170</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1980&pages=3161-3170&author=M.+Naraauthor=S.+Terashimaauthor=S.+Yamada&title=Stereochemical+Studies%E2%80%94LVII+Synthesis+of+Optically+Active+Compounds+by+the+Novel+Use+of+Meso-Compounds%E2%80%941.+Efficient+Synthesis+of+Two+Structural+Types+of+Optically+Pure+Prostaglandin+Intermediates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DM.%26aulast%3DTerashima%26aufirst%3DS.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DStereochemical%2520Studies%25E2%2580%2594LVII%2520Synthesis%2520of%2520Optically%2520Active%2520Compounds%2520by%2520the%2520Novel%2520Use%2520of%2520Meso-Compounds%25E2%2580%25941.%2520Efficient%2520Synthesis%2520of%2520Two%2520Structural%2520Types%2520of%2520Optically%2520Pure%2520Prostaglandin%2520Intermediates%26jtitle%3DTetrahedron%26date%3D1980%26volume%3D36%26spage%3D3161%26epage%3D3170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Moriarty, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, B. R.,  III.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, I.</span><span> </span><span class="NLM_article-title">Capture of Electron-Deficient Species with Aryl Halides. New Syntheses of Hypervalent Iodonium Ylides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1375</span><span class="NLM_x">–</span> <span class="NLM_lpage">1378</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00291a044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=1985&pages=1375-1378&author=R.+M.+Moriartyauthor=B.+R.+Baileyauthor=O.+Prakashauthor=I.+Prakash&title=Capture+of+Electron-Deficient+Species+with+Aryl+Halides.+New+Syntheses+of+Hypervalent+Iodonium+Ylides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja00291a044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00291a044%26sid%3Dliteratum%253Aachs%26aulast%3DMoriarty%26aufirst%3DR.%2BM.%26aulast%3DBailey%26aufirst%3DB.%2BR.%26aulast%3DPrakash%26aufirst%3DO.%26aulast%3DPrakash%26aufirst%3DI.%26atitle%3DCapture%2520of%2520Electron-Deficient%2520Species%2520with%2520Aryl%2520Halides.%2520New%2520Syntheses%2520of%2520Hypervalent%2520Iodonium%2520Ylides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1985%26volume%3D107%26spage%3D1375%26epage%3D1378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Müller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allenbach, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardinelli, G.</span><span> </span><span class="NLM_article-title">On the Enantioselectivity of Transition Metal-Catalyzed 1,3-Cycloadditions of 2-Diazocyclohexane-1,3-diones</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">3164</span><span class="NLM_x">–</span> <span class="NLM_lpage">3178</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2003&pages=3164-3178&author=P.+M%C3%BCllerauthor=Y.+F.+Allenbachauthor=G.+Bernardinelli&title=On+the+Enantioselectivity+of+Transition+Metal-Catalyzed+1%2C3-Cycloadditions+of+2-Diazocyclohexane-1%2C3-diones"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DAllenbach%26aufirst%3DY.%2BF.%26aulast%3DBernardinelli%26aufirst%3DG.%26atitle%3DOn%2520the%2520Enantioselectivity%2520of%2520Transition%2520Metal-Catalyzed%25201%252C3-Cycloadditions%2520of%25202-Diazocyclohexane-1%252C3-diones%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2003%26volume%3D86%26spage%3D3164%26epage%3D3178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Ferrie, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reymond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdevielle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossy, J.</span><span> </span><span class="NLM_article-title">Formal Chemoselective Synthesis of Leucascandrolide A</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2461</span><span class="NLM_x">–</span> <span class="NLM_lpage">2464</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol070670a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=2461-2464&author=L.+Ferrieauthor=S.+Reymondauthor=P.+Capdevielleauthor=J.+Cossy&title=Formal+Chemoselective+Synthesis+of+Leucascandrolide+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fol070670a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol070670a%26sid%3Dliteratum%253Aachs%26aulast%3DFerrie%26aufirst%3DL.%26aulast%3DReymond%26aufirst%3DS.%26aulast%3DCapdevielle%26aufirst%3DP.%26aulast%3DCossy%26aufirst%3DJ.%26atitle%3DFormal%2520Chemoselective%2520Synthesis%2520of%2520Leucascandrolide%2520A%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D2461%26epage%3D2464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tsantali, G. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takakis, I. M.</span><span> </span><span class="NLM_article-title">Expeditious Copper-Catalyzed Conjugate 1,4-Addition of Bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to α,β-Cycloalkenones and Subsequent Tranformations</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">6455</span><span class="NLM_x">–</span> <span class="NLM_lpage">6458</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo034350q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=6455-6458&author=G.+G.+Tsantaliauthor=I.+M.+Takakis&title=Expeditious+Copper-Catalyzed+Conjugate+1%2C4-Addition+of+Bromo%5B2-%281%2C3-dioxolan-2-yl%29ethyl%5Dmagnesium+to+%CE%B1%2C%CE%B2-Cycloalkenones+and+Subsequent+Tranformations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo034350q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034350q%26sid%3Dliteratum%253Aachs%26aulast%3DTsantali%26aufirst%3DG.%2BG.%26aulast%3DTakakis%26aufirst%3DI.%2BM.%26atitle%3DExpeditious%2520Copper-Catalyzed%2520Conjugate%25201%252C4-Addition%2520of%2520Bromo%255B2-%25281%252C3-dioxolan-2-yl%2529ethyl%255Dmagnesium%2520to%2520%25CE%25B1%252C%25CE%25B2-Cycloalkenones%2520and%2520Subsequent%2520Tranformations%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D6455%26epage%3D6458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Shen, Z.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geo, G.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, T.-P.</span><span> </span><span class="NLM_article-title">Indium-Copper and Indium-Silver Mediated Barbier Grignard Type Alkylation Reaction of Aldehydes Using Unactivated Alkyl Halides in Water</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">3922</span><span class="NLM_x">–</span> <span class="NLM_lpage">3924</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo8000589" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=3922-3924&author=Z.-L.+Shenauthor=G.-L.+Geoauthor=T.-P.+Loh&title=Indium-Copper+and+Indium-Silver+Mediated+Barbier+Grignard+Type+Alkylation+Reaction+of+Aldehydes+Using+Unactivated+Alkyl+Halides+in+Water"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjo8000589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo8000589%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DZ.-L.%26aulast%3DGeo%26aufirst%3DG.-L.%26aulast%3DLoh%26aufirst%3DT.-P.%26atitle%3DIndium-Copper%2520and%2520Indium-Silver%2520Mediated%2520Barbier%2520Grignard%2520Type%2520Alkylation%2520Reaction%2520of%2520Aldehydes%2520Using%2520Unactivated%2520Alkyl%2520Halides%2520in%2520Water%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D3922%26epage%3D3924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ghosh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leschenko, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noetzel, M.</span><span> </span><span class="NLM_article-title">Stereoselective Photochemical 1,3-Dioxolane Addition to 5-Alkoxymethyl-2(5<i>H</i>)-furanone: Synthesis of Bis-tetrahydrofuranyl Ligand for HIV Protease Inhibitor UIC-94017 (TMC-114)</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">7822</span><span class="NLM_x">–</span> <span class="NLM_lpage">7829</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo049156y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=7822-7829&author=A.+K.+Ghoshauthor=S.+Leschenkoauthor=M.+Noetzel&title=Stereoselective+Photochemical+1%2C3-Dioxolane+Addition+to+5-Alkoxymethyl-2%285H%29-furanone%3A+Synthesis+of+Bis-tetrahydrofuranyl+Ligand+for+HIV+Protease+Inhibitor+UIC-94017+%28TMC-114%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo049156y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049156y%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DLeschenko%26aufirst%3DS.%26aulast%3DNoetzel%26aufirst%3DM.%26atitle%3DStereoselective%2520Photochemical%25201%252C3-Dioxolane%2520Addition%2520to%25205-Alkoxymethyl-2%25285H%2529-furanone%253A%2520Synthesis%2520of%2520Bis-tetrahydrofuranyl%2520Ligand%2520for%2520HIV%2520Protease%2520Inhibitor%2520UIC-94017%2520%2528TMC-114%2529%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D7822%26epage%3D7829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Toth, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, G. R.</span><span> </span><span class="NLM_article-title">A Simple Continuous Fluorometric Assay for HIV Protease</span> <span class="citation_source-journal">Int. J. Pept. Protein Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">544</span><span class="NLM_x">–</span> <span class="NLM_lpage">550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm1012787&amp;key=10.1111%2Fj.1399-3011.1990.tb00994.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm1012787&amp;key=2090647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm1012787&amp;key=1%3ACAS%3A528%3ADyaK3MXhvVSrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1990&pages=544-550&author=M.+V.+Tothauthor=G.+R.+Marshall&title=A+Simple+Continuous+Fluorometric+Assay+for+HIV+Protease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A simple, continuous fluorometric assay for HIV protease</span></div><div class="casAuthors">Toth, Mihaly V.; Marshall, Garland R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Peptide & Protein Research</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-50</span>CODEN:
                <span class="NLM_cas:coden">IJPPC3</span>;
        ISSN:<span class="NLM_cas:issn">0367-8377</span>.
    </div><div class="casAbstract">Novel fluorogenic substrates for human immunodeficiency virus (HIV) aspartic protease were developed based on the principle of fluorescence energy transfer.  Starting from a p24/p15 cleavage site-derived hexapeptide substrate, Ac-Thr-Ile-Nle-Nle-Gln-Arg-NH2, incorporation of 2-aminobenzoic acid in place of the Ac group as the donor and p-nitrophenylalanine at the P1' position as acceptor gave the intramolecularly quenched fluorogenic substrate.  Cleavage of the substrate by HIV protease released the fluorescent N-terminal tripeptide from its close apposition to the quenching nitrobenzyl group, resulting in enhanced fluorescence.  An automated assay based on 96-well microtiter plates and a fluorometric plate reader were developed, which allowed high throughput of compds. in the search for HIV protease inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQqXZE66Ff9rVg90H21EOLACvtfcHk0ljWmjwOLb_L9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvVSrur8%253D&md5=dd889560b9da071462f0f07723802392</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.1990.tb00994.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.1990.tb00994.x%26sid%3Dliteratum%253Aachs%26aulast%3DToth%26aufirst%3DM.%2BV.%26aulast%3DMarshall%26aufirst%3DG.%2BR.%26atitle%3DA%2520Simple%2520Continuous%2520Fluorometric%2520Assay%2520for%2520HIV%2520Protease%26jtitle%3DInt.%2520J.%2520Pept.%2520Protein%2520Res.%26date%3D1990%26volume%3D36%26spage%3D544%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">MMFF VII. Characterization of MMFF94, MMFF94s, and Other Widely Available Force Fields for Conformational Energies and for Intermolecular-Interaction Energies and Geometries</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=730-748&author=T.+A.+Halgren&title=MMFF+VII.+Characterization+of+MMFF94%2C+MMFF94s%2C+and+Other+Widely+Available+Force+Fields+for+Conformational+Energies+and+for+Intermolecular-Interaction+Energies+and+Geometries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DMMFF%2520VII.%2520Characterization%2520of%2520MMFF94%252C%2520MMFF94s%252C%2520and%2520Other%2520Widely%2520Available%2520Force%2520Fields%2520for%2520Conformational%2520Energies%2520and%2520for%2520Intermolecular-Interaction%2520Energies%2520and%2520Geometries%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1999%26volume%3D20%26spage%3D730%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Hodgson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marriot, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisedale, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span> </span><span class="NLM_article-title">Isomerisations of Cycloalkene- and Bicycloalkene-Derived Achiral Epoxides by Enantioselective α-Deprotonation</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_fpage">2151</span><span class="NLM_x">–</span> <span class="NLM_lpage">2161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=2151-2161&author=D.+M.+Hodgsonauthor=G.+P.+Leeauthor=R.+E.+Marriotauthor=A.+J.+Thompsonauthor=R.+Wisedaleauthor=J.+Witherington&title=Isomerisations+of+Cycloalkene-+and+Bicycloalkene-Derived+Achiral+Epoxides+by+Enantioselective+%CE%B1-Deprotonation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DLee%26aufirst%3DG.%2BP.%26aulast%3DMarriot%26aufirst%3DR.%2BE.%26aulast%3DThompson%26aufirst%3DA.%2BJ.%26aulast%3DWisedale%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26atitle%3DIsomerisations%2520of%2520Cycloalkene-%2520and%2520Bicycloalkene-Derived%2520Achiral%2520Epoxides%2520by%2520Enantioselective%2520%25CE%25B1-Deprotonation%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1998%26spage%3D2151%26epage%3D2161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I7E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3I7E','PDB','3I7E'); return false;">PDB: 3I7E</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i53"><a href="/doi/suppl/10.1021/jm1012787">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46220"></div></div></div></div></div><hr /></hr><p class="last">HPLC and HRMS data of inhibitors <b>35a</b>−<b>g</b>, <b>36</b>, and <b>37</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm1012787/suppl_file/jm1012787_si_001.pdf">jm1012787_si_001.pdf (43.53 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm1012787&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-2%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm1012787" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm1012787" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a01aad081991","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
